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The liver executes a myriad of endocrine and exocrine functions vital for the normal 
functioning of many organs and systems of the body. Cancer of the liver arises when 
there is a loss of equilibrium between the positive and negative regulators of cell 
growth, differentiation and cellular adhesion. The major form of primary liver cancer 
in human is hepatocellular carcinoma (HCC). HCC is one of the most common 
malignancies worldwide, especially in Asia and sub-Saharan Africa. Despite a few 
advances made in the diagnosis and treatment of HCC, the overall prognosis of HCC 
remains extremely poor. Hopefully, understanding the yet unclear molecular 
pathogenesis of HCC will provide a rational basis for the development of new 
diagnostic and prognostic interventions as well as identifying novel targets for a more 
effective management of HCC. 
 
Using the technique of suppression subtractive hybridization, 45 novel genes 
differentially expressed in HCC were identified. Among these genes, a transcript, 
designated as HEPN1, was found to be frequently lost while the other, HEPT3, was 
frequently elevated in HCC patients. Intriguingly, the identification of HEPN1 led to 
the isolation of another novel gene, hepaCAM, which contained the full-length cDNA 
of HEPN1 on its antisense strand in the 3’-untranslated region. The aim of this study 
was to clone the full-length cDNAs of HEPN1, hepaCAM and HEPT3, as well as to 
investigate their expression and biological functions in HCC and other malignant 
cells. The data pertaining to these three novel genes, with particularly interesting 




Gene HEPN1 was downregulated in 22/23 of HCC samples and 4/4 of HCC cell lines, 
and completely lost in 10/12 of human cancer cell lines derived from different tumor 
types. Sequence analyses revealed that HEPN1 was an intronless gene mapped to 
human chromosome 11q24.2. The gene encoded a putative 10-kDa peptide of 88 
amino acids that had no homology to known proteins. The peptide was predominantly 
localized in the cytoplasm of mammalian cells. Re-expression of HEPN1 in HCC cell 
line HepG2 inhibited cell growth and induced apoptosis. The data suggest that 
silencing of HEPN1 may be associated with carcinogenesis of hepatocytes. 
 
Gene hepaCAM was expressed in a wide variety of normal human tissues, but 
frequently suppressed in HCC and diverse tumors. The gene was mapped to human 
chromosome 11q24.2 and contained 7 exons. The gene product of 416 amino acids 
displayed the typical structure of immunoglobulin (Ig)-like cell adhesion molecules, 
including an extracellular domain comprising a signal peptide and two Ig-like loops, a 
transmembrane segment, and a cytoplasmic tail. Biochemical analyses demonstrated 
that hepaCAM was glycosylated and phosphorylated, and formed cis-homodimers on 
cell surface. The subcellular localization of hepaCAM appeared cell density-
dependent; in well spread cells, hepaCAM was distributed to cell protrusions, whereas 
in confluent cells, hepaCAM was predominantly accumulated at the sites of cell-cell 
contact on the plasma membrane. In polarized cells, hepaCAM was recruited to the 
basolateral membrane, and, lacking physical interaction, colocalized with E-cadherin 
at the lateral membrane. Furthermore, deletion mutagenesis of hepaCAM revealed 
that the extracellular/transmembrane domains of hepaCAM were essential for its 
dimerization and localization on plasma membrane. Exogenous expression of 




tumor suppressor p53, suggesting a role of hepaCAM as a negative regulator of cell 
growth. Furthermore, cell adhesion and motility assays demonstrated that hepaCAM 
increased cell spreading on matrices fibronectin and matrigel, delayed cell 
detachment, and enhanced cell migration. Deletion of the cytoplasmic domain 
significantly reduced cell-matrix adhesion and abolished wound healing, indicating 
that hepaCAM modulates cell-matrix interaction and cell migration essentially 
through its cytoplasmic domain.  
 
Cell adhesion and migration signaling require the coordinated interaction amongst 
transmembrane proteins, actin cytoskeleton and membrane lipids. Detergent solubility 
assay showed that hepaCAM was partially insoluble in Triton X-100, suggesting a 
possible interaction between hepaCAM and the actin cytoskeleton and/or lipid rafts. 
Extensive deletion mutagenesis of hepaCAM revealed that while the cytoplasmic 
domain, specifically residues located within 319-416, conferred the detergent-resistant 
nature of the molecule, the extracellular Ig domains regulated the insolubility. 
Colocalization studies showed that hepaCAM colocalized with cytoskeletal 
filamentous actin (F-actin). Depolymerization of F-actin altered the solubility and 
disrupted the subcellular distribution of hepaCAM. When the cytoplasmic domain of 
hepaCAM was cloned and transfected into cells, the protein was no longer localized 
on the plasma membrane, and its solubility could not be affected by F-actin 
depolymerization, suggesting that recruitment of the cytoplasmic domain to the 
plasma membrane is necessary for its interaction with F-actin. In addition, sucrose 
density gradients demonstrated that hepaCAM, preferentially its dimeric form, 
partitioned into the lipid rafts. Dispersion of cholesterol in the lipid rafts affected the 




markers caveolin-1 and fyn. These results indicate that hepaCAM interacts with the 
actin cytoskeleton and resides in the lipid rafts, implicating an involvement of the 
glycoprotein in cell signaling.  
 
Gene HEPT3 was transcriptionally upregulated in 20/23 of HCC patients and 5/5 of 
HCC cell lines. HEPT3 was an intronless gene mapped to human chromosome 6q13-
14. The gene transcript lacked extensive open reading frame and contained an Alu 
sequence near the 5’ terminus, indicating that HEPT3 encoded a noncoding RNA. 
Antisense studies showed that, when endogenous HEPT3 expression level was 
reduced, colony formation and cell growth of HCC cell line C3A were significantly 
inhibited. The data suggest that the HEPT3 may function through its noncoding RNA 
and its overexpression may play a role in hepatocarcinogenesis. 
 
In conclusion, the data generated to date have demonstrated the importance of 
HEPN1, hepaCAM, and HEPT3 in cell signaling and growth regulation, as well as 
their possible involvement in carcinogenesis. The frequent alterations of their 
expression in HCC and other malignancies suggest that these novel genes may emerge 
as biomarkers/targets for diagnosis/management of human cancer. However, further 
studies are to be carried out to elucidate the molecular mechanisms of tumor 
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CHAPTER 1 INTRODUCTION 
 
1.1  Liver – The metabolic centre  
The liver is the largest internal organ in the human body and it executes a myriad of 
endocrine and exocrine functions essential for the normal functioning of many organs 
and systems of the body. It is involved in the regulation, synthesis, storage, and 
secretion of many important proteins and nutrients; as well as the purification, 
transformation, and removal of toxic or unwanted substances. Broadly, these 
functions can be classified into the following three overlapping categories. 
 
1.1.1  Regulation, synthesis, and secretion 
1.1.1.1  Glucose 
The liver plays a major role in maintaining the homeostasis of blood glucose, either 
by storing glucose in the form of glycogen or releasing glucose when needed, in 
response to the pancreatic hormones insulin and glucagon. 
 
1.1.1.2 Proteins 
The liver produces and secretes the majority of blood proteins such as albumin. It also 
produces most of the proteins required for blood clotting including the prothrombin 
group of clotting factors. Furthermore, it is the centre for synthesis of lipoproteins, 
ceruloplasmin, transferrin and glycoproteins. 
 
1.1.1.3  Lipids 
The liver is involved in fat metabolism. It converts excess carbohydrates and proteins 




tissues. Additionally, it manufactures cholesterol from acetate. Cholesterol is a type of 
lipid present on cell membranes that helps maintain the physical integrity of cells. It is 
packaged after synthesis and is then distributed to the body to be used or excreted into 
bile for removal from the body. The liver also synthesizes lipoproteins, which are 
made up of cholesterol, triglycerides, phospholipids and proteins. Lipoproteins 
circulate in the blood and transport cholesterol and fatty acids between the liver and 
body tissues. 
 
1.1.1.4  Bile 
The liver produces bile which contains cholesterol, phospholipids, bilirubin and bile 
salts. Bile is secreted into bile canaliculus that joins the bile duct. The bile duct then 
transports the bile to the gallbladder where it is drained into the small intestine to 
digest and absorb dietary fats. Bile also facilitates the absorption of substances such as 
vitamins A, D, E and K. 
 
1.1.2  Storage 
The liver stores important substances such as glycogen, fat-soluble vitamins (vitamins 
A, D, E and K), folate, vitamin B12, and minerals such as copper and iron. 
 
1.1.3  Purification, transformation, and clearance 
The liver eliminates harmful substances from the blood to maintain homeostasis and 
protect the body against ingested toxins. It is capable of metabolizing or modifying 
toxins into less harmful compounds. These toxic substances include poisons, 
ammonia and bilirubin. In addition, the liver metabolizes most hormones and drugs to 




1.2  Liver organogenesis 
In vertebrate models, the development of liver can be conceptualized in a series of 
stages that require intimate cooperation between cell adhesion and signaling events 
(Zaret, 2002; Gumbiner, 1996). Figure 1-1 depicts the sequence of events. During 
gastrulation, the endoderm forms a monolayer-thick sheet that covers the mesoderm 
and ectoderm of the embryo, which will eventually develop into liver, pancreas, lung, 
thyroid, and epithelial cells of the gastrointestinal system (Wells and Melton, 1999). 
Subsequent morphogenetic movements result in the patterning of the endoderm into 
broad domains along the anterior-posterior axis. The anterior endoderm then gains 
competence to generate the foregut. A combination of external positive inductive 
signals from the cardiogenic mesoderm and suppressive signals from the trunk 
mesoderm specifies a mass of cells in the ventral foregut endoderm to develop into a 
liver (Fukuda-Taira, 1981; Gualdi et al., 1996; Le Douarin, 1975). The hepatic 
endoderm epithelium thickens, proliferates, and migrates into the surrounding septum 
transversum mesenchyme to form the liver bud. Sustained epithelial/mesenchymal 
interactions promote cell propagation and morphogenesis as the embryonic liver 
matures. Remodelling of extracellular matrix (ECM) and formation of cell-cell and 
cell-ECM contacts accompany this event. The undifferentiated cells in the liver bud, 
known as hepatoblasts, are bi-potential, and have the ability to differentiate into either 
hepatocytes or biliary epithelial cells. The hepatocytes become polarized with three 
distinct membrane domains: sinusoidal (basal), lateral, and canalicular (apical). The 
basal membrane faces the sinusoids that contain blood. The lateral surface is 
associated with the adjacent hepatocyte. The apical domain lines the bile canaliculi 
that connect to bile ducts. Primitive endothelial cells residing near the hepatoblasts 




FIGURE 1-1 Organogenesis of liver. The liver development in mouse at four developmental stages; gastrula (far left), 4-8 
somite stage, isolated gut tubes at liver bud , and adult liver (far right). During gastrulation, the endoderm (yellow) is specified 
and patterned so that the anterior endoderm (pink) acquires the competence to form foregut lineages. Between 4-8 somite stages, 
a subset of the ventral foregut endoderm (arrows) is induced by the adjacent cardiogenic mesoderm (cm) to adopt a hepatic fate. 
The hepatic epithelium then invades the septum transversum mesenchyme (st) and proliferates to form the liver bud (lb), which 




Liver bud Proliferation 
Morphogenesis







contributing to the development of blood vessels in which hematopoietic cells later 
invade. 
 
1.3  Liver architecture 
1.3.1  The liver is composed of acinar units 
The liver is arranged into lobules that can be described as a collection of acini which 
are the basic subunits of liver structure. Each liver acinus is a small three-dimensional 
mass of hepatocytes supplied by the terminal branches of the portal vein and hepatic 
artery, and drained by the terminal branches of the hepatic vein (Figure 1-2). It can be 
divided into 3 zones that are anatomically related to the liver's blood supply and 
drainage. The blood enters zone one first, and then passes through the second and 
third zones before leaving the liver. The hepatocytes at zone 1 closest to the portal 
areas receive the most oxygen and nutrients as well as a high concentration of 
enzymes important for oxidative energy metabolism, amino acid metabolism, 
ureagenesis, gluconeogenesis, cholesterol synthesis, and bile formation. The 
hepatocytes in zone 3 closest to the central veins receive the least oxygen and 
nutrients and are predominantly involved in glycogen synthesis, glycolysis, 
liponeogenesis, ketogenesis, xenobiotic metabolism, and glutamine formation. 
Therefore, the hepatocytes in zone 3 are more specialized in the detoxification 
processes and the biotransformation of drugs. Zone 2 is the intermediate area of 








FIGURE 1-2 The acinus is divided into zones that correspond to distance from the arterial blood supply. Hepatocytes









1.3.2 The liver has a unique dual blood supply, but a single venous 
drainage system 
The liver receives a dual blood supply. The hepatic portal vein contributes about 70-
80% of the liver’s blood supply while the hepatic artery provides the remaining 20-
30%. The hepatic artery supplies the liver with blood from the heart that is rich in 
oxygen and the portal vein carries nutrient-rich blood from the gastrointestinal tract. 
Blood from both the portal vein and the hepatic artery branch eventually converge 
together as they enter the sinusoids in the liver. The sinusoids flow into the central 
veins, coalesce into hepatic vein, and subsequently leave the liver to join the inferior 
vena cava. 
 
1.3.3  Major cell types in liver 
The liver cells are made up of parenchymal and non-parenchymal cells. As shown in 
Table 1-1, hepatocytes are the main parenchymal cells which constitute 80% of all 
liver cells, while the non-parenchymal cells consisting of sinusoidal endothelial cells, 
stellate cells, kupffer cells, pit cells, and biliary cells constitute the remaining 20-25%.  
 
TABLE 1-1 Cell types in liver (modified from http://hupo.org/files/hlpp/ 
HLPP_Summary_030930.pdf) 
 Parenchyma Non-Parenchyma 
Cell type Hepatocytes Endothelial, Ito, Kupffer, Pit, Biliary 
 






Fraction of Non-parenchymal cells 
Endothelial:    70% 
Ito:                  10% 
Kupffer:          20% 
Pit:                    1% 






1.3.3.1  Parenchymal cells 
1.3.3.1.1 Hepatocytes 
Hepatocytes are the functional units of the liver and they perform the majority of  
liver functions. The prominent intracellular golgi system and rough endoplasmic 
reticulum in hepatocytes enable the cells to synthesize and secrete large amounts of 
proteins into the blood. These cells are also involved in protein storage; 
transformation of carbohydrates; synthesis of cholesterol, bile salts and phospholipids; 
as well as detoxification, modification, and excretion of exogenous and endogenous 
substances. The hepatocytes also form and secrete bile. 
 
Hepatocytes are arranged in one-cell thick hepatic plates that anastomose with one 
another (Figure 1-3). The cells are polygonal in shape and separate the tiny 
canalicular lumen containing bile from the sinusoid containing blood. The basal 
domains of the hepatocytes are in contact with ECM components in the space of Disse 
which separates the hepatocytes from the cells of the hepatic sinusoids.  
 
1.3.3.2  Non-parenchymal cells 
1.3.3.2.1  Sinusoidal endothelial cells  
The sinusoidal endothelial cells form a fenestrated monolayer that separates 
hepatocytes from the passing blood (Figure 1-3). They serve as sieve-like plates that 
permit ready exchange of plasma solutes between the blood and hepatocytes. Unique 
from other endothelial cells, the sinusoidal endothelial cells lack basement 
















1.3.3.2.2   Kupffer cells   
Kupffer cells are associated with the endothelial cells within the lumen of the 
sinusoids (Figure 1-3) and function as resident macrophages that phagocytize 
particulates and unwanted materials (e.g. bacteria, virus particles, fibrin-fibrinogen 
complexes, damaged erythrocytes, and immune complexes) from the circulation. In 
addition, they modulate the immune response through the release of mediators and 
cytotoxic agents. 
 
1.3.3.2.3 Ito/Stellate cells 
Ito/Stellate cells are fat-storing cells found between the sinusoidal endothelial cells 
and hepatocytes in the perisinusoidal space of Disse (Figure 1-3; Wake, 1980). They 
are involved in vitamin A metabolism and are responsible for the storage of 80-90% 
of the vitamin A in the liver in the form of lipid droplets (Hendriks et al., 1985). In 
addition, these cells are the main source of ECM macromolecules such as collagen 
and ECM-degrading enzymes (Arthur, 2000). Furthermore, they are involved in 
releasing an array of proinflammatory cytokines and recruiting leukocytes. Therefore, 
upon liver damage, the ito cells may contribute to host defense, inflammation, and 
ultimately to fibrogenesis and the development of liver cirrhosis (Weiler-Normann 
and Rehermann, 2004).  
 
1.3.3.2.4   Pit cells 
Pit cells are large, mobile, granular lymphocytes that are found in the sinusoids and 
often adhere to the endothelial cells (Figure 1-3). Pseudopodia of pit cells can 
penetrate the pores of the endothelial cells to enter the space of Disse. They function 




1.3.4   Extracellular space 
The extracellular space is made up of perisinusoidal space of Disse, hepatic sinusoids, 
bile canaliculi and ECM (Stamatoglou and Hughes, 1994). 
 
1.3.4.1   Space of Disse 
The perisinusoidal space of Disse is located in between the sinusoidal domain of 
hepatocyte plasma membrane and the endothelial cells that form the walls of the 
hepatic sinusoids (Figure 1-3). This location where substances released from 
sinusoidal blood and hepatocytes mix is filled with microvilli of the hepatocytes. 
These microvilli will absorb nutrients, oxygen, and toxins from the blood as well as 
release their endocrine secretory products e.g. albumin and prothrombin to the blood 
via this perisinusoidal space. The space of Disse also functions as the liver's lymphatic 
capillary. Lymph flows through the space of Disse to collect in small lymphatic 
capillaries in the portal spaces. 
 
1.3.4.2   Hepatic sinusoids 
Hepatic sinusoids carry the blood flow from the portal vein and the hepatic artery. 
The four major sinusoidal cells are endothelial cells, kupffer cells, ito cells and pit 
cells (Figure 1-3; Wisse et al., 1996). Sinusoids lack basement membrane and are 
composed of a discontinuous layer of fenestrated endothelial cells. The pores can 
undergo dynamic changes in size to permit most solutes, except for large complexes, 
to gain access to the intervening space of Disse. Blood from the hepatic sinusoids 






1.3.4.3   Biliary canaliculi 
The bile canaliculi are formed by the invaginations between the adjacent plasma 
membranes of two hepatocytes (Figure 1-3). Bile secreted by the hepatocytes 
accumulates in canaliculi, drains via collecting ducts to small liver ducts, and finally 
to the hepatic duct that joins the cystic duct from the gallbladder to form the common 
bile duct. 
 
1.3.4.4   Extracellular matrix 
The ECM components occupy the space of Disse and are composed of type IV 
collagen, laminin, fibronectin and heparan sulfate proteoglycans (Hughes and 
Stamatoglou, 1987).  
 
1.4  Liver and immunity 
The liver plays a vital role in fighting infections. Functionally, the liver is involved in 
the uptake, metabolism, detoxification, and storage of a plethora of macromolecules. 
Therefore, it is constantly exposed to pathogens and foreign antigens. To protect 
against infectious pathogens, the liver must be able to induce immune responses 
against these harmful substances while maintain tolerance against food antigens. A 
large population of resident and migratory cells that patrol the liver including kupffer 
cells, pit cells, dendritic cells, and lymphocytes carry out these immunological 
functions. Lymphocytes, for example, in the presence of the appropriate migratory 
signals, have the capacity to bind to adhesion molecules expressed on the endothelial 
cells and migrate across the endothelial cells to the tissue where they follow a 
chemotactic gradient towards the site of inflammation (Weiler-Normann and 




1.5  Liver regeneration 
The liver possesses the extraordinary ability to heal after severe liver injury or 
resection. This process involves controlled hyperplasia (cell division). In a normal 
healthy adult liver, the vast majority of hepatocytes are in a state of growth arrest at 
the G0 phase of the cell cycle, during which cells do not proliferate. It has been shown 
that partial hepatectomy stimulates ~95% of quiescent hepatocytes within the acinar 
architecture of the intact liver to rapidly re-enter the cell cycle. Liver regeneration is 
regulated by endogenous growth factors and cytokines such as tumor necrosis factor-
alpha (TNF-α), interleukin-6, and hepatocyte growth factor. These growth factors and 
cytokines activate signaling cascades and thus induce the hepatocytes to undergo 
several cycles of proliferation and to migrate in order to restore the lost parenchymal 
liver mass and functional capacity. Restorative growth ceases when the organ reaches 
the appropriate size (Michalopoulos and DeFrances, 1997; Fausto et al., 1995). 
 
In severe or chronic liver injury caused by hepatitis viral infections or alcohol when 
hepatocytes undergo recurring necrosis, subsequent chronic inflammation, 
regeneration and liver matrix remodeling will result in a fibrotic liver that may 
eventually progress to cirrhosis. The increased turnover rate of hepatocytes is likely to 
promote genetic alterations, and through clonal expansion of cells with a proliferation 












1.6  Hepatocellular carcinoma  
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer in 
adults. It arises from hepatocytes, the major cell type in liver. HCC accounts for 80-
90% of primary liver cancers and is one of the most frequent malignancies worldwide. 
The major risk factors for the development of HCC have been identified and 
characterized. Despite few advances in the treatment of HCC, the overall prognosis 
remains poor. The pitfalls in the conventional diagnosis, staging, and treatment of 
HCC urged scientists to unravel the yet unclear mechanism of HCC pathogenesis in 
the hope of developing new effective interventions to improve the management of 
HCC. 
 
1.6.1  Global epidemiology of HCC 
Hepatocellular carcinoma is one of the most frequent malignancies in the world, and 
its incidence varies greatly with geographic location, ethnic background and gender. 
In year 2000, an estimated 564,000 new cases of HCC and almost as many deaths 
were recorded (Ferlay et al., 2001; Parkin et al., 2001). As shown in Table 1-2, the 
geographic areas with a very high incidence (>20 cases/100,000 inhabitants) of HCC 
include Asia and sub-Saharan Africa. Southern Europe, Argentina and Switzerland 
are at intermediate risk (5-10 cases/100,000). Geographic areas of lowest incidence 
(<5 cases/100,000) include Western Europe and the United States (Thomas, 2005). In 
most parts of the world, the incidence of HCC is escalating. The incidence of HCC in 
the United States increased from 1.4/100,000 per year from 1976-1980 to 2.4/100,000 
per year from 1991-1995 (El-Serag and Mason, 1999). Similar increases have also 








     
            TABLE 1-2 Epidemiology of HCC (Thomas, 2005) 
Region Incidence in Males 
(occurrences/100,000 
population)  
Incidence in Females 
(occurrences/100,000 
population)  
Major Risk Factors 
Asia, Sub-Saharan Africa 
Japan 





















1997; Deuffic et al., 1998). In all regions studied, men are at greater risk of 
developing liver cancer than women. The average sex ratio for age-adjusted incidence 
rates (men/women) for year 2000 is 2.72 (Bosch and Ribes, 2002). 
 
The incidence of HCC also varies with ethnic groups and regions of origin of patients 
who have migrated. For example, in the United States during 1988-1992, lower rates 
are found in the non-Hispanic white population, when compared to American Indians, 
Blacks and Hispanics. The highest incidence rates for North Americans have been 
observed among immigrants from high-risk countries, especially Chinese, Filipinos, 
Japanese and Koreans, although their United States-born descendents showed lower 
incidence rates (Bosch and Ribes, 2002). In addition, a local study showed that HCC 
is the third most frequent cancer among Singapore males, with more than 1,500 cases 
diagnosed between 1998 and 2002. HCC is more common in men than women, with a 
sex ratio of 3.4:1. The Chinese has the highest rates of HCC compared to Malays and 
Indians (Seow et al., 2004). 
 
The majority of HCC patients do not survive for more than a year. The five-year 
relative survival rate in Europe (1985-1989) and North America (1983-1988) was 5% 
and 6%, respectively. There are no differences in the survival rates of male and 
female HCC patients. In Europe, the relative survival rate is higher in young patients 
(<45 years of age), which is attributed to curative treatment such as liver 





1.6.2  Risk factors of HCC 
The etiological factors responsible for development of HCC are now well recognized. 
The geographical variability in HCC incidence rates strongly suggests differences in 
exposure to the risk factors. The major viral and environmental agents linked to HCC 
consisting of chronic infections with hepatits B virus and hepatitis C virus, and 
aflatoxin B1 exposure account for about 80% of HCC (Bosch et al., 1999). 
Furthermore, synergistic interplays between HBV and aflatoxin B1 (Kew, 2003), and 
between HCV and alcohol (Regev and Jeffers, 1999) have been documented to 
amplify the risk of HCC development. However, it is still debated whether various 
chemical agents are responsible for the recently observed increase in HCC incidences. 
 
1.6.2.1  Hepatitis B virus infection 
Hepatitis B virus (HBV) infection is the major cause of HCC in developing countries 
like China and Africa. Chronic HBV infection causes liver cirrhosis, and in most 
patients with HBV-associated HCC, the tumor occurs in the setting of cirrhosis. 
Therefore, with increasing duration or severity of chronic HBV infection, the chance 
of infected hepatocytes undergoing malignant transformation becomes progressively 
higher. 
 
It has been implicated that the oncogenic mechanism of HBV is attributed to the 
integration of HBV DNA into the host cell genome (Shafritz et al., 1981), leading to 
undesired activation of multiple cellular genes as well as chromosomal instability. 
Specifically, integration of the hepatitis B virus X protein (HBX), a known causative 
agent in the formation of HCC, has been shown to stimulate cytoplasmic signal 




al., 2000), AP-1 (Benn et al., 1996), Ras/Raf/MAPK (Benn and Schneider, 1994), 
JAK/STAT (Lee and Yun, 1998) and Wnt (Cha et al., 2004), thus promoting cell 
survival and initiating HCC development. 
 
Indirectly, persistent HBV infection provokes an immune response and chronic 
inflammation with continuous regeneration and fibrosis that may eventually lead to 
cirrhosis. It is known that HBV-infected liver cells can be killed by cytotoxic T cells 
or injured by the cytokines from other specific cells. To retain adequate liver function, 
the liver cells must regenerate to replace the loss. These two events of immune-
mediated injuries and reactive hyperplasia of the infected liver cells roll into a vicious 
cycle, and inevitably increase the risk of mutations which can be passed on to the 
daughter cells during proliferation (Thomas, 2005).  
 
In addition, synergistic interactions between HBV and other factors such as aflatoxin 
B1 exposure, hepatitis D virus (HDV), HCV, and alcohol have been found to promote 
HCC development (Yeh et al., 1989; Sheen et al., 1994; Okuda and Ohnishi, 1994). 
 
1.6.2.2  Hepatitis C virus infection 
Hepatitis C virus (HCV) infection is also associated with the development of HCC, 
particularly in developed countries e.g. Japan and United States, and it contributes to 
the increasing rise in HCC incidence in these countries (Kiyosawa and Tanaka, 2002; 
Hassan et al., 2002). HCV is a plus-strand RNA virus that is not reverse transcribed 
into cDNA, and therefore is not integrated into the host genome. The mechanism in 
which HCV causes HCC is still obscure. Persistent infection with HCV will result in 




HCV in the pathogenesis of HCC. However, it is possible for an individual who has 
HCV but no cirrhosis to develop HCC. Growing evidence show that the core protein 
of HCV is capable of modulating cell proliferation by impeding apoptosis through 
interacting with Bax (Chung et al., 2003), interfering the normal function of tumor 
suppressors p53 and p21waf1/cip1 (Ray et al., 1997; Kao et al., 2004; Oka et al., 2003), 
or upregulating cell growth-related genes, particularly Wnt-1 (Fukutomi et al., 2005). 
An observation that 15% of alcoholics with cirrhosis were infected with low level of 
HCV implicates that alcoholics may have increased exposure and acquisition of 
persistent HCV infection for unknown reasons (von Weizsacker et al., 1995). 
 
1.6.2.3  Aflatoxin B1 
Aflatoxin B1 has long been linked to the development of HCC because areas with a 
large dietary consumption of this toxin coincide with areas with a high incidence of 
HCC. Aflatoxin B1 is a toxic product of a mold called Aspergillus flavus, which is 
found in food that has been stored in a hot and humid environment. In most countries 
of sub-Saharan Africa, and some parts of China and Southeast Asia, food including 
peanuts, rice, soybeans, corn, and wheat is often highly contaminated with aflatoxin 
B1. Experimental studies have shown clearly that aflatoxin B1 is capable of causing 
HCC (Busby and Wogan, 1984). It is a very potent mutagen that is metabolized by the 
liver into the exo-8,9-epoxide intermediate. This epoxide binds selectively to guanine 
in DNA to form the N7 guanine adduct (Groopman et al., 1985), inducing a specific 
genetic change that is associated with development of HCC. The frequent base change 
is a specific G to T mutation at the third position of codon 249 of the tumor 




coexposures to aflatoxin B1 and HBV infection has been documented to increase the 
risk of HCC by 3-fold (Sun et al., 1999). 
 
1.6.2.4  Alcohol 
Chronic alcohol abuse is well known to cause liver injury and development of 
cirrhosis. Furthermore, the risk of developing cirrhosis among individuals who drink 
heavily is significantly increased by the coexistence of chronic HBV (Ohnishi et al., 
1982) or HCV (Regev and Jeffers, 1999) infection. Alcohol has not been 
experimentally proven to initiate liver carcinogenesis. Rather, it has been proposed 
that alcohol may cause chronic liver damage and cirrhosis which may eventually lead 
to HCC formation. 
 
1.6.2.5  Oral contraceptives 
Studies have revealed that sex steroids (either estrogen or testosterone) may be 
associated with the development of liver adenomas (Dourakis and Tolis, 1998). These 
are benign liver tumors that occasionally developed into HCC in women who are 
long-term users of oral contraceptives. In countries like Europe and the United States, 
where oral contraceptives are widely used and HBV infection is rare, many cases of 
HCC developing in women appear to correlate with the long term use of oral 
contraceptives (Deugnier and Turlin, 1997). 
 
1.6.2.6  Hemochromatosis 
HCC will develop in up to 30% of patients with hereditary hemochromatosis (Powell 
et al., 1980). Hereditary hemochromatosis is a disorder characterized by the 




who develop cirrhosis with their hemochromatosis. Once cirrhosis is established, 
effective removal of excess iron will not decrease the risk of developing HCC. 
 
1.6.2.7  Cirrhosis 
Individuals with liver cirrhosis are prone to developing HCC. Approximately 70-90% 
of HCC develop on a background of cirrhosis (Okuda et al., 1982). In addition to the 
conditions described above (HBV, HCV, alcohol, and hemochromatosis), alpha 1 
anti-trypsin deficiency, a hereditary condition that can cause emphysema and 
cirrhosis, may also result in HCC development (Eriksson et al., 1986). Liver cancer is 
also strongly associated with hereditary tyrosinemia, a childhood biochemical 
abnormality that leads to early cirrhosis (Dehner et al., 1989). 
 
1.6.3   Diagnosis of HCC 
HCC is generally asymptomatic and is often advanced at the time of diagnosis when 
no curative therapy can be offered. Early diagnosis of small asymptomatic HCC, 
especially in high-risk patients, may prolong the survival of patients. Several 
diagnostic tools have been routinely employed for early detection of HCC.  
 
1.6.3.1  Blood tests 
Blood tests may be used to assess liver function. The most commonly used 
biochemical blood test is alpha-fetoprotein (AFP), a protein normally produced by 
immature liver cells in the fetus. At birth, infants have relatively high levels of AFP, 
which declines to normal adult levels by one year old. In addition, pregnant women 
carrying babies with neural tube defects may have high levels of AFP. Serum AFP 




500 ng/ml is very indicative of HCC, and this level rapidly normalizes after HCC 
resection. The AFP test, however, cannot be used solely to confirm a diagnosis of 
liver cancer, because chronic hepatitis or cirrhosis can also produce high AFP levels.  
 
1.6.3.2  Imaging studies 
Imaging is used regularly to detect HCC in high-risk patients together with serum 
AFP assay, as well as to provide information relating to the location of the tumor, size 
of the tumor, the number of tumors, and whether the tumor has involved major blood 
vessels locally or spread outside of the liver. Ultrasound allows screening of the entire 
liver in a noninvasive manner and successfully visualizes HCC nodules as small as 
0.5 cm in diameter. Computed tomography (CT) scan is useful in the diagnosis of 
HCC in patients when ultrasound is unsuccessful because of intervening bones, air in 
the intestine or lung, dense post-operative scar tissue, or presence of fatty tissue. It 
can detect HCC, differentiate various focal lesions of the liver, evaluate the location 
and extension of these lesions, and determine the size of tumors post-treatment. 
Magnetic resonance imaging (MRI) can provide very high-resolution, multiplanar 
images of the body. MRI is very useful for the differential diagnosis of hepatic masses 
and is slightly more sensitive than CT in detecting smaller tumors. Imaging studies, 
however, cannot tell the difference between a hepatoma and other abnormal nodules 
in the liver. A sample of liver tissue for biopsy is needed to make the definitive 
diagnosis of primary liver cancer. CT or ultrasound can be used to guide the doctor in 





1.6.3.3  Liver biopsy 
Liver biopsy is considered to provide the definite diagnosis of liver cancer. This 
technique can target tumors as small as 0.5 cm in diameter. A sample of the liver or 
tissue fluid is removed with a fine needle, which is directed through the skin of the 
abdomen into the liver under ultrasound or CT guidance; and the biopsy is examined 
under a microscope for cancer cells. One drawback is that post biopsy bleeding can be 
fatal in cirrhotic patients with low platelet count, prolonged clotting time, and 
enlarged blood vessels that are under high pressure (portal hypertension). 
 
1.6.4   Staging of HCC 
Clinical staging of HCC provides guides to the prediction of prognosis and directs the 
appropriate therapeutic interventions. It is also an essential research tool that enables 
comparison between groups in clinical trials and between different studies. The ideal 
staging system should incorporate parameters related to: (a) the stage, aggressiveness, 
and growth rate of the tumor; (b) the general health of the patient; (c) the liver 
function of the patient; and (d) the specific therapeutic intervention. Staging systems 
that omit some factors or use only one factor will have a poor survival predictive 
power. Several staging systems have been proposed. However, there is no worldwide 
consensus on which is the most accurate. 
 
The most commonly used classifications for HCC are the Child-Pugh score (Pugh et 
al., 1973), Okuda classification (Okuda et al., 1985), and the tumor node metastasis 
(TNM) classification (UICC, 1997). However, each has its own limitations for 
classifying patients. The Child-Pugh score is used for identification of HCC 




without considering tumor-related parameters including tumor size, number, location, 
vascular invasion and metastasis. Conversely, the tumor node metastasis (TNM) 
classification uses tumor-related parameters without addressing the functional 
capacity of the liver. TNM classification is widely used in HCC candidates for 
treatment by hepatic resection or transplantation. The Okuda classification provides a 
tool for the combined assessment of both tumor characteristics and liver function 
factors including ascites, serum albumin and serum total bilirubin. Nevertheless, it 
lacks a means of assessing important tumor factors, such as whether the tumor is 
unifocal, multifocal or diffuse; or whether there is vascular invasion; all of which 
have important prognostic significance. 
 
New staging paradigms have recently been proposed. The Barcelona clinic liver 
cancer (BCLC) staging classification was developed to address the weakness of the 
TNM and Okuda staging systems (Llovet et al., 1999). It considers tumor stage, liver 
functional status, physical status, and cancer-related symptoms; divides patients into 
early, intermediate, advanced, and end-stage categories (Sala et al., 2005); and links 
the prognostic prediction to a treatment algorithm. The Cancer of the Liver Italian 
Program (CLIP) score combines the Child-Pugh classification with tumor size, portal 
vein invasion, and AFP; and predicts patient survival more precisely than the Okuda 
staging system. However, it failed to identify patients at early stages of disease and is 
only applicable to patients with advanced tumors (Colombo and Sangiovanni, 2004). 
The Japan Integrated Staging (JIS) score includes TNM stage and Child-Pugh grade. 
BCLC scoring system has been demonstrated to provide a better prediction of 




JIS was shown to perform better than the CLIP scoring system in selecting the best 
prognostic patient group (Kudo et al., 2003). 
 
1.6.5    Treatment of HCC 
HCC is extremely difficult to manage. Early-stage HCC is typically clinically silent, 
and HCC is often advanced at the time of diagnosis. Without treatment, HCC is 
relentlessly progressive, with a 5-year survival rate of less than 5% (Clark et al., 
2005). The current management of HCC is confusing due to the lack of consensus 
guidelines for treatment as well as the lack of well-designed, randomized clinical 
trials comparing various treatment modalities. The treatment options are dictated by 
the stage of HCC, patient's clinical state, and hepatic function. Surgical interventions 
including tumor resection and liver transplantation offer the best curative treatment. 
Surgery is limited to patients whose tumors are less than 5 cm and confined to the 
liver, with no invasion of the blood vessels, cirrhosis, jaundice, or ascites. Therefore, 
only a few patients are eligible for surgery. All the other therapies to treat 
unresectable HCC are palliative and are with limitations. A downstaging of 
unresectable HCC can be achieved by trans-arterial chemoembolization (TACE) or 
percutaneous ablation using ethanol injection, cryosurgery and radiofrequency. 
Percutaneous treatments provide good results but are unable to achieve response rates 
and outcomes comparable to those of surgical treatments. Small solitary tumors of 
less than 2 cm can be completely ablated using the percutaneous approach. However, 
when tumor size exceeds 3 cm and/or the number of nodules is greater than 3, the 
success rate of treatment is significantly decreased. In patients with well-preserved 
liver function and large/multifocal asymptomatic tumors without vascular invasion, 




improvement in survival is chemoembolization. There is no proven chemotherapy 
regimen for HCC. Systemic administration of chemotherapeutic agents such as 5-
fluorouracil (5-FU), doxorubicin and cisplatin has resulted in unsatisfactory clinical 
effects (Clark et al., 2005; Blum, 2005; Carr, 2004; Beaugrand et al., 2005; Llovet, 
2005). Long-term survival of patients is uncommon because of the frequent 
recurrence after tumor resection, metastasis, or the development of new primary 
tumors. Overall, despite advances made in the diagnosis and management of HCC, 
the prognosis of HCC remains poor, especially in patients with unfavorable tumor 
characteristics. Therefore, elucidation of the genetic and molecular pathogenesis of 
HCC may provide new insights that will lead to the development of innovative 
strategies to manage HCC. 
 
1.6.5.1  Liver resection 
The goal of liver resection is to completely remove the tumor and the appropriate 
surrounding liver tissue. This option is limited to patients with one or two small (3 cm 
or less) tumors and excellent liver function without cirrhosis. Hence, very few patients 
with HCC are suitable to undergo liver resection. When a portion of a normal liver is 
removed, the remaining liver can regenerate to the original size within one to two 
weeks. 
 
The greatest concern about resection is that the patient may develop liver failure after 
operation. Liver failure can occur if the remaining portion of the liver is inadequate to 
provide the necessary support for life. Even in carefully selected patients, about 10% 
of them are expected to die shortly post-surgery, usually as a result of liver failure. 




to 40% (Cha et al., 2003). However, the probability of recurrence of HCC elsewhere 
in the liver of these patients is high. 
 
1.6.5.2  Liver transplantation 
Liver transplantation is the best option for patients with tumors that are less than 5 cm 
in size and with signs of liver failure. Patients with small tumors less than 3 cm and 
no involvement of blood vessels have a less than 15% risk of recurrent HCC after 
transplant (Befeler and Di Bisceglie, 2002). Conversely, patients with tumors greater 
than 5 cm or with involvement of blood vessels have a very high risk of recurrence. 
 
Biopsy or aspiration of HCC should be avoided in patients considering liver 
transplantation to prevent seeding cancer cells from the tumor by the needle into the 
liver along the needle track. Patients who have undergone liver transplantation must 
consume powerful anti-rejection medications to prevent the patient’s immune system 
from rejecting the new liver. However, the suppressed immune system may allow new 
foci of cancer to develop. 
 
1.6.5.3  Percutaneous ethanol injection 
Ethanol treatment of HCC involves injecting pure ethanol percutaneously into the 
tumor using a very thin needle with the help of ultrasound or CT visual guidance. 
Alcohol induces tumor destruction by dehydrating the cytoplasm of tumor cells, 
leading to the denaturation of cellular protein structures and eventually necrosis. It 





Percutaneous ethanol injection (PEI) therapy is only suitable for patients with fewer 
than three tumors, each less than 3-4 cm in size or with small single lesions less than  
5 cm. In addition, patients with HCC undergoing alcohol injection should have no 
signs of chronic liver failure, such as ascites or jaundice. 
 
The most common side effect of PEI therapy is leakage of alcohol onto the surface of 
the liver and into the abdominal cavity, causing pain and fever. It is important that the 
blood vessels and/or bile ducts that are adjacent to a tumor are clearly identified to 
protect them from accidental injection or injury during the procedure. 
 
1.6.5.4  Cryosurgery 
Cryosurgery is performed percutaneously laparoscopically, or more frequently, during 
an open surgey. The procedure involves freezing the tumor to stop its growth. 
Cryoprobes are placed directly into the liver and supercooled liquid nitrogen/argon 
gas circulates through the probes to freeze the tumor and a half inch margin of normal 
liver, resulting in cellular crystallization, cell shrinkage and membrane damage. 
Thawing leads to further damage as the area becomes hypotonic and smaller crystals 
re-crystallize to larger ones. Usually, two freeze-thaw cycles are carried out in each 
area because it has been shown to produce a better destruction of cancer cells than a 
single cycle. The tumor is not removed and the destroyed cancer cells are left in the 
body. Cryosurgery may have fewer side effects than other types of treatments, and is 







1.6.5.5  Radiofrequency ablation  
Radiofrequency ablation (RFA) is a thermal technique that can be performed 
percutaneously laparoscopically or during an open surgery. An electrode is placed in 
the tumor and radio waves in the frequency range of 200 to 1200 MHz cause cells to 
oscillate. The heat generated ranging from 80°C to 110°C causes necrosis of tumor 
cells. The ideal size of an HCC tumor for RFA is less than 3 cm. Tumors that are 
larger may require more than one session. It is relatively safe and can be performed 
minimally invasively. 
 
1.6.5.6  Trans-arterial chemoembolization  
Liver tumors receive its blood supply exclusively from the hepatic artery unlike 
normal liver parenchyma that is supplied by both portal vein and hepatic artery. A 
downstaging of unresectable HCC can be achieved by trans-arterial 
chemoembolization (TACE). In this technique, small branches of the tumor hepatic 
artery are directly infused with chemotherapeutic agents before occlusion 
(embolization) with various types of materials, such as gelatin sponge or small metal 
coils. The tumor is thus exposed to high concentrations of anticancer agents which are 
confined locally since they are not carried away by the bloodstream. Furthermore, the 
technique deprives the tumor of blood supply, leading to tissue ischemic and 
eventually necrosis. 
 
1.6.5.7   Chemotherapy 
Chemotherapy of HCC is administered either intra-arterially or systemically. The 
most commonly used chemotherapeutic agents for HCC are doxorubicin, 5-FU, 




established chemotherapeutic regimens have produced a responsive effect against 
HCC. The failure of treatment could be caused by suboptimal dosages of anticancer 
drugs, tumor heterogeneity, or overexpression of the multidrug resistance gene (Lai et 
al., 1990; Dexter and Leith, 1986; Huang et al., 1992). 
 
1.7    Role of cell adhesion in liver  
Cell adhesion in the liver plays a key role in liver organogenesis, immunity, 
regeneration, and HCC development. Cell adhesion is mediated by a large and 
complex number of cell adhesion molecules (CAMs) expressed on the cell surface 
that interact with one another in a spatially and temporally regulated manner. 
Intracellularly, the cytosolic domains of the CAMs associate with cytoplasmic plaque 
or peripheral membrane proteins. The cytoplasmic plaque proteins function as a 
bridge that links the adhesion systems to the cytoskeleton. Therefore, apart from 
linking cells to each other or to components of the ECM, an exciting concept that has 
emerged from recent cell biological research is that CAMs function also as receptors 
critical in modulating signal transduction (Gumbiner, 1996). Such interactions are 
vital for the regulation of a wide variety of cellular processes such as cell 
morphology, cell adhesion and cell motility; and are regulated by signaling complexes 
formed by the assembly of transmembrane and cytosolic proteins and membrane 
lipids (Engqvist-Goldstein and Drubin, 2003; Sechi and Wehland, 2000; Fais and 
Malorni, 2003). 
 
1.7.1  Classification of cell adhesion molecules 
Cell adhesion molecules are responsible for adhesion of cells to neighbouring cells or 




structural and functional features, these transmembrane receptors can be generally 
classified into six families: the immunoglobulin superfamily, integrins, cadherins, 
selectins, hyaluronate receptors, and receptor protein tyrosine phosphatases.  
 
1.7.1.1  Immunoglobulin superfamily  
Immunoglobulin superfamily (IgSF) is one of the largest protein families in 
vertebrates and is widely expressed in a variety of cell types, including neurons, 
leukocytes, epithelial and endothelial cells. The IgSF CAMs are calcium-independent 
transmembrane glycoproteins that function by both homophilic and heterophilic 
interactions. The heterogeneous expression pattern of these CAMs implicates their 
involvement in diverse biological processes including immune responses, 
morphogenesis, brain development, tissue sorting, and development of the vascular 
network. 
 
A typical IgSF CAM comprises of an extracellular domain which contains several Ig-
like intrachain disulfide-bonded loops with conserved cysteine residues, a 
transmembrane domain, and a cytoplasmic domain. In addition, the ectodomain of 
these CAMs may possess several fibronectin type III (FNIII) repeats. Members of the 
IgSF include intercellular adhesion molecule (ICAM), vascular-cell adhesion 
molecule (VCAM), platelet-endothelial-cell adhesion molecule (PECAM), and 
neural-cell adhesion molecule (NCAM). Typically, they are capable of binding to 





1.7.1.2  Integrins 
Integrins are cell-surface receptors important for a variety of cellular functions such as 
growth, development, immune response, and wound repair. They constitute non-
covalently bound heterodimer composed of an α and a β subunit. To date, there are at 
least 22 integrin heterodimers composed of different combinations of the 17 
α subunits and 8 β subunits. However, not every α and β combination exist. Although 
both subunits contribute to adhesion, the binding specificity of integrins primarily 
depends on the extracellular portion of the α-subunit. The β1 and β3 subfamilies 
predominantly mediate cell-matrix interactions, while members of the β2 classes are 
cell-cell adhesion molecules. Integrins are capable of mediating cell-ECM and cell-
cell interactions (Hynes, 1987). They can bind to a variety of ECM proteins including 
fibronectin, fibrinogen, laminin, collagen, vitronectin and von Willenbrand factor 
(Haas and Plow, 1994). They can also associate with adhesion molecules like E-
cadherin (Cepek et al., 1994) and those belonging to the IgSF such as ICAM and 
VCAM. 
 
Integrins are constitutively expressed, but require activation in order to bind their 
ligand to mediate cell-cell or cell-ECM adhesion. Moreover, integrins play a critical 
role in signal transduction, exhibiting both "inside-out" and "outside-in" signaling 
properties. An example of "inside-out" signaling occurs when a cell stimulus, for 
example, triggering of the TCR/CD3 complex on an immune cell, stimulates the 
integrin receptor, leading to its activation via binding to its ligand. "Inside-out" 
signaling may also downregulate integrin activation. "Outside-in" signaling occurs 
after the integrin receptor binds its ligand and a signal is transmitted from the integrin 




cell survival is focal adhesion kinase (FAK), which is activated following integrin 
ligation (Nojima et al., 1995). It activates downstream survival pathways, such as 
PI3K, Akt and MAPK/ERK. The affinity of integrins for their ligands is not very 
strong. Therefore, to form effective cell-cell or cell-ECM contacts in response to 
specific stimuli, integrins that are usually diffusely distributed over the cell surface 
cluster at focal contacts (Jockusch et al., 1995). Their combined affinities create a 
region with sufficient adhesive capacity to adhere to the ECM. This allows cells to 
bind to a large number of matrix molecules simultaneously while still maintaining 
their ability to explore their environment. Integrins are capable of binding divalent 
cations such as calcium, magnesium and manganese. Magnesium and manganese 
alone are capable of activating integrins. 
 
1.7.1.3  Cadherins 
Cadherins are transmembrane glycoproteins that function as regulators of a wide 
variety of processes such as cell adhesion, cell sorting, cell survival, morphogenesis, 
formation of intercellular junctions, maintenance of tissue integrity, and 
tumorigenesis. They have been divided into several families, including type I 
(classical) and type II cadherins which are linked to the actin cytoskeleton; 
protocadherins which are expressed primarily in the central nervous system; and 
desmosomal cadherins (desmocollins and desmogleins) which are attached to 
intermediate filaments (Buxton et al., 1993). 
 
Classical cadherins include E-, N-, and VE-cadherins. They were named after the 
tissues in which they were first identified (epithelial, neural, and vascular endothelial 




single-pass transmembrane proteins that mediate Ca2+-dependent homophilic cell-cell 
adhesion. Interestingly, there is evidence suggesting a heterophilic interaction 
between E-cadherin and αEβ7 integrin on the surface of lymphocytes (Cepek et al., 
1994). Structurally, cadherins consist of five tandem repeated extracellular domains 
that are important for promoting cell-cell adhesion, a membrane-spanning segment, 
and a cytoplasmic region which links to the cytoskeleton via adaptor proteins like 
catenins and plakoglobin. These adhesion molecules depend on calcium for their 
adhesive function and prevention of protease digestion (Grunwald et al., 1981; Hyafil 
et al., 1981; Takeichi, 1977, 1988; Yoshida and Takeichi, 1982). In addition, they 
have been implicated to participate in transducing extracellular signals to the 
cytoplasm of cells (Juliano, 2002). 
 
1.7.1.4  Selectins 
Selectins are important for leukocyte recruitment. They are expressed on the surface 
of leukocytes, endothelial cells and platelets; and are responsible for mediating 
transient attachment and rolling of leukocytes along the activated vascular 
endothelium before development of tight adhesion and subsequent extravasation of 
leukocytes at sites of vascular injury and inflammation. The selectins have 
characteristic extracellular regions composed of an amino-terminal calcium-
dependent lectin domain that binds a carbohydrate ligand, an epidermal growth factor-
like domain, and two to nine short consensus repeat units similiar to domains found in 
complement binding proteins. There are three major groups of selectins: the L-
selectins, which are homing receptors for specific adhesion of lymphocytes to 
endothelial cells of peripheral lymph nodes; the E-selectins, which are important 




stimulation by inflammatory mediators; and P-selectins, which are expressed in 
endothelial cells and contained in storage granules of platelets whereby they are 
released during clotting and at times of platelet activation. P-selectins also mediate 
adhesion between leukocytes and platelets (Tedder et al., 1995; Freemont and 
Hoyland, 1996). 
 
1.7.1.5  Hyaluronate receptors 
Hyaluronan (also called hyaluronic acid or hyaluronate) is a naturally occurring 
member of the glycosaminoglycan family and is a linear polysaccharide composed of 
alternating glucuronic acid and N-acetylglucosamine [β1,4-GlcUA-β1,3-GlcNAc-]n. 
Hyaluronan is an important structural element localized in ECM, at cell surface, and 
inside cells. It is ubiquitously distributed in the tissues of vertebrates, but is 
particularly abundant in extracellular matrices surrounding proliferating and migrating 
cells (Toole, 2002). Cells can bind to hyaluronan through cell surface hyaluronate 
receptor proteins such as CD44 and receptor for hyaluronate mediated motility 
(RHAMM; Peach et al., 1993; Yang et al., 1993), thereby modulating important 
biological processes including angiogenesis (Savani et al., 2001), proliferation (Mast 
et al., 1993; Wiig et al., 1996), cell motility (Chen et al., 1989), wound healing 
(Nishida et al., 1991), and cell adhesion (Klein et al., 1996). 
 
1.7.1.6  Receptor protein tyrosine phosphatases  
Receptor protein tyrosine phosphatases (RPTPs) form a subfamily of the classical 
protein tyrosine phosphatases (PTPs) and are involved in intracellular signaling and 
regulation of cell-cell adhesion (Tonks, 1993; Beckman and Bork, 1993). While the 




to enzymes within the cytoplasm to influence intracellular events, the RPTPs have 
catalytic active cytosolic tyrosine phosphatase domains that have the potential to 
modulate intracellular signaling events directly (Freemont, 1998). Their extracellular 
domains are highly variable but many contain motifs of cell adhesion molecules that 
may function as ligand binding domains. Some RPTPs such as PTP-µ have CAM-like 
extracellular segments that mediate homophilic cell-cell interaction and associate with 
cadherins in vivo (Brady-Kalnay et al., 1998). On the other hand, PTP-α localizes to 
focal adhesions (Lammers et al., 2000). Cells overexpressing PTP-α show increased 
cell-substratum association (Harder et al., 1998), while cells deficient of PTP-α 
exhibit defective spreading on fibronectin (Su et al., 1999). 
 
1.7.2  Types of cell adhesions 
Cell adhesion mediated by cell-cell and cell-matrix interactions is necessary for tissue 
organization and integrity. Specialized cell-cell and cell-matrix junctions exist with 
their particular constellation of multiprotein complexes that connect the cytoskeleton 
to the plasma membrane to form stable adhesive contacts between cells and their 
extracellular environment. 
 
1.7.2.1  Cell-cell adhesions 
Cells are linked to one another via four distinct junctional complexes – gap junctions, 
adherens junctions, desmosomes, and tight junctions. Both tight junctions and 
adherens junctions are linked to the actin cytoskeleton while desmosomes are linked 






1.7.2.1.1 Gap junctions 
Gap junctions form cylindrical hydrophilic channels that serve as direct connections 
between adjacent cells, allowing passive diffusion of the ions and small molecules in 
aqueous intercellular channels (connexons) between the cytoplasm of the 
neighbouring cells (Kumar and Gilula, 1996). Most cells in normal tissues including 
epithelial cells, endothelial cells, and the cells of cardiac and smooth muscle 
communicate via these junctions. Each gap junction is composed of an assembly of 6 
transmembrane proteins called connexins. 
 
1.7.2.1.2 Adherens junctions 
Adherens junctions, also known as zonula adherens, are made up of calcium-
dependent homophilic interactions between the extracellular domains of cadherins of 
adjoining cells and are critical for the establishment and maintenance of epithelial 
layers. Actin filaments are associated with the intracellular domains of cadherins via 
catenins located at the undercoat of the adherens junctions (Geiger and Ginsberg, 
1991). E-cadherin, for example, is capable of binding to β-catenin or to γ-catenin 
(plakoglobin), which in turn, forms the linkage to α-catenin that connects to the actin 
cytoskeleton (Yamada and Geiger, 1997). 
 
1.7.2.1.3 Desmosomes 
Desmosomes are specialized form of adherens junctions that connect intermediate 
filaments such as cytokeratins along the lateral membrane of adjacent epithelial cells 
(Schwarz et al., 1990). Desmosomal structures consist of members of the cadherin 




intermediate filament network by several cytoplasmic plaque proteins including the 
desmoplakins and plakoglobin (Garrod, 1993; Gumbiner, 1996). 
 
1.7.2.1.4 Tight junctions 
Tight junctions are the most apical intercellular junctions that create physiological 
semi-permeable barriers between epithelial or endothelial cells. They maintain distinct 
tissue compartments and prevent protein and lipid diffusion between the apical and 
basolateral plasma membrane domains (Tsukita et al., 1999). The proteins involved in 
the formation of tight junctions include integral membrane proteins such as occludin, 
claudin and junctional adhesion molecule (JAM); and peripheral membrane proteins 
such as membrane-associated guanylate kinase (MAGUK) homologue proteins 
including ZO-1, -2, -3, cingulin, symplekin, 19B1 and AF-6 (Furuse et al., 1993, 
1998; Martin-Padura et al., 1998; Stevenson et al., 1986; Jesaitis and Goodenough, 
1994; Haskins et al., 1998; Citi et al., 1988). The cytoplasmic domains of claudin and 
occludin interact with F-actin-binding scaffold molecules, ZO-1, -2, and -3 (Furuse et 
al., 1994; Jesaitis and Goodenough, 1994; Fanning et al., 1998; Itoh et al., 1999; 
Haskins et al., 1998); and JAM interacts with ZO-1 (Martin-Padura et al., 1998; 
Bazzoni et al., 2000; Ebnet et al., 2000). 
 
1.7.2.2  Cell-matrix adhesions 
Cell-matrix adhesion occurs at specialized zones on the cell surface, where activated 
or clustered adhesion molecules bind to their respective ECM ligands and link 
intracellularly to the cytoskeleton. The importance of such adhesion is underscored by 
the existence of many genetic and autoimmune diseases caused by the perturbations 




adhesion junctions can be classified into focal adhesions, hemidesmosomes, and 
dystroglycan complex. 
 
1.7.2.2.1 Focal adhesions 
Focal adhesions are the structural connections between the ECM and the actin 
cytoskeleton. At these sites, integrins make linkage with the actin cytoskeleton via 
vinculin, talin, α-actinin, paxillin, FAK, and Src family tyrosine kinases to control the 
assembly of focal adhesion (Beckerle et al., 1987; Jaken et al., 1989; Burridge and 
Chrzanowska-Wodnicka, 1996; Kaplan et al., 1994; Zamir and Geiger, 2001). 
 
1.7.2.2.2 Hemidesmosomes 
Hemidesmosomes are multimeric protein complexes that attach epithelial cells to their 
underlying matrix and serve as cell surface anchorage sites for the keratin 
intermediate filaments. They are morphologically similar to desmosomes and are 
localized to the basal surface of some epithelial cell types (Garrod, 1993). Keratin 
bundles associate to the hemidesmosome plaques via protein complexes consisting of 
α6β4 integrin and BP180 that act as transmembrane proteins, and BP230 and plectin 
that act as cytoplasmic plaque proteins (Green and Jones, 1996). 
 
1.7.2.2.3 Dystroglycan complex 
Dystroglycan is the transmembrane adhesive receptor that links the ECM protein 
laminin to the actin cytoskeleton via its cytoplasmic plaque protein dystrophin. 





1.7.3  Cell migration 
Cell-matrix adhesion is a key aspect of cell migration. Cell migration is a highly 
integrated multistep process that choreographs a wide variety of biological 
phenomena. Cell movement is important for morphogenesis throughout 
embryogenesis. Migration remains prominent during adulthood, in normal physiology 
involving tissue repair, regeneration and immune surveillance, as well as in pathology 
involving angiogenesis, tumor invasion and metastasis (Ridley et al., 2003). 
 
1.7.3.1  The migration cycle 
In general, cell migration can be conceptualized as a cyclic process of attachment and 
detachment of cell across the substratum (Lauffenburger and Horwitz, 1996). In 
response to migratory stimulus, the cell becomes polarized by intracellular actin 
cytoskeleton polymerization, coordinately elongates its protrusions in the direction of 
migration, and forms new adhesions at the leading edge. These protrusions can be 
either lamellipodia or filopodia (Welch and Mullins, 2002). Both lamellipodia and 
filopodia are stabilized by adhering to the ECM or adjacent cells via transmembrane 
adhesion receptors, which are linked intracellularly to the actin cytoskeleton, either 
directly or indirectly via cytoplasmic adaptors. Such adhesions serve as traction sites 
for migration as the cell moves forward over them; and disassembly of these adhesive 
contacts and cytoskeletal-dependent retraction at the tailing edge then lead to the 
detachment of cell at its rear end (Webb et al., 2002; Ridley et al., 2003). 
 
1.7.3.2  Organization of actin cytoskeleton during cell motility 
The actin cytoskeleton is a highly dynamic filamentous network composed of 




undergoes extensive remodeling in motile cells fundamental for the regulation of cell 
adhesion, cell spreading and motility (Mitchison and Cramer, 1996). The ability of a 
eukaryotic cell to move is largely driven by the assembly of actin filaments from the 
actin monomers near the plasma membrane and by the myosin motors that contract 
the filaments. Cellular actin exists in two forms: as monomeric globular actin (G-
actin) and as filamentous actin (F-actin). In the physiological ATP-magnesium ion-
rich cell medium, ATP-G-actin and F-actin are maintained in a dynamic steady state. 
In response to actin polymerization, the flux of ATP-G-actin binding onto the barbed, 
fast growing ends of the filaments at the leading edge is balanced by the dissociation 
flux of hydrolyzed actin subunits from the pointed (slower growing) ends of the 
filaments at the rear. This cycle is continuous and is known as treadmilling. F-actin is 
generally organized into filopodia ⎯ finger-like protrusions that contain a backbone 
of actin filaments organized into long parallel bundles in the direction of the 
protrusion; lamellipodia ⎯ branching “dendritic” network of actin filaments that 
dominates the leading edges of motile cells; and stress fibers ⎯ bundles of actin 
filaments that traverse the cell and are linked to the ECM through focal adhesions. 
 
1.7.3.3  Roles of Rho GTPases in migration 
Precise actin cytoskeleton remodeling entails tight spatial and temporal regulation of 
actin filament assembly and organization. The activity of the actin cytoskeleton is 
regulated by proteins of the Rho family GTPases, of which Rho, Rac, and Cdc42 are 
best characterized. Cdc42 activation maintains cell polarity and induces filopodium 
extension (Kozma et al., 1995; Nobes and Hall, 1995). Activation of Rac results in the 
formation of lamellipodia and membrane ruffles (Ridley et al., 1992). Rho activation 




actomyosin bundles into stress fibres (Ridley and Hall, 1992). Stimulation of Cdc42 
and Rac suppresses Rho activity. Most Rho GTPases alternate between an active 
GTP-bound form and inactive GDP-bound form. Their activity is regulated by 
guanine nucleotide exchange factors (GEFs), which promote the exchange of GDP for 
GTP, and GTPase-activating proteins (GAPs) that promote GTP hydrolysis. In their 
active GTP-bound conformation, these central regulatory proteins act on the 
membrane and recruit a hierarchical cascade of effector proteins, mainly either 
kinases such as p21-associated kinase (PAK), Rho-associated kinase (ROCK), 
phosphatidylinositol phosphate (PIP) 5-kinase, or scaffolding proteins such as 
Wiskott-Aldrich Syndrome protein (WASP), IRSp53 and mDIA. These effector 
proteins then trigger actin-based cell motility via activating diverse signaling 
pathways that promote nucleating, capping, severing, or crosslinking of actin 
filaments (Ahmadian et al., 2002; Hall, 1994; Lauffenburger and Horwitz, 1996). 
 
1.7.3.4  Receptor-mediated adhesion during migration 
For migration to occur, a protrusion must form and be stabilized by adhering to the 
environment. Many different adhesion receptors have been reported to participate in 
migration, and integrins are the established class of migration-promoting receptors. 
Integrins are capable of mediating adhesion of cells to ECM proteins. Activated 
integrins cluster in the membrane to form organized adhesive contacts called focal 
adhesions. Focal adhesions recruit scaffolding and signaling components to link the 
ECM proteins to the actin cytoskeleton as well as to transduce signals important for 
cell movement (Lauffenburger and Horwitz, 1996; Klemke et al., 1997; Liu et al., 
2000; Sastry and Burridge, 2000). These adhesions are stationary at the leading edge 




retracting at the rear of the cell (Ballestrem et al., 2001). Recently, it has also become 
apparent that integrin-mediated adhesion to the ECM regulates the activity of the Rho 
family of small GTP-binding proteins (GTPases; Barry et al., 1997; Clark et al., 1998; 
Price et al., 1998). 
 
Apart from integrins, members of the IgSF have also been documented to regulate 
migration. For example, studies have shown that nectins are capable of binding to 
afadin, an F-actin binding protein, through their cytoplasmic domains (Takahashi et 
al., 1999). These Ig-like adhesion molecules can induce the activation of Cdc42 and 
Rac protein (Kawakatsu et al., 2002) and associate with Par-3, a cell polarity protein 
(Takekuni et al., 2003). Through these activities, nectins modulate a range of cellular 
functions consisting of cell adhesion, migration and polarization. It is also known that 
another Ig-like adhesion molecule, L1, stimulates neuronal cell migration (Lindner et 
al., 1983), and neurite fasciculation and outgrowth (Lagenaur and Lemmon, 1987). 
Furthermore, Ll has been found to be a heterophilic ligand for members of the 
integrin family (Felding-Habermann et al., 1997). 
 
1.7.3.5  Lipid rafts 
For more than 30 years, the Singer-Nicolson fluid mosaic concept has provided the 
foundation of the structure of cell membrane. This model proposes that both lipids 
and membrane proteins are free to diffuse in the membrane bilayer, implying a 
random organization of proteins in lipid (Singer and Nicolson, 1972). More recently, 
however, it has been recognized that the biological membranes exhibit a much more 
complex structure. Within the disordered fluid membrane bilayer, cellular lipids can 




cholesterol. These microdomains have the ability to recruit and spatially organize 
signaling molecules as well as regulate actin dynamics and recruit cytoskeletal 
associated proteins important for many signaling processes. They are most abundant 
on the plasma membrane, but can also be found in intracellular membranes such as 
the endocytotic pathway or the Golgi apparatus (Gkantiragas et al., 2001).  
 
The unique lipid composition of these sphingolipid-cholesterol microdomains makes 
them resistant to solubilization by cold non-ionic detergents such as Triton X-100. In 
addition, because of their high lipid content, these detergent-resistant membrane 
(DRM) complexes float to low density in sucrose gradients and are rich in raft-
associated proteins and lipids. Therefore, sucrose density gradient ultracentrifugation 
provides a simple means for isolating and identifying raft components (Brown and 
Rose, 1992; Brown and London, 1998). 
 
DRMs can be subdivided into lipid rafts and its derivative, caveolae. Lipid rafts are 
presumed to be too small and transient to be directly identified in cells, while 
caveolae are microscopically identifiable flask-shaped invaginations of the plasma 
membrane. Caveolae are distinguished from lipid rafts by the presence of cholesterol-
binding caveolin-1 that stabilizes the invaginated structure of caveolae. Both lipid 
rafts and caveolae are enriched with proteins such as glycosylphosphatidylinositol 
(GPI)-anchored proteins; doubly acylated proteins including tyrosine kinases of the 
Src family; and transmembrane receptors and adhesion molecules. Because these 
microdomains can move laterally and cluster into larger patches, they have been 
implicated to function as platforms for the attachment and trafficking of proteins in 




complexes to facilitate signal transduction (Niethammer et al., 2002; Roepstorff et al., 
2002; Quest et al., 2004; Simons and Toomre, 2000; Simons and Ikonen, 1997). 
 
1.8  Molecular pathogenesis of HCC 
The development of HCC, or hepatocarcinogenesis, is a multifactorial and multistage 
process. It represents a sequential process that drives hepatocytes to develop a 
malignant phenotype. In the background of chronic hepatitis infection and/or 
cirrhosis, the inflamed liver displays accelerated proliferation of hepatocytes, 
resulting in the development of a more aberrant monoclonal population of hepatocytes 
in focal lesions, and subsequently giving rise to hyperplastic hepatocyte nodules 
which escalate to dysplastic nodules that evolve into HCC (Thorgeirsson and 
Grisham, 2002). 
 
Distortion of normal tissue morphology is one of the early events observed in the 
development of HCC and other malignant tumors. Since cell adhesion molecules play 
a crucial role in the formation and maintenance of normal tissue architecture as well 
as regulation of cellular interactions, it is extremely relevant for these molecules to 
contribute to cancer development. There are accumulating evidence suggesting that 
perturbations of cell adhesion molecules accompany tumor progression, invasion, and 
subsequent metastatic dissemination of tumor cells (Stamatoglou and Hughes, 1994). 
 
Although the major risk factors of HCC are now well recognized, knowledge on the 
molecular interactions implicated in HCC development is still fragmentary. Genomic 
alterations, regarded as the hallmark of cancers, are commonly identified during the  




deletions, rearrangements, aneuploidy, gene amplifications, and mutations) and 
epigenetic aberrations (including DNA hypermethylation) combine to inactivate 
tumor suppressor genes and activate proto-oncogenes, resulting in cells with 
autonomous growth potential. The extensive genetic heterogeneity of HCC suggests 
that multiple and different regulatory pathways may participate in the genesis of 
subsets of hepatocellular neoplasms. Therefore, functional characterization of both 
known and unknown genes altered in HCC is essential to refine our understanding on 
the molecular pathogenesis of this malignancy. 
 
1.8.1  Tumor suppressor genes 
Tumor suppressor genes usually encode proteins that regulate cell division, DNA 
repair, apoptosis and cell adhesion; and they function in important cellular processes 
involved in growth, development, and cell signaling pathways. Loss of function of 
these genes results in uncontrolled cell growth. Knudson's two-hit paradigm of tumor 
suppressor genes (Knudson et al., 1975) stipulates that mutation of both alleles of a 
tumor suppressor gene is required to initiate tumorigenesis. Because tumor suppressor 
genes are recessive, inheritance of an inactivated allele (the first hit) of a suppressor 
gene from a parent increases the risk of cancer development. It is only after the 
successive loss of the second allele (the second hit) that then triggers deregulated 
proliferation. However, this concept is now being challenged by increasing evidences 
showing that disruption of a single allele of a tumor suppressor gene may be sufficient 
to exert a cellular phenotype, and, as a consequence, lead to tumor formation without 
having to inactivate the second allele. This conjecture is supported by 
haploinsufficient genes that require the inactivation of only one allele (Largaespada, 




1.8.1.1  Rb 
Expression of tumor suppressor genes involved in cell cycle progression is important 
for effective inhibition of cell division. The Rb gene encodes a cell cycle regulator 
protein critical for the regulation of G1-S phase transition of the cell cycle. 
Hypophosphorylated Rb can form complexes with and repress transcriptional 
activation of E2F transcription factors, blocking cell cycle progression during G1 
phase. In response to mitogenic signaling, cyclin-dependent kinase (Cdk) 4/6 
complexes with cyclin D and phosphorylates Rb. This inactivated form of Rb then 
dissociates from E2F, allowing E2F to promote transcription of major S phase genes 
such as cyclin E, driving cell cycle progression. The cyclin D-Cdk4/6 complexes are, 
in turn, antagonized by Cdk inhibitors e.g. p16INK4A and p15INK4B. 
 
Aberrant expression of Rb is a common and significant event in human 
hepatocarcinogenesis. The Rb gene can be inactivated by different modes, including 
loss of heterozygosity (LOH; Walker et al., 1991; Murakami et al., 1991), mutations, 
loss of TGF-β responsiveness, and alterations of Rb regulatory proteins such as 
p16INK4A, p15INK4B, cyclin D, or Cdk4/6 (Hanahan and Weinberg, 2000; Levy et al., 
2002). In HCC, mutations of Rb are observed in about 15% of the cases (Kekule et 
al., 1993). LOH at chromosome 13q14 where Rb is located is frequently observed in 
HCC, with a prevalence of 30% (Kekule et al., 1993). In addition, it has been shown 
that Rb expression is significantly decreased in 30-50% of tumors (Hsia et al., 1994). 
Silencing of p16 by promoter methylation is a major mode of inhibiting Rb (Levy et 
al., 2002). The discovery of a new oncogene, termed gankyrin, defines a novel 
pathway leading to Rb inactivation. Gankyrin is a six ankyrin-repeat protein 




It is capable of binding to Rb and promoting degradation by the ubiquitin-proteosome 
pathway (Higashitsuji et al., 2000). An amplification of cyclins has been observed in 
about 10-13% of HCC cases (Zhang et al., 1993). Cyclin D is a known oncogene and 
a key regulator of cell cycle progression. The upregulated expression of the cyclin D 
gene has been associated with aggressive forms of human HCC (Nishida et al., 1994). 
It has recently been shown in a transgenic mouse model that overexpression of cyclin 
D is sufficient to initiate hepatocarcinogenesis (Deane et al., 2001). The transduction 
of antisense cyclin D arrests tumor growth in a xenograft hepatoma model (Ivorra et 
al., 2003). 
 
1.8.1.2  p53 
The p53 tumor suppressor gene is known as the guardian of the genome and is 
responsible for regulating cell cycle checkpoints and apoptosis (Levine, 1997). In 
response to DNA damage induced by chemicals, irradiation or other causes, wildtype 
p53 is activated. p53 induces cell cycle arrest by activating p21waf1/cip1 protein which 
suppresses Cdk2, thereby arresting transition from G1 phase to S phase to permit 
DNA repair. DNA repair is carried out by a DNA mismatch repair gene, 
predominantly hMLH1 and hMLH2. In HCC, both hMLH1 and hMLH2 are rarely 
altered or mutated, implying that defective DNA mismatch repair does not play a 
significant role in HCC development (Macdonald et al., 1998; Salvucci et al., 1999). 
In the event when the damaged DNA is beyond repair, a normal cell undergoes self-
destruction through apoptosis. p53 is capable of inducing the transcription of several 
key players of apoptosis, including apoptosis protease-activating factor-1 (Apaf-1; 
Moroni et al., 2001) and Bax protein (Miyashita and Reed, 1995). Bax protein 




cascade is then activated and apoptosis takes place. Normally, MDM2 binds to p53 
preventing its expression and promoting p53 ubiquitination for proteasomal 
degradation. MDM2, however, can be sequestered by p14ARF, leading to the 
stabilization of p53 and promotion of cell growth arrest or apoptosis (Weber et al., 
2002). 
 
p53 is commonly mutated or inactivated in human cancers through LOH and missense 
mutations. These mutations occur mainly at the DNA binding domain of p53 
(Pavletich et al., 1993) that is critical for correct folding of the protein 
(Balagurumoorthy et al., 1995). Mutations of p53 are also associated with a prolonged 
half-life of the protein, which accumulates in the cell nuclei, suggesting that it has 
acquired an oncogenic gain of function. 
 
In HCC, mutations of p53 are common. LOH at chromosome 17p13 has been 
observed in 25-60% of tumors, and p53 mutations were found in about 28% of HCC 
worldwide (Levy et al., 2002). The frequency and type of mutations differ depending 
on geographic location and cause of the tumor. There is a strong correlation between 
p53 mutations, large tumor size, and poor differentiation state. HBV infection or the 
presence of HBV DNA in the tumor has been associated with the functional 
inactivation of p53. It has been shown that HBX can bind to p53 and block p53-
mediated transcriptional transactivation in vivo (Truant et al., 1995). Furthermore, 
HBX interferes with in vitro associations of p53 with transcription factors involved in 
nucleotide excision repair such as XPB (ERCC3) or XPD (Wang et al., 1994). These 
observations suggest that HBX is capable of disrupting the normal cellular 




HCC. It is now clear that the unique “hot spot” 249 missense mutation of p53 is the 
hallmark of dietary exposure to aflatoxin B1. In regions where aflatoxin exposure is 
rare, p53 mutations remain prevalent but occur at sites other than codon 249 
(Murakami et al., 1991; Nishida et al., 1993; Sheu et al., 1992). 
 
1.8.1.3  E-cadherin 
Several proteins involved in cell adhesion inhibit tumor dispersion, prevent loss of 
contact inhibition, and inhibit metastasis. E-cadherin is an adhesion molecule that 
functions as a potent tumor suppressor of epithelial tumor cell invasion and metastasis 
(Birchmeier and Behrens, 1994; Takeichi, 1993). The cytoplasmic domain of E-
cadherin interacts with α- and β-catenin molecules that establish an intracellular 
linkage with the actin cytoskeleton. This E-cadherin-catenin complex plays a crucial 
role in epithelial cell-cell adhesion for the maintenance of tissue architecture, 
migration and signal transduction. Consequently, perturbation in the expression or 
function of this complex disrupts the mediated intercellular adhesion and signaling, 
leading to tumor progression and metastasis. 
 
E-cadherin is commonly downregulated in poorly differentiated HCC (Endo et al., 
2000). While somatic mutations of E-cadherin have been described in poorly 
differentiated breast (Berx et al., 1995) and gastric cancers (Becker et al., 1994), E-
cadherin is rarely mutated in HCC. However, alterations of E-cadherin caused by 
LOH or hypermethylation are evident in HCC (Matsumura et al., 2001; Kanai et al., 
1997). Loss of E-cadherin activity has been associated with enhanced cell 




in mice result in lethality at a very early stage (Laure et al., 1994). Aberrant 
expression of β-catenin also contributes to the inhibition of E-cadherin.  
 
1.8.1.4  Transforming growth factor-β  
Transforming growth factor (TGF)-β is a multifunctional cytokine that functions as a 
potent growth inhibitor involved in cell proliferation (Wollenberg et al., 1987), 
cellular differentiation (Nagy et al., 1989), fibrogenesis (Gressner et al., 2002), and 
apoptosis in the liver (Gressner et al., 1997). TGF-β signaling pathway constitutes 
TGF-β Type I and Type II receptors which are serine-threonine kinases that signal 
through the Smad family of proteins. Binding of TGF-β to its cell surface receptor 
Type II leads to the phosphorylation of the Type I receptor. Activated TGF-β Type I 
receptor then activates cytoplasmic Smad2 and Smad3 by phosphorylation, allowing 
them to form a heteromeric complex with Smad4. This Smad complex can induce 
TGF-β responsive gene transcription after it is translocated to nucleus and bound to 
the specific target nuclear matrix site. Genetic alterations of the TGF-β pathway are 
mediated by mutations of the Smad2 and Smad4 genes, which occur in about 10% of 
HCC cases. Mutations of the TGF-β receptor II gene have been detected in patients 
with HCC and may also abrogate TGF-β signaling. 
 
1.8.2  Oncogenes 
Oncogenes are mutated forms of proto-oncogenes, which are the genes involved in 
promoting the differentiation and proliferation of normal cells. When a proto-
oncogene mutates into an oncogene, it becomes permanently "turned on" and results 




of oncogenes encode oncoproteins that function as signal transducers, apoptosis 
regulators, transcription factors, growth factors or their receptors.  
 
1.8.2.1  Ras 
The Ras family consists of 3 highly conserved genes, H-Ras, K-Ras and N-Ras. 
Localized in the inner plasma membrane, Ras proteins relay mitogenic and growth 
signals from growth factor receptors via multiple downstream effector pathways and 
thereby regulate important cellular processes such as differentiation, proliferation and 
apoptosis. They function as G-regulatory proteins, which act as molecular switches 
that alternate between inactive GDP-bound and active GTP-bound states. Upon 
ligand-stimulated activation of growth factor receptors, Ras becomes activated by 
exchanging GDP for GTP. In its GTP-bound state, the wildtype Ras stimulates its 
effector pathways such as the Raf/MAPK and PI3K/PKB pathways (Rebollo and 
Martínez-A, 1999). Elevated expression of Ras induced by hypomethylation (Shen et 
al., 1998) or point mutations (Pascale et al., 1993) has been implicated in HCC. The 
constitutively active GTP-bound Ras promotes hepatocarcinogenesis by incessantly 
triggering downstream effector pathways in the absence of extracellular stimuli. These 
signaling pathways, in turn, induce cell growth as well as cooperate with other 
oncogenes, such as c-myc, in oncogenesis (Born et al., 1994; Feitelson, 2005). 
 
1.8.2.2  c-myc 
c-myc encodes a transcription factor and has been implicated to regulate cell 
proliferation, differentiation, immortalization, transformation, angiogenesis and 
apoptosis (Amati et al., 1998; Oster et al., 2002). It induces G1-S progression through 




p21waf1/cip1 and p27Kip1 from binding to cyclin E-Cdk2. In addition, c-myc induces 
synthesis of cyclin D (Perez-Roger et al., 1999; Bouchard et al., 1999). 
 
In HCC, upregulation of c-myc and its gene product occurs by hypomethylation (Shen 
et al., 1998), point mutation (Pascale et al., 1993), or gene amplification (Abou-Elella 
et al., 1996). Transgenic animal models have shown that elevation of myc can induce 
HCC formation (Sandgren et al., 1989; Murakami et al., 1993; Wu et al., 2002). 
Conversely, inhibition of myc results in a loss of the carcinoma’s neoplastic 
properties (Simile et al., 2003). Furthermore, Shachaf et al. demonstrated that myc 
stimulates the malignant expansion of immature liver cells with stem cell features. 
Upon inactivation of myc, the tumors begin to differentiate into normal cellular 
lineages and tissue structures of liver, while retaining their latent potential to become 
cancerous again upon reactivation of myc (Shachaf et al., 2004). 
 
1.8.2.3  Transforming growth factor-α  
Transforming growth factor (TGF)-α is a potent mitogen for hepatocyte growth. It 
was found to be present at elevated levels in human HCC (Harada et al., 1999; Kira et 
al., 1997; Heinze et al., 1999), often in association with HBV infection (Jakubczak et 
al., 1997). Specifically, TGF-α is detected more frequently in patients whose adjacent 
non-tumorous livers have detectable HBV surface antigen and/or HBV core antigen 
than in those whose livers lack these viral proteins. It is still unclear if increased 
expression of this growth factor is mechanistically related to hepatocarcinogenesis or 
if it results from liver regeneration in response to chronic HBV infection since 




hepatitis and without HCC. TGF-α may promote tumor angiogenesis by upregulating 
vascular endothelial growth factor. 
 
1.8.2.4  β-catenin 
Apart from linking E-cadherin transmembrane receptors to the actin cytoskeleton 
(Aberle et al., 1996), β-catenin also plays an important role in the Wingless/Wnt 
signal transduction pathway during embryonic development. In the absence of Wnt 
signaling, β-catenin is localized at the plasma membrane in complex with E-cadherin 
and α-catenin at the sites of adherens junctions. Excess β-catenin is normally bound to 
axin and the adenomatous polyposis coli (APC) protein, phosphorylated at the N-
terminal serine/threonine residues by glycogen synthase kinase 3β (GSK3β), and 
subsequently targeted for ubiquitination and degradation in the 26S proteasome, thus 
reducing the level of cytosolic β-catenin (Rubinfeld et al., 1996; Kishida et al., 1998). 
The Wnt signal is stimulated when the Wnt ligand binds a frizzled (Fz)/low-density 
lipoprotein receptor related protein (LRP) complex and activates the cytoplasmic 
protein dishevelled (Dsh in Drosophila and Dvl in vertebrates). Dsh/Dvl stabilizes the 
cytosolic β-catenin by preventing GSK3β from phosphorylating β-catenin. The 
stabilized β-catenin will then translocate into the nucleus and binds members of the T-
cell factor (TCF)/Lymphoid enhancing factor (LEF) family of transcription factors 
(Behrens et al., 1996), leading to the transcriptional activation of Wnt-responsive 
genes. 
 
Mutations of the β-catenin gene, particularly at exon 3 which encodes 
serine/threonine phosphorylation residues for GSK3β, confer resistance to 




nuclear β-catenin (Miyoshi et al., 1998; Orford et al., 1997; Rubinfeld et al., 1996). It 
was reported that the nuclear accumulation of β-catenin mutants in HCC promotes 
tumor cell growth (Van Nhieu et al., 1999). Conversely, in non-tumorous livers, 
dysplastic lesions and cirrhotic nodules, β-catenin immunostaining is restricted to the 
plasma membrane. Furthermore, it was shown that cyclin D, which facilitates the 
inactivation of tumor suppressor Rb, is one of the target genes of the β-catenin/TCF 
complex (Shtutman et al., 1999) A significant correlation between β-catenin and 
cyclin D was detected in breast (Lin et al., 2000) and colon cancers (Tetsu and 
McCormick; 1999), and more recently, in HCC (Ueta et al., 2002). Somatic mutations 
of APC are rare in HCC, but biallelic inactivation of APC gene may contribute to the 
development of HCC in patients with familial adenomatous (Su et al., 2001). Axin is 
mutated in about 10% of HCC cases (Satoh et al., 2000), leading to an activation of 
the Wnt pathway. Loss of function of axin induces β-catenin accumulation in the 
nucleus. Tyrosine phosphorylation of β-catenin in v-Src- (Behrens et al., 1993) or 
Ras- (Kinch et al., 1995) transformed cells or in cells stimulated with epidermal 
growth factor (Hoschuetzky et al., 1994) induces disassembly of the E-cadherin-




CHAPTER 2 OBJECTIVES 
 
Hepatocellular carcinoma (HCC) is one of the most common malignancies 
worldwide, and its incidence is escalating. Extensive epidemiologic studies have 
identified multiple risk factors of HCC, including hepatitis viral infections, liver 
cirrhosis, and environmental carcinogens like aflatoxin B1. Differences in exposure to 
these risk factors contribute to the wide geographical variation in incidence, with the 
highest frequencies observed in the sub-Saharan Africa and Asia. HCC is generally 
asymptomatic and is often at the advanced stage when diagnosed. No curative therapy 
can be offered to these patients who are often presented with large and/or multi-focal 
HCC. Despite progresses made in the treatment of HCC, surgery remains as the most 
effective therapeutic modality. However, long-term survival is uncommon because of 
the propensity of HCC recurrence after surgery. Moreover, current methodologies for 
staging of HCC are still evolving and none is widely accepted. The limitations present 
in each staging system impede the selection of an optimal treatment strategy for the 
individual HCC patient. Furthermore, the lack of effective palliation to prolong the 
survival of patients contributes to the pitfalls of HCC management. All these 
difficulties in treating HCC resulted in the overall poor prognosis of the disease. 
Hence, there is an urgent need of developing accurate measures to determine the 
degree of the malignancy as well as to design new interventions for a more efficacious 
management of HCC. 
 
Identification of key molecular targets and pathways involved in the onset and 
progression of HCC may provide a rational basis for the development of new 




genetic mechanism leading to HCC has not yet been fully elucidated, it is well 
established that HCC arises because of a loss of equilibrium between the positive and 
negative regulators of cell growth, differentiation and cellular adhesion. Therefore, 
the long-term goal of this research is to unravel the genetic changes that contribute to 
HCC of different etiologies, and to understand the correlation between these changes 
and tumor progression. 
 
The groundwork was initiated by examining the differences in gene expression 
between a pair of HCC tumor and its surrounding non-tumorous liver tissues using the 
technique of suppression subtractive hybridization. With this approach, a total of 272 
differentially expressed transcripts of both known and unknown genes were 
identified. Among these genes, 142 genes (18 novel genes) were upregulated while 
130 genes (27 novel genes) were downregulated in the tumor. Subsequently, using 
RT-PCR to screen the expressions of all the novel genes against a panel of liver 
specimens, it was found that one transcript, designated as HEPN1, was frequently lost 
while the other, HEPT3, was frequently elevated in HCC patients. Intriguingly, the 
identification of HEPN1 led to the isolation of an uncharacterized gene, hepaCAM, 
containing the full-length cDNA of HEPN1 on its antisense strand in the 3’-
noncoding region. Therefore, this study aimed to clone the full-length cDNAs of these 
three novel genes and to characterize them by investigating their expressions and 








The principal objectives of this study include: 
1. Examination of HEPN1, hepaCAM and HEPT3 expression levels in HCC 
patients and human HCC cell lines, and in tissues and cell lines derived from 
different human tumor types; 
2. Isolation and cloning of the full-length cDNA sequences of HEPN1, 
hepaCAM and HEPT3; 
3. Sequence and structural analyses of HEPN1, hepaCAM and HEPT3; 
4. Biochemical analyses of hepaCAM protein; 




CHAPTER 3  MATERIALS AND METHODS 
 
3.1   Cell cultures 
3.1.1  Cell lines and culture conditions 
Twenty human cancer cell lines including Huh7 (HCC), C3A (HCC), HepG2 (HCC), 
Hep3B (HCC), SK-HEP1 (HCC), HT29 (colorectal cancer), Colo205 (colorectal 
cancer), HCT116 (colorectal cancer), Jurkat (leukaemia), HL60 (leukaemia), K562 
(leukaemia), NCI-H82 (lung cancer), NCI-H23 (lung cancer), NCI-H69 (lung cancer), 
NCI-H2066 (lung cancer), MCF7 (breast cancer), Hs683 (glioblastoma), SK-N-SH 
(neuroblastoma), HeLa (cervical cancer) and M14 (melanoma); a HeLa-contaminated 
immortalized non-tumor liver cell line Chang liver; and a mouse fibroblast cell line 
NIH3T3 were purchased from the American Type Culture Collection (Manassas, VA) 
and used in the study. All cells were maintained in an incubator at 37°C with 5% CO2 
humidified atmosphere in different culture media. 
 
Chang liver, C3A, HepG2, Hep3B, MCF7, Hs683, HeLa, M14, NCI-H2066 and 
NIH3T3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, 
Life Technologies, Gaithersburg, MD). 
 
HCT116 and HT29 cells were cultured in McCoy’s medium containing 10% FBS. 
 
SK-N-SH and SK-HEP1 cells were cultured in minimum essential medium (MEM; 





Huh7, Colo205, NCI-H82, NCI-H69, NCI-H23, Jurkat, K562 and HL60 cells were 
maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma) 
supplemented with 10% FBS. 
 
3.1.2  Passaging cells 
Cells were subcultured when they reached 80-100% confluence. The culture medium 
was removed and the cells were washed once with 1X PBS. To cells in T75 flasks, 2 
ml of 1X Trypsin/EDTA (Gibco BRL) was added and incubated at 37°C for 2-5 min 
or until the cells were detached. Approximately 5 ml of culture medium was added to 
the flask and the cells in clumps were dispersed by repeated pipetting. Five milliliters 
of cells were removed and fresh medium was added to the remaining cells in the flask 
to a final volume of 10 ml. If cells were to be counted, 50 µl of the cell suspension 
was mixed with 50 µl of 0.8 mM trypan blue in PBS on a piece of parafilm. The 
mixture was then applied to a haemocytometer and at least 100 cells were counted. 
The number of cells/ml was calculated using the following formula: 
 
Number of cells/ml = the average count per square of haemocytometer X the dilution 
factor X 104  
 
3.1.3  Storing cells 
Trypsinized cells were pelleted at 1,000 rpm for 5 min. The supernatant was discarded 
and the cells were resuspended in fresh freezing medium made up of 8% DMSO in 
culture medium containing 10% FBS. The concentration of cells should be about 2 X 




dispensed into each cryotube and stored at -80°C for overnight before transferring to 
liquid nitrogen for long-term storage. 
 
3.2  Liver tissue specimens 
Paired liver specimens from 23 patients (HCC together with its adjacent non-
tumorous liver tissue) and normal liver tissues were collected from the No. 3 Hospital 
of Chongqing in China. Each sample was snap-frozen and stored in liquid nitrogen 
before experiment. The final diagnosis of HCC was confirmed and classified by 
histological examination. 
 
3.3  Determination of nucleic acid concentration 
The concentration and purity of DNA and RNA were determined by measuring their 
optical density (OD) at 260 and 280 nm. The concentration of DNA or RNA in a 
diluted solution was calculated using the molar extinction coefficient (OD260 = 1 = 50 




X dilution factor X 50 µg/µl = Concentration of DNA µg/µl  
OD
260 
X dilution factor X 40 µg/µl = Concentration of RNA µg/µl  
 
The ratio OD260/OD280 was determined to estimate the purity of nucleic acids. Pure 
DNA or RNA has a ratio of 1.8-2.0. A ratio less than 1.8 indicates that there may be 
proteins and/or other UV (ultraviolet) absorbers in the sample. A ratio higher than 2.0 






3.4  Isolation of total RNA from cells or tissues 
Total RNA was prepared from either liver tissues or cultured cells using the RNeasy 
Kit (Qiagen, Hilden, Germany), and when necessary, contaminating DNA was 
digested on-column using the RNase-Free DNase Set (Qiagen). Tissues or cells were 
resuspended in 600 µl of β-mercaptoethanol-containing RLT buffer and homogenized 
by repeated pipetting or by passing through a 20-guage needle fitted to syringe. One 
volume of 70% ethanol was then added to the lysate and mixed. The mixture was 
applied to an RNeasy spin column with a 2-ml collection tube and centrifuged. The 
flow-through was discarded and 350 µl of buffer RW1 was pipetted into the spin 
column. After centrifugation, the spin column was transferred to a new 2-ml 
collection tube and washed twice with 500 µl of buffer RPE. The RNA was then 
eluted into a fresh collection tube from the spin column by adding 30 µl of RNase free 
water and centrifuging at 10,000 rpm for 1 min. Unless otherwise stated, all 
centrifugations were carried out at 10,000 rpm for 15 sec.  
 
Digestion of DNA could be carried out during RNA extraction. After immobilization 
of RNA on the spin column and washing with buffer RW1, DNase I mix containing 
10 µl (30 units) of DNase I stock solution and 70 µl of buffer RDD was added directly 
onto the spin column membrane and incubated at room temperature for 20 min. The 
reaction was terminated by the addition of 350 µl of buffer RW1 for 5 min. After 
centrifugation, the column was washed with buffer RPE as described above. 
 
To ensure the integrity of RNA, samples of the purified RNA were separated by gel 
electrophoresis using standard 1% agarose gels containing ethidium bromide as 




bands on the stained gel. In addition, the intensity of the 28S ribosomal RNA band 
should be approximately twice the amounts of the 18S RNA. 
 
3.5  Northern blot analysis 
Northern blot analysis is a standard method for detection and quantitation of mRNA 
levels; and is the preferred method for determining transcript size and for detecting 
alternatively spliced transcripts. Northern analysis was carried out with the DIG high 
prime DNA labeling and detection starter kit I (Roche, Basel, Switzerland). Solutions 
and gel apparatus were treated with 0.1% DEPC accordingly. 
 
3.5.1  Random primed labeling of probe 
The probe used in Northern analysis was non-isotopically labeled. An 893 bp HEPT3 
cDNA was synthesized by PCR using T3seq-f1 (5’ctactcgggaggctgaggcag3’) and 
T3seq-r1 (5’gtaacatctcctaggtaacag3’), electrophoresed, and purified from agarose gel. 
Five hundred nanograms of the cDNA template in a final volume of 16 µl was boiled 
for 10 min and rapidly chilled on ice. Four microliters of digoxigenin-11-dUTP 
(DIG)-high primer was then added to the denatured sample and incubated overnight at 
37°C. The reaction was terminated by adding 2 µl of 0.2 M EDTA pH 8.0 and heating 
the sample to 65°C for 10 min. The yield of the labeled probe was quantitated by 
spotting various dilutions of the probe on a positively charged nylon membrane 
(Hybond-XL; Amersham Pharmacia, Germany) and detecting DIG in the spots with 





3.5.2  Electrophoresis of RNA on denaturing formaldehyde/MOPS gel 
Forty micrograms of total RNA mixed with 2 volumes of freshly made loading buffer 
was denatured at 65°C for 10 min and chilled on ice until use. The sample was 
electrophoresed on a 1% formaldehyde/MOPS gel in 1X MOPS buffer at 40 V for 2-3 
hours or until the RNA was well-separated. The quality of the RNA after 
electrophoresis was assessed under UV light. 
 
3.5.3  Transferring RNA to nylon membrane 
The gel was soaked twice for 15 min in 20X SSC to remove formaldehyde. The RNA 
was transferred overnight from the gel to the nylon membrane using the transfer set-
up as shown in Figure 3-1. On the following day, the RNA was immobilized onto the 
membrane by UV crosslinking using a UV Stratalinker at 120 mJ. 
             
Weight (200-500g)
Glass plate
Stack of paper towels
Whatman 3 MM paper, dry
Nylon membrane
Agarose gel
Whatman 3 MM paper, soaked
Bridge resting in a reservoir of 20X SSC                              
FIGURE 3-1  Northern blot transfer by capillary action. 
 
3.5.4  Pre-hybridization, hybridization with probe and washing of blot 
The blot was placed in a roller bottle and blocked with 8 ml of DIG Easy Hyb buffer 
for 1 hour at 50°C. Towards the end of pre-hybridization, 50 ng of labeled probe was 




immediately cooled on ice prior to mixing with 8 ml of fresh prewarmed DIG Easy 
Hyb buffer. The pre-hybridization buffer was discarded and replaced with the probe-
containing DIG Easy Hyb buffer. After overnight incubation at 50°C, the blot was 
washed twice for 5 min in Low Stringency buffer at room temperature to remove the 
hybridization solution and unhybridized probe, followed by two 15-min washes with 
preheated High Stringency buffer at 60°C to remove partially hybridized molecules.  
 
3.5.5  Detection 
Detection was performed at room temperature. The membrane was incubated in 
Washing buffer followed by Blocking solution for 2 min and 30 min, respectively. 
Antibody solution was added to the membrane for 30 min and the membrane was 
washed twice for 15 min in Washing buffer. The membrane was then equilibrated for 
3 min in Detection buffer. Subsequently, CSPD was applied over the surface of the 
blot and incubated for 5 min prior to autoradiography. 
 
3.6  Dot blotting of Matched Tumor/Normal Expression Array 
The Matched Tumor/Normal Expression Array (Clontech, Palo Alto, CA, USA) is a 
nylon membrane dotted and immobilized with full-length cDNAs synthesized from 
human tumors and the corresponding normal tissues. Dot blotting was carried out 
according to the manufacturer’s instructions with modifications. A 550 bp probe of 
hepaCAM cDNA was generated by PCR using primers hCAM-F2 
(5’cgagatctccatcaccgacgacacc3’) and hCAM-R (5’cttccgttcctgctcaccacttcga3’) and 
then labeled with DIG (Roche) as described in Section 3.5.1. The probe was 
denatured with 150 µg of sheared salmon testis DNA (Sigma) and 50 µl of 20X SSC 




solution of ExpressHyb and heat-denatured sheared salmon testis DNA for 1 hour, the 
denatured probe mixed in fresh pre-hybridization solution was allowed to hybridize 
onto the array for overnight at 65°C. The array was washed at 65°C in prewarmed 
Wash solution 1 and then Wash solution 2 for 30 min each. A final 5-min wash in 2X 
SSC was performed before detection using the DIG detection system (Roche) as 
described in Section 3.5.5. The probe was stripped by boiling the membrane in 0.5% 
SDS solution for 10 min. A second hybridization with the provided human ubiquitin 
control cDNA probe was performed to normalize the relative gene expression. 
 
3.7  Semi-quantitative RT-PCR 
RT-PCR was performed to screen the mRNA expression of the gene of interest in 
HCC patients and in cell lines derived from various tumor types. RT-PCR reactions 
were prepared using the OneStep RT-PCR kit (Qiagen).  
 
TABLE 3-1 Primers for RT-PCR 











































TABLE 3-2 Semi-quantitative RT-PCR components 
Component Volume (µl) 
H2O 11 
5X 1-step RT-PCR buffer  5 
dNTP Mix (10 mM)  1 
Primer 1 (10 µM)   1.5 
Primer 2 (10 µM)  1.5 
DNase-treated RNA (50 ng/µl)                           4 
1-step RT-PCR Enzyme Mix    1 
  
Final volume 25 
Q solution was added into the reaction for amplifying template with high GC content. 
 
TABLE 3-3 Semi-quantitative RT-PCR conditions 
Reaction Temperature Time Cycles 
RT 50 or 55°C 
(55°C for GC-rich 
template) 
 
30 min 1 
 
Inactivation of RT 
 





















3.8  Real-time RT-PCR 
The expression level of gene transcript was quantitated by real-time RT-PCR using 
the LightCycler (Roche). Reactions were prepared in 20-µl volumes using the 
LightCycler RNA Amplification Kit SYBR Green I (Roche) in thin-walled glass 
capillaries. PCR primer pairs used for quantitative RT-PCR were those used in semi-
quantitative RT-PCR. The results were normalized and presented as percentage 





TABLE 3-4 Real-time RT-PCR components 
Component Volume (µl) 
H2O 6.2 
SYBR Green I 4 
MgCl2 solution 2.4 
Primer 1 (10 µM)   1 
Primer 2 (10 µM)  1 
DNase-treated RNA (50 ng/µl)                            5 
RT-PCR Enzyme Mix   0.4 
  
Final volume 20 
 
 
TABLE 3-5 Real-time RT-PCR conditions 
Reaction Temperature Time Cycles 
RT 55°C 10 min 1 
 
Inactivation of RT 
 






















3.9  Rapid amplification of cDNA ends 
The Normal Human Liver Marathon-Ready cDNA used in rapid amplification of 
cDNA ends (RACE) was purchased from Clontech. 
 
3.9.1  5’ RACE 
5’ RACE was performed on the Human Liver Marathon-Ready cDNA using the gene-
specific primers listed in Table 3-6 in combination with the provided adapter primer 
AP1 or nested adapter primer AP2 to amplify the 5’ portion of the HEPN1, hepaCAM 
and HEPT3 cDNAs. Advantage 2 PCR Enzyme System (Clontech) was used to set up 




depending on the Tm of the primers used. The amplified product was cloned in the 
pGEM-T vector (Promega, Madison, WI) and sequenced. 
 
TABLE 3-6 Gene-specific primers for 5’ RACE 
Primer name Sequence 
HEPN1: 
N1-RACE-R 



















TABLE 3-7 5’ RACE PCR components 
Component Volume (µl) 
H2O 36 
10X cDNA PCR Reaction buffer 5 
dNTP Mix (10 mM)  1 
Gene-specific primer (10 µM)    1 
AP1 or AP2 (10 µM)  1 
Human Liver Marathon-Ready cDNA                         5 
Advantage 2 Polymerase Mix (50X)   1 
  
Final volume 50 
Q solution was added into the reaction for amplifying template with high GC content. 
 
TABLE 3-8 Standard PCR conditions 
Reaction Temperature Time Cycles 
Initial Denaturation 
 

























TABLE 3-9 Touchdown PCR conditions (if gene-specific primer Tm >70°C) 
























4 min 20-25 
 
 
3.9.2  3’ RACE 
3’ RACE was performed on the Human Liver Marathon-Ready cDNA using the gene-
specific primers listed in Table 3-10 in combination with the provided adapter primer 
AP1 or nested adapter primer AP2 to amplify the 3’ portion of the HEPN1 and 
HEPT3 cDNAs. The PCR reaction set-up and PCR conditions used were as described 
in Section 3.9.1. The amplified product was cloned in the pGEM-T vector and 
sequenced. 
 
TABLE 3-10 Gene-specific primers for 3’ RACE 















3.10  Plasmid constructs 
The cDNA insert of a plasmid construct was generated by PCR using the respective 
pair of primers listed in Table 3-11. The PCR product was purified, digested with the 





TABLE 3-11 Primers for generating cDNA insert 
Construct 
name 




























































































































































































TABLE 3-12 PCR components for generating cDNA insert 
Component Volume (µl) 
H2O 36 
10X cDNA PCR Reaction buffer 5 
dNTP Mix (10 mM) 2 
Primer 1 (10 µM)   2 
Primer 2 (10 µM)  2 
Template (1 ng/µl)                2 
Advantage 2 Polymerase Mix (50X)                  1 
  
Final volume 50 
Q solution was added into the reaction for amplifying template with high GC content. 
 
TABLE 3-13 PCR conditions for generating cDNA insert 
Reaction Temperature Time Cycles 






















3.11  Preparation of CaCl2 competent E. coli cells 
E. coli strain JM109 frozen stock was streaked onto an LB agar plate and incubated 
overnight at 37°C. Following the protocol obtained from the Current Protocols in 




and cultured overnight at 37°C with shaking at 250 rpm. Two milliliters of bacterial 
culture was added into 200 ml of prewarmed LB medium and grown to an OD590 of 
0.375. The bacteria were aliquoted into four 50-ml prechilled, sterile polypropylene 
tubes and incubated on ice for 10 min. The cells were harvested by centrifugation 
without brake at 3,000 rpm for 7 min at 4°C. Each pellet was gently resuspended on 
ice in 10 ml of ice-cold CaCl2 solution followed by centrifugation at 2,500 rpm for 5 
min at 4°C. A second resuspension in 10 ml of ice-cold CaCl2 solution was carried 
out. The cells were incubated for 30 min on ice before centrifugation. Finally, each 
pellet was resuspended in 2 ml of ice-cold CaCl2 solution and dispensed in 100 µl-
aliquots into pre-chilled sterile 1.5-ml microcentrifuge tubes before storing at -80°C. 
 
3.12 Restriction endonuclease digestion of DNA 
Most restriction digestions were generally carried out in a final volume of 20 µl or  
50 µl containing the DNA, restriction enzyme/s, bovine serum albumin (BSA) and 
applicable buffer as supplied by Promega. The reactions were incubated for a 
minimum of 1 hour at 37°C. Double digests were carried out simultaneously unless 
the buffer conditions were not suitable for both enzymes. In the latter cases, one 
digest was performed, purified with the QIAquick PCR Purification kit (Qiagen) as 
described in Section 3.14.2, and followed by the second enzyme digest. 
 
3.13  Agarose gel electrophoresis 
DNA or RNA was usually separated on a 1% agarose gel. To prepare a 1% SeaKem 
LE agarose (BioWhittaker, Walkersville, MD) gel, 0.5 g of agarose was added to  
50 ml of 1X TAE buffer and microwaved until the agarose was completely dissolved. 




2.5 µl of 10 mg/ml ethidium bromide (Biorad, Richmond, CA). The mixture was then 
poured into a cast with a well comb and allowed to solidify. Once set, the comb was 
removed and the gel was submerged in 1X TAE buffer in the electrophoresis tank. 
Samples were mixed with gel loading buffer prior to application to the wells. The gel 
was then electrophoresed at 120 V for approximately 45 min. The nucleic acid was 
visualized under UV light. 
 
3.14  Purification of DNA from agarose gel 
The desired DNA fragment was quickly excised under UV light and the DNA was 
recovered by centrifuging the gel slice over siliconized glasswool in a 0.6-ml 
microcentrifuge tube placed in a 1.5-ml microcentrifuge tube. The DNA eluant was 
purified using either the phenol/chloroform method or the QIAquick PCR Purification 
kit (Qiagen).  
 
3.14.1  Phenol/chloroform method 
The DNA eluant was mixed with 1 volume of phenol (Invitrogen, Carlsbad, CA), 
vortexed, and centrifuged at 13,000 rpm for 5 min. The aqueous layer was transferred 
into a tube containing 1 volume of chloroform and mixed. After a 5-min 
centrifugation at 13,000 rpm, the aqueous layer was precipitated with 2.5 volumes of  
-20°C absolute ethanol and 1/10 volume of 3 M sodium acetate for 30 min at -80°C. 
The precipitated DNA was pelleted at 13,000 rpm for 15 min at 4°C and washed once 





3.14.2   QIAquick PCR Purification kit 
Five volumes of buffer PB were added to 1 volume of the eluant. The mixture was 
transferred into a QIAquick spin column and centrifuged. The column was washed 
with 750 µl of buffer PE. Subsequently, DNA was eluted with 10-50 µl of H2O. All 
centrifugation steps were carried out at 13,000 rpm for 1 min at room temperature. 
 
3.15  DNA ligation 
In a ligation reaction, T4 DNA ligase (Promega) covalently links the phosphodiester 
bonds between the insert DNA and the vector DNA to join the two fragments 
together. Ligation was performed in a total volume of 10 µl containing appropriate 
molar ratios of vector and insert DNA (usually 1:2), 1 µl T4 DNA ligase and 1X 
ligase buffer, and incubated either for 1-2 hours at room temperature or overnight at 
4°C. 
 
3.16  Transformation of E. coli 
Transformation facilitates the uptake and expression of DNA by a living cell. Ten 
microliters of ligation mix was added to 100 µl of JM109 competent cells, mixed, and 
left on ice for 30 min. The cells were then heat-shocked at 42°C for 45 sec before 
rapidly returning the tube to ice for two min. After addition of 900 µl of LB medium, 
the bacteria were incubated with shaking at 150 rpm for 90 min at 37°C. The cells 
were then pelleted by centrifugation at 2,000 rpm for 3 min. Excess supernatant was 
discarded, leaving approximately 200 µl in the tube. The cells were then resuspended 
and plated onto LB agar plates containing the appropriate antibiotic. For blue/white 
selection, the LB agar plates were spread with 20 µl of X-Gal and 100 µl of IPTG 




3.17  Screening of bacterial colony by PCR 
Screening of bacteria colonies by PCR enables the identification of positive bacteria 
clones that contain the transformed plasmid. In this procedure, each bacterial colony 
was picked with a sterile pipette tip and transferred into a 1.5-ml microcentrifuge tube 
containing 50 µl of sterile H2O. The tip was agitated in the H2O to remove the colony 
from the tip. An aliquot of the bacteria was used as template in the PCR reaction. The 
presence of the insert was determined by using either two insert-specific primers or 
two vector-specific primers. If insert orientation needs to be determined, a vector-
specific primer paired with an insert-specific primer was used. The PCR reaction was 
prepared in a final volume of 25 µl using Promega’s Taq DNA polymerase. The 
resulting PCR products were checked on an agarose gel for the presence of the 
predicted band. Positive bacteria in H2O were directly inoculated in LB medium 
containing the appropriate antibiotic and cultured overnight for plasmid miniprep. 
 
TABLE 3-14 PCR components for screening of bacterial colony 
Component Volume (µl) 
10X buffer 2.5 
MgCl2 2 
dNTP Mix (10 mM) 1 
Primer 1 (10 µM)   0.5 
Primer 2 (10 µM)  0.5 
Bacteria in H2O                18.25 
Taq DNA polymerase                      0.25 
  
Final volume 25 





TABLE 3-15 PCR conditions for screening bacterial colony 
Reaction Temperature Time Cycles 






















3.18  Plasmid miniprep 
A bacterial colony or an aliquot of bacterial glycerol stock was inoculated into 3 ml of 
LB medium supplemented with the appropriate antibiotic. The inoculated bacteria 
were cultured at 37°C overnight with shaking at 250 rpm. Two milliliters of bacteria 
were pelleted by centrifugation at 13,000 rpm for 1 min. Plasmid extraction was 
carried out using the Wizard Mini-prep kit from Promega according to the 
manufacturer’s instruction. The pellet was resuspended in 250 µl of Cell 
Resuspension solution before lysing in 250 µl of Cell Lysis solution. The mixture was 
gently inverted several times till a clear and viscous lysate was obtained. Ten 
microliters of Alkaline Protease were pipetted into the solution, mixed, and incubated 
for 5 min. Unwanted materials including bacterial cell wall fragments, proteins, and 
chromosomal DNA were precipitated by the addition of 350 µl of Neutralization 
solution and centrifugation at 13,000 rpm for 10 min. The clear supernatant 
containing plasmid DNA was transferred to a spin column and centrifuged at 13,000 
rpm for 1 min. The column was washed with a 750 µl and a subsequent 250 µl of 






3.19  Bacterial glycerol stock 
Glycerol was diluted to 50% in H2O and filter-sterilized. Three hundred and fifty 
microliters of bacterial culture was mixed with 150 µl of 50% glycerol and stored at  
-80°C. 
 
3.20  Automated DNA sequencing   
DNA Sequencing reactions were performed with the ABI PRISM Big Dye Reaction 
Terminator Cycle Sequencing Kit version 3.1 (Applied Biosystems, Foster City, CA) 
with slight modifications to the manufacturer’s instruction. 
 
TABLE 3-16 Primers for sequencing 








pcDNA3.1 or pcDNA6B/V5-His vector-specific: 












































TABLE 3-17 Sequencing components 
Component Volume (µl) 
Double-stranded plasmid 
Big Dye terminator mix 
5X Sequencing buffer 






Final volume Add H2O to a final volume of 20 µl 
 
 
TABLE 3-18 Sequencing conditions 













The sequencing product was precipitated with 2 µl of 125 mM EDTA, 2 µl of 3 M 
sodium acetate and 50 µl of absolute ethanol for 15 min at room temperature before 
centrifugation at 13,000 rpm for 15 min at 4°C. The pellet was washed in 250 µl of 
70% ethanol and centrifuged at 13,000 rpm for 5 min at 4°C. The final pellet was air-
dried before being reconstituted in sequencing loading buffer and analyzed on an ABI 
PRISM™ TM 337 automated sequencer (Applied Biosystems). 
 
3.21  Transient and stable transfection 
Cells used for transfection were seeded one day before transfection at a density such 
that they would be 40-70% confluent on the day of transfection. Transfections were 
carried out with the reagent of Lipofectamine Plus (Invitrogen) according to the 
manufacturer’s instructions. Cells were transfected in serum-free DMEM with DNA 
precomplexed with PLUS and Lipofectamine reagents for 3-5 hours, after which, the 
medium containing the complexes was removed and replaced with DMEM medium 




For stable transfections, cells transfected in 35-mm plates were reseeded into 100-mm 
plates or T75 flasks after 24 hours of transfection and selected under 800 µg/ml of 
G418 (Sigma) or 10 µg/ml of blasticidin (Invitrogen) for 2 weeks. Thereafter, the 
cells were trypsinized and each cell picked under microscope was transferred into a 
well of a 24-well plate containing parental cells at 20% confluence. Parental cells 
were added to stimulate the growth of the stable cell. The cells were then allowed to 
propagate in culture medium without antibiotics for two days before replacing with 
selection medium. The cells were kept in selection medium until all the parental cells 
were killed and the stable clone reached confluence. Alternatively, after trypsinizing 
the stable cells, the cells were seeded at very low density to allow it to grow into a 
small colony of about 40 cells. Under microscope, the colony was gently detached 
and aspirated using a pipette tip and transferred to a 24-well plate. The cells were 
maintained until confluent in selection medium. Once the cells were confluent, a 
fraction of them was used for Western blot analysis and immunocytochemistry to 
confirm the expression of the desired protein and cell homogeneity, respectively. The 
positive clones were subsequently expanded.  
 
For transient transfections, the transfected cells were cultured without antibiotic 
selection for 24-48 hours before assaying. 
 
For transient transfections with time-course, HepG2 cells were transfected with either 
HEPN1-EGFP or vector pEGFP-N2 and examined by fluorescence microscopy 





3.22  Immunocytochemistry 
3.22.1   Visualization of V5-tagged protein expression 
Cells grown on coverslips were washed twice with PBS and fixed with 3.7% 
paraformaldehyde for 15 min at 37°C. The subsequent steps were all carried out at 
room temperature. Following three 5-min washes with PBS, the cells were 
permeabilized with 0.2% Triton X-100 in PBS for 5 min. A second set of washing 
was carried out and the nonspecific sites on coverslips were blocked in 10% normal 
goat serum (Santa Cruz, Santa Cruz, CA) in PBS. The cells were then incubated for 1 
hour with mouse anti-V5 antibody (Invitrogen; 1:200 dilution) diluted in 1.5% normal 
goat serum, washed, and exposed for 1 hour to biotin-conjugated goat anti-mouse IgG 
antibody (Santa Cruz; 1.5:100 dilution) diluted in 3% normal goat serum. After 
washing, avidin-fluorescein isothiocyanate (FITC; Santa Cruz; 2:100 dilution) in PBS 
was added to the cells and incubated for 15 min in the dark. Excess avidin-FITC was 
removed by washing in PBS. After a final rinse in H2O, the coverslips were mounted 
onto the microscopic slides with FluorSave reagent (Calbiochem, La Jolla, CA), and 
analyzed by fluorescence microscopy (Carl Zeiss, Germany) or confocal microscopy 
(LSM 510; Carl Zeiss). 
 
3.22.2   Disruption of cellular F-actin 
Cellular F-actin was disrupted by cytochalasin B (Sigma). Stock solution of 
cytochalasin B was prepared in DMSO at a concentration of 10 mM. Cells were 
incubated with 10 µM of cytochalasin B in culture medium containing 10% FBS for 





3.22.3   Detection of mitochondria 
Mitochondria were detected by treating cells with Mitotracker-orange (Molecular 
Probes, Inc., Eugene, OR). Stock solution of 1 mM was prepared in DMSO. To detect 
mitochondria, live cells were treated with 250 nM of Mitotracker-orange (Molecular 
Probes, Inc., Eugene, OR) diluted in culture medium containing 10% FBS for 25 min 
at 37°C. The cells were then rinsed with culture medium before fixing in 
paraformaldehyde. 
 
3.22.4   Labeling of F-actin 
F-actin may be efficiently labeled with fluorescent phalloidin conjugates. Phalloidin is 
a fungal toxin produced by the poisonous mushroom Amanita phalloides that acts by 
binding to and stabilizing F-actin. Stock solution of tetramethylrhodamine 
isothiocyanate (TRITC)-conjugated phalloidin (Sigma) was prepared in DMSO at  
1 mg/ml. F-actin of fixed and permeabilized cells was labeled with 1 µg/ml of 
TRITC-conjugated phalloidin diluted in PBS for 1 hour at room temperature. 
 
3.22.5   Nuclear staining 
4',6-Diamidino-2-phenylindole (DAPI; Roche) stock was prepared as 1 mg/ml in 
DMSO. Fixed cell nuclei were stained with 1 µg/ml of DAPI in PBS for 15 min at 
37°C. 
 
3.22.6   Colocalization of hepaCAM-GFP and E-cadherin in polarized cells 
MCF7 cells stably expressing hepaCAM-GFP were seeded at 10% confluence and 
allowed to grow to confluence on 0.4-µm Transwell filters (Costar, Cambridge, MA). 




E-cadherin was detected by mouse anti-E-cadherin antibody (Zymed, San Francisco, 
CA; 1.2:100 dilution), biotin-conjugated goat anti-mouse IgG antibody, and 
subsequently avidin-TRITC conjugate (Sigma; 1:100 dilution). To mount the filter, 
the excised filter with the cells side up was placed onto a drop of mountant on a 
microscopic slide. Another drop of mountant was dropped onto the cell surface and a 
coverslip was gently placed over it. The cells were examined by confocal microscopy 
(LSM 510) with sectioning performed at 0.5 µm. 
 
3.22.7   Localization of detergent-resistant hepaCAM-V5 proteins 
MCF7 cells on coverslips were transiently transfected with hepaCAM-V5 for 48 
hours before permeabilizing with ice-cold 1% Triton X-100 in PBS for 3 min. The 
cells were then fixed and blocked, and the detergent-insoluble hepaCAM-V5 was 
detected by mouse anti-V5 antibody as described in Section 3.22.1. The control cells 
were fixed prior to permeabilization with 1% Triton X-100. 
 
3.22.8   Colocalization of hepaCAM-V5 with lipid raft proteins 
NIH3T3 cells grown on coverslips were transiently transfected with hepaCAM-V5 for 
48 hours. The cells were permeabilized with ice-cold 0.5% Triton X-100 in PBS for  
3 min prior to fixing and blocking. Double-staining of hepaCAM and caveolin-1 or 
fyn was carried out with mouse anti-V5 antibody and rabbit anti-caveolin-1 (Santa 
Cruz; 1:100 dilution) or rabbit anti-fyn antibody (Santa Cruz; 1:100 dilution) diluted 
in 1.5% normal goat serum. The anti-V5 antibody was detected with FITC-conjugated 
goat anti-mouse IgG antibody (Santa Cruz; 1:50 dilution) while anti-caveolin-1 and 




antibody (1.5:200 dilution) and avidin-TRITC conjugate (Sigma; 1:100 dilution). The 
cells were analyzed by confocal microscopy. 
 
3.23  MTT assay 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay measures 
cell viability. The assay is based on the reduction of the yellow MTT into purple 
formazan crystals catalyzed by enzymes produced only in metabolically active live 
cells. 
 
To evaluate cell viability, a volume of 100 µl of MTT (Roche; 5 mg/ml in PBS) was 
added to cells transfected for 48 h in a 6-well culture plate. After 3 h of incubation at 
37°C, cells were lysed and formazan crystals were dissolved in 1 ml of isopropanol 
with 0.4 N HCl. Wells containing all admixtures except cells were used as blanks. 
Optical density was read at 570 nm using an ELISA reader. Transfection efficiency, 
approximately 40% in this study, was detected by transfecting HepG2 cells with the 
pEGFP-N2 vector and calculated based on the number of flouorescent cells against 
the total number of cells in the test. Cell viability (CV) was computed by the 
following equation: 
 





where TE = transfection efficiency, i.e., 40% in this study; ODe = OD reading of 






To assess the rate of cell proliferation, 2 X 104 cells were seeded and cultured in six 6-
well plates in triplicates. MTT assay was carried out once the cells had attached to 
establish the base line of cell growth. At every 24 hours of cell culture for 5 days, 
MTT assay was performed to evaluate the cell viability. The growth rate of each cell 
line was presented as fold of increase in cell viability against the respective base line 
obtained on the day of seeding cells. 
 
3.24  Colony formation  
This assay was performed to evaluate the effect of the gene of interest on cell growth 
in colony form. Transfected cells were cultured in selection medium containing  
10 µg/ml of blasticidin or 800 µg/ml of G418 for 2 weeks without trypsinization 
while medium was refreshed every 2 days or 3-4 days, respectively. The cell colonies 
formed at the end of experiment were visible and the number of colonies was counted. 
 
3.25  Detection of apoptosis by Annexin V 
ApoAlert Annexin V (Clontech) was used to detect changes in the position of 
phosphatidylserine (PS) in the cell membrane characteristic of apoptosis. At 16 hours 
after transfection, cells grown on coverslips were rinsed with 1X binding buffer, 
incubated with 5 µl of Annexin V and 10 µl of propidium iodide for 10 minutes, and 
examined by fluorescence microscopy 
 
3.26  Cell aggregation assay  
In the cell aggregation study, cells were washed once with PBS and detached by 
incubation with 1 mM EDTA in PBS at 37°C for about 15 minutes. Culture medium 




for 5 min. The cell pellet was washed once with Ca2+-free Hanks’ balanced salt 
solution (HBSS; JRH Biosciences, Lenexa, KS) and resuspended in Ca2+-free HBSS. 
Single-cell suspensions were prepared by passing the cells through an 18-gauge 
needle for 20 passages. The cells were counted using the trypan blue method as 
described in Section 3.1.2. Single cells were seeded at a concentration of 4 X 105 
cells/ml in a final volume of 3 ml into 60-mm petri-dishes precoated overnight at 4°C 
with 1% BSA. The cells were incubated for 1 hour at 37°C with gentle agitation at 
100 rpm. The cell aggregates formed were observed under the inverted light 
microscope.  
 
3.27  Cell spreading assay 
Coverslips were coated with either matrigel (40 µg/ml; Clontech) or fibronectin  
(10 µg/ml; Santa Cruz) and allowed to polymerize for 1 hour at 37°C or at room 
temperature, respectively. Cells were seeded onto the coated coverslips and incubated 
under standard culture conditions. Cell morphology was observed by microscopy. 
Unspread cells were defined as round cells while spread cells were defined as cells 
with extended processes (Richardson et al., 1997). The percentage of cells 
demonstrating spread morphology was quantified in 10 randomly selected fields. 
 
3.28  Cell detachment assay 
A confluent monolayer of cells was detached in 1 mM EDTA in PBS at 37°C. Cell 
detachment was observed under the inverted microscope at 5 minutes and 15 minutes 
of incubation. Concurrently, the dissociated cells were harvested and counted in 10 





3.29  Boyden chamber assay 
Cell migration was assessed using the transwell chambers with 8-µm pore size 
membrane (Costar) coated with 20 µg of matrigel in 24-well plate. The cells were 
starved overnight in serum-free DMEM medium containing 0.1% BSA prior to 
initiation of the assay. Fifty thousand cells resuspended in DMEM with 1% FBS were 
loaded into the upper transwell chamber and allowed to migrate through the 
membrane into the bottom chamber containing DMEM supplemented with 10% FBS 
which acted as a chemoattractant. Migrated cells were harvested 24 hours later by 
trypsinizing the lower surface of the membrane and collected into a new 24-well 
plate. The migration activity was quantified by blind counting of the migrated cells in 
10 randomly selected microscopic fields. 
 
3.30  Wound healing assay
Cell motility was also assessed by the wound healing experiment on monolayer cells. 
Cells were seeded in 35-mm culture plates at high density and allowed to form 
confluent monolayers overnight. Wounds were made by sterile plastic 200-µl 
micropipette tips and allowed to be healed in culture medium containing 10% FBS. 
Microscopic pictures representing the changes in diameter (D) of each wound were 
taken at 24 and 48 hours. By measuring the remaining gap space on the pictures, the 
percentage of wound closure was computed into ratio (D24/48h/Dinitial X 100%).  
 
3.31  N-linked glycosylation analysis  
For inhibiting N-linked glycosylation, cells were cultured in tunicamycin (Sigma) 
after transient transfection at the indicated concentrations for 24 hours before lysis. 




peptide N-glycosidase F (PNGase F; NEB, Beverly, MA) according to the 
manufacturer’s instructions. A 10-µl reaction containing 20 µg of cell lysate and 1X 
glycoprotein denaturing buffer was denatured at 100°C for 10 minutes, followed by  
1 hour incubation at 37°C in 1X G7 buffer, 1% Nonidet P-40 and 1,000 units of 
PNGase F. A control without PNGase F was treated concurrently. These samples 
were then subjected to Western blot analysis.  
 
3.32  Alkaline phosphatase treatment  
Cell lysate was incubated in dephosphorylation buffer for 10 min at 30°C. Calf 
intestinal alkaline phosphatase (CIP; Roche) was added and incubated for a further 
15-60 min prior to Western blot analysis.  
 
3.33  Chemical crosslinking  
A monolayer or a single suspension of cells was incubated in PBS containing 3 mM 
bis(sulfosuccinimidyl) suberate (BS3; Pierce, Rockford, IL) or 3,3'-Dithiobis 
(sulphosuccinimidyl propionate) (DTSSP; Pierce) at room temperature for 30 min. 
The reaction was quenched with the addition of 20 mM Tris-HCl pH 7.5 for 15 min. 
Single-cell suspension was assured by microscopic observation before and after 
chemical crosslinking reaction. DTSSP-crosslinked proteins were resuspended in 
Laemmli sample buffer without reducing agent 50 mM dithiothreitol (DTT) unless 
indicated. Cell lysate was prepared in radioimmunoprecipitation assay (RIPA) buffer 
containing 10 mM iodoacetamide to inhibit formation of nonspecific disulfide 





3.34  Preparation of whole cell extracts  
Cells were scraped in RIPA buffer containing protease inhibitors followed by 
sonication or incubation on ice for 15 min. Tissues were homogenized in RIPA buffer 
using a Dounce homogenizer. The cell lysate was cleared by centrifugation at  
13,000 rpm for 10 min at 4°C. Protein samples were mixed with an equal volume of 
2X or ¼ volume of 5X Laemmli sample buffer and boiled for 5 min before Western 
blot analysis. 
 
3.34.1   Subcellular fractionation  
Cells grown on 100-mm plate or T75 flask were scraped using a rubber policeman in 
hypotonic buffer supplemented with protease inhibitors. The cell lysate was incubated 
on ice for 10 min prior to 20-40 strokes of Dounce homogenization at 4°C. The cell 
homogenate was centrifuged at 1,500 rpm for 10 min to remove nuclei, cell debris and 
unbroken cells. The supernatant (S1) was then centrifuged for 1 hour at 100,000 g in 
an SW55Ti rotor (Beckman, Columbia, Md) at 4°C, resulting in the supernatant 
(S100) and the pellet (P100). The S100 supernatant contained cytoplasmic 
components while the P100 pellet contained the cellular membrane and cytoskeletal 
components. 
 
3.34.2   Detergent extraction 
For detergent solubility assay, cells or P100 fractions were resuspended in 1 volume 
of ice-cold 1% Triton X-100 in PBS containing protease inhibitors and incubated on 
ice for 15 min. One molar of potassium iodide (KI; Sigma) was added into the 1% 




insoluble material was pelleted at 13,000 rpm for 10 min at 4°C, and boiled in  
1 volume of 2X Laemmli sample buffer for 10 min. 
 
To investigate if hepaCAM might be associated with the detergent-resistant 
membrane (DRM), P100 pellet was resuspended in 1 volume of ice-cold 1% Triton 
X-100 in PBS and placed on ice for 15 min. The Triton X-100-resistant material was 
pelleted at 13,000 rpm for 10 min at 4°C. To solubilize some DRM, the Triton X-100-
insoluble pellet was further resuspended in 1 volume of ice-cold 100 mM N-octyl-β-
D-glucopyranoside (n-OG; Fluka Biochemika, Buchs, Switzerland) in PBS, placed on 
ice for 15 min, followed by another centrifugation at 13,000 rpm for 10 min at 4°C. 
The remaining pellet containing the detergent-insoluble DRM was resuspended in  
1 volume of 2X Laemmli sample buffer and boiled for 10 min.  
 
An equal volume of each fraction was resolved by SDS-PAGE and subjected to 
Western blot analysis. 
 
3.35  Sucrose density gradient ultracentrifugation  
Forty-eight hours post-transfection, transfected NIH3T3 cells in 100-mm plates were 
washed twice in PBS, lysed in 500 µl of ice-cold lysis buffer supplemented with 
protease inhibitors, incubated on ice for 20 min, and homogenized with a Dounce 
homogenizer. The lysates were adjusted to a final concentration of 40% sucrose by 
adding 500 µl of 80% sucrose in TNE buffer to the samples. Reverse layering of 
gradient was performed to minimize disturbance caused during layering. In an ultra-
clear centrifuge tube (Beckman), using 21-guage needle fitted on 3-ml syringe, the 




1.5 ml of 30% sucrose, and finally the samples to the bottom of the tubes. Samples 
were spun at 100,000 g for 24 h at 4°C in an SW55Ti rotor. After centrifugation, 
seven 0.5-ml fractions were collected starting from the bottom layer to the top. 
Proteins were precipitated by the tricholoracetic acid (TCA)/ethanol precipitation 
method. Five hundred microliters of 20% TCA in H2O was added to each fraction, 
placed on ice for 20 min, and spun at 13,000 rpm for 15 min at 4°C. The pellet was 
washed with absolute ethanol, dried, resuspended in 40 µl of 2X Laemmli sample 
buffer, and boiled for 10 min. Twenty microliters of each fraction were 
electrophoresed by SDS-PAGE and analyzed by Western blotting. 
 
3.36  Cholesterol depletion 
For cholesterol depletion, cells were washed twice with PBS and then incubated with 
10 mM methyl-β-cyclodextrin (MCD; Sigma) in DMEM at 37°C for 30 min prior to 
cell lysis. 
 
3.37  Determination of protein concentration by the Bradford method 
The Bradford assay is a dye-binding assay based on the differential color change of 
Coomassie blue G dye as it binds to protein. In this study, the concentrations of 
proteins were determined by Bradford assay (Biorad) at OD595. 
 
One part of the Dye Reagent Concentrate was diluted in 4 parts of H2O to constitute 
the working solution. Twenty microliters of protein diluted in PBS was mixed with  
1 ml of working dye solution and the absorbance measured. A standard curve was 




mg/ml (Figure 3-2). The concentrations of test proteins were then determined from 
this curve. 
















FIGURE 3-2  Protein standard curve.  
 
3.38  Western blot analysis 
3.38.1   Separation of proteins by polyacrylamide gel electrophoresis 
Denatured protein samples were loaded usually onto 10% SDS-PAGE gel and 
resolved by running in 1X SDS-PAGE running buffer at 150 V for 70 min or until the 
desired distance was reached. 
 
3.38.2   Protein transfer 
After electrophoresis, proteins were transferred from the gel onto PVDF membrane 
(Biorad) using BioRad’s Mini Trans-Blot Electrophoretic Transfer Cell. The gel, 
membrane, Whatman filter papers and fiber pads were equilibrated in Towbin buffer 




from the gel (negative electrode) to the membrane (positive electrode) at 100 V for 60 
minutes in Towbin buffer containing 0.1% SDS. 
                                       
 
 
FIGURE 3-3  Assembly for protein transfer. (Source: instruction manual of 
Biorad’s Mini Trans-Blot Electrophoretic Transfer Cell) 
 
3.38.3   Western blotting 
The membrane was rinsed with 1X TBS and blocked in blocking buffer for 1 hour. 
Incubation with primary antibodies diluted in blocking buffer was carried out either at 
room temperature for 1 hour or 4°C overnight. The primary antibodies used included 
rabbit anti-hepaCAM polyclonal antiserum (1:2,000 dilution; generated by Miss 
Zhang Chunli), mouse anti-V5 antibody (1:5,000 dilution), mouse anti-GFP antibody 
(Santa Cruz; 1:200 dilution), mouse anti-p53 (Santa Cruz; 1:5,000 dilution), mouse 
anti-E-cadherin (1:500 dilution), rabbit anti-caveolin-1 antibody (1:200 dilution), or 
goat anti-actin antibody (Santa Cruz; 1:100 dilution). Blots were then washed three 
times in TBS-T, 5 min each, and then incubated for 1 hour in the appropriate 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz; 1:5,000 dilution). 
After four 5-min washes, the enzymatic activity was detected with 




3.38.4   Stripping of Western blot 
The Western blot to be re-probed was stripped in two 15-min washes of Stripping 
buffer. The membrane was then rinsed with 1X TBS before re-blocking.    
 
3.39  Immunoprecipitation 
Immunoprecipitation was used to detect protein-protein interactions. Cell lysate 
prepared in RIPA buffer was precleared with Protein G-agarose beads (Santa Cruz) 
for 1 hour at 4°C with agitation. The supernatant was recovered by centrifugation at 
2,500 rpm for 1 min. The precleared lysate was then mixed with protein G-agarose 
beads and specific antibody, and incubated overnight at 4°C before washing four times 
with RIPA buffer or PBS when a reduced stringency was desired. The beads were 
resuspended in 2X Laemmli sample buffer, boiled for 10 min and the eluted proteins 
were subjected to Western blot analysis. 
 
3.40  Bioinformatics and statistical analysis 
Database searches were carried out using National Center for Biotechnology 
Information (NCBI), Ensembl, ExPASy and Swiss-Prot; and motif searches were 
performed with programs like Scansite, PROSCAN, PROSITE, PSORT II, 
RepeatMasker, MatInspector, big-PI and NetPhos2.0. Mann-Whitney test was 
performed to compare two means of samples with small sample size (n = 6). Two-
tailed Student’s t test was used to assess data with sample size larger than 6. 
Nonparametric ANOVA was performed to compare the difference among more than 
two means. Fisher’s exact test was used to assess the correlation between two 
parameters. Software InStat 3.0 (GraphPad) was employed and P < 0.05 was 




CHAPTER 4 RESULTS 
 
4.1  Gene HEPN1 
4.1.1  Loss of HEPN1 expression in human tumors 
4.1.1.1  Suppression of HEPN1 in HCC patients 
Suppression subtractive hybridization (SSH) revealed that a novel gene, designated as 
HEPN1, was downregulated in HCC. Based on the partial HEPN1 cDNA sequence 
information obtained from SSH, a pair of HEPN1-specific primers, N1-F and N1-R, 
was synthesized and used in semi-quantitative RT-PCR to analyze the frequency of 
HEPN1 suppression in 23 HCC patients. The RT-PCR result (Figure 4-1) showed that 
HEPN1 was ubiquitously expressed in 23 non-tumorous liver tissues, but either 
downregulated or lost in 22 HCC tissues (except for sample 16), demonstrating 
suppression of HEPN1 in 95.7% of 23 HCC samples tested. Real-time RT-PCR was 
further performed on the same batch of liver specimens to quantitate the level of 
HEPN1 expression (Figure 4-2). In addition to obtaining reproducible results 
pertaining to the frequency of HEPN1 suppression in HCC by both experimental 
approaches, real-time RT-PCR detected a significant reduction of HEPN1 expression 
in HCC. The average expression level in HCC (7.2±10.4) was 5.7-fold lower than that 
in non-tumorous liver tissues (40.8±10.0), P < 0.0001. No correlations between 
HEPN1 and the clinicopathologic parameters could be detected. This could be due to 




FIGURE 4-1 Expression of HEPN1 transcript in 23 HCC 
patients by semi-quantitative RT-PCR. RT-PCR products of 
HEPN1 generated by primers N1-F and N1-R were analyzed by gel 
electrophoresis. b-actin was included as internal control. , sample 
that shows no clear difference in HEPN1 expression; N, non-
tumorous liver tissue; T, HCC liver tissue.
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FIGURE 4-2 Expression of HEPN1 transcript in 23 HCC 
patients by quantitative real-time RT-PCR. The expression level 
of HEPN1 in each sample was determined by real-time RT-PCR. 
Results were normalized and converted into percentage against the 
expression level of GAPDH. The average level of expression (mean
± SD, n = 23) is represented on the right, * P < 0.0001. N, non-





















TABLE 4-1 Correlation between HEPN1 suppression and the      











Total number 22 1 95.7  
Sex     
Male 16 2 89 NS 
Female 4 1 80 NS 
Grade     
well 3 0 100 NS 
moderate 12 2 86 NS 
poor 5 1 83 NS 
Cirrhosis 16 3 84 NS 
Hepatitis virus     
HBV 18 2 90 NS 
HCV 3 0 100 NS 
HBV + HCV 2 0 100 NS 
Grade, histological differentiation of HCC; NS, not significant; P was revealed  





4.1.1.2  Suppression of HEPN1 in HCC cell lines 
Furthermore, in 4 HCC cell lines tested, semi-quantitative RT-PCR showed that 
HEPN1 was significantly suppressed in Hep3B, Huh7 and SK-Hep1, and completely 
silenced in HepG2 cells as compared to a non-tumorous liver specimen (Figure 4-3). 
 
4.1.1.3  Suppression of HEPN1 in cell lines derived from diverse cancers 
HEPN1 mRNA expression was screened in a panel of human cancer cell lines 
consisting of Jurkat, HL60, K562, HT29, HCT116, Colo205, MCF7, SK-N-SH, NCI-
H82, NCI-H23, NCI-H69, and NCI-H2066 derived from leukemia, colorectal cancer, 
breast cancer, neuroblastoma and lung cancer (Figure 4-4). Semi-quantitative RT-
PCR showed that HEPN1 was expressed in Jurkat and HCT116 cells, but markedly 
suppressed in HL60, K562, HT29 and Colo205 cells, and undetectable in MCF7, SK-
N-SH, NCI-H82, NCI-H23, NCI-H69 and NCI-H2066 cells, representing a significant 
loss of HEPN1 in 83.3% (10/12) of the cell lines.  
 
4.1.2   Isolation of HEPN1 full-length cDNA 
The technique of RACE was used to extend the sequence knowledge of HEPN1. 5’- 
and 3’ RACE were performed to isolate the respective 5’ and 3’ ends of HEPN1 from 
human normal liver cDNA library. 5’ RACE using gene-specific primer N1-RACE-R 
and adaptor primer AP1, followed by a nested 5’ RACE using nested primers N1-
RACE-nR and AP2 yielded a fragment of ~600 bp (Figure 4-5). A single round of 3’-
RACE using primers N1-RACE-F and AP1 generated a 3’ cDNA fragment of ~1.2 
kb. The RACE fragments were cloned separately into the pGEM-T vector and 
sequenced. The overlapping sequences of the 5’ and 3’ RACE products were aligned 


















FIGURE 4-3 Expression of HEPN1 transcript in 4 HCC cell 
lines. Semi-quantitative RT-PCR was used to amplify HEPN1
mRNA and GAPDH (an internal control). RT-PCR products were 
analyzed by gel electrophoresis. The expression of HEPN1 in four 
HCC cell lines, HepG2, Hep3B, Huh7 and SK-Hep1, was 







































FIGURE 4-4 Expression of HEPN1 transcript in cell lines 
derived from different tumor types. Semi-quantitative RT-PCR 
was performed to amplify HEPN1 mRNA and GAPDH (an internal 
control). RT-PCR products were analyzed by gel electrophoresis. 
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FIGURE 4-5 Isolation of HEPN1 full-length cDNA by RACE. 
RACE-PCR products were analyzed by gel electrophoresis. A, 
Nested 5’ RACE product was generated by primers N1-RACE-nR 
and AP2; B, 3’ RACE product was generated by primers N1-
RACE-F and AP1; C, Full- length HEPN1 cDNA was amplified by 














1  TTCATCAAAA GTTTATTGAG CATCCAGTAT GTGCTAGGCA CTCTGCTGGA TGCTAGTAAT ACAAAGATGA AGATGAAAAC AACACAAAAA CAAACCCCAC 
101  TTCCTTACTT ACCCCTCCCC ACCCCCAATT TAAGGCAGAT TTGGCCTAAG CCTGGCAAGC TGGCCCCTCA GGGATTCAGC ACCAGGGTAT GGCATGTTCT 
201  CATCTCACCC TAACCTTCAC CTGTGCATCT CAAGGCTGAC CAGCAGGTAC TCCTTATCCA AGTCCTGCTG CCTCTTCCAC CTTCTTGAGA AACTTTTCCC 
301  CTACATGCAT TATCTCATTA TGGATGAGGC ACCTGGGAAG TTTAGGGGAG CTGCGAAGGC ACACCTGCTC AAATGAGCCT GGGGAAGTGC CGAGGGACAG 
401  GGAGCTGAGA CAGGCATGCT GTGGGGTTCA GGGCAGAGGG GGCAAACTAG AAATGTCAGT GCCTTTGGGG CTGAGACAAA ACTTGACCTG GTGTGGAGGT
501 G ATG GGT AAC TGG GGC CTT GGA ATT GCT CCA TGG GTT GAT GGC GAA TCA 
Met Gly Asn Trp Gly Leu Gly Ile Ala Pro Trp Val Asp Gly Glu Ser 
GAG CTG GAG TTT AGG AGA CTA GGG ATG CAA GGA CCC TTG GAG GCA TTA AGG 
Glu Leu Glu Phe Arg Arg Leu Gly Met Gln Gly Pro Leu Glu Ala Leu Arg
601 AGG AGG GAA CGG AAT ACA CAG AGG GCC TCC TTC TCT TTC AGC TTT TTA ATT
Arg Arg Glu Arg Asn Thr Gln Arg Ala Ser Phe Ser Phe Ser Phe Leu Ile
GCC CTC TCT CCT CAC ACA GTA GAT TAC TGC CAC TCC TAT GAA CTG TTC
Ala Leu Ser Pro His Thr Val Asp Tyr Cys His Ser Tyr Glu Leu Phe
700 AAT AGG CGG TGG CAT GGG CAT GTC CTG GCT ACA CAG CGG CCC AGC CTC TTT 
Asn Arg Arg Trp His Gly His Val Leu Ala Thr Gln Arg Pro Ser Leu Phe
ATT TTG ATG TTA GTG TGA TT AGGGAGTCTG CCTTTTTCTG TGCCCTGGGA
Ile Leu Met Leu Val ***
801  CCTGAGCATG TGGGAGCAGG GCAGATGGGT GGCAGAGGCC AGGGGTTGGA TCATGTTCCC CCCAAATGCT GGGAAGCAAT AAGCCTCCTC CTCCCCCCAC 
901  CATTTCTCTG GAGATTAGGA CTTATTCTCA CAGCTGGAGA AGCTCAACAA CTTTCCTGAG GACAATGATT GTTTGAAAGG CTTGTTTTGT AAGAAGCCAG 
1001 GAGGAATATA TGAGTTTGAT GAGCTAAAAC AGTTCCTCAT TTGGTCTAGT TTTCGGGCCA GGGGAGTAAG TGAAATTCAC TTCTCTATAA GAATAAGCCC 
1101 ATCCATCTCT TTTATTCATG AACAGAGACA GAAAGAGTGC TTGGCATGGC ATGCCTCCGA GGGAGGCTGT GGGAGGAGGC CAAGCTGGCA GGCTCGGGTT 
1201 CTTTGCCCTT GCTAGCGCCC AGGTCAGAGG GAAAAGGAAT GTACTCGTAC CCTTCCCTCA CCACCTTGTA GGTCCCCAGG TACCAGGTGC CCAGGGAAGA 
1301 AGGCCTTCAC AATGATCCCC CCAGCTCAGA ACAGCCCCTG CACACCCAGT AACCGGCATC TGGCTTCTCC TTAGCTTAGT GCAGCTGTGG ATTCTGGGAA 
1401 AGTGGCCTCT CTAATCTGAA CTTGAAAAAA AAAAAAAAAA AAAAAAAA
FIGURE 4-6 Sequences of HEPN1 cDNA and the predicted 
amino acid. The full- length cDNA of HEPN1 is approximately 1.4 
kb long. The open reading frame (ORF), start codon (ATG), stop 
codon (TGA), and the Kozak sequence are highlighted. The 
sequence data for HEPN1 is available in GenBank Accession no. 
AY275431.
cDNA






Amino acids : 88
MW : 10 kDa
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was deposited into the GenBank (Accession no. AY275431). Based on this sequence, 
primers N1ful-F and N1ful-R corresponding to the 5’ and 3’ ends of HEPN1 cDNA 
were synthesized and applied in end-to-end PCR to amplify the complete cDNA of 
HEPN1. The cDNA was then cloned into the pGEM-T vector and sequenced for 
verification.  
 
4.1.3  Sequence characteristics of HEPN1 
4.1.3.1  Sequence analysis of HEPN1 cDNA 
The full-length cDNA of HEPN1 (Figure 4-6) contained an open reading frame 
(ORF) of 267 base pairs. The start codon ATG, the stop codon TGA, and the Kozak 
sequence (Kozak, 1990) surrounding the initiation codon were identified. However, 
no consensus polyadenylation signal was detected upstream of the poly-A tail. 
Searching HEPN1 against human EST databases yielded a number of aligned 
fragments identified mainly in the brain.  
 
4.1.3.2  Sequence analysis of HEPN1 protein 
The putative HEPN1 peptide consisted of 88 amino acids (Figure 4-6) with a 
calculated molecular weight of ~10 kDa and a pI (isoelectric point) of 9.29. The gene 
product was predicted to be unstable with a half-life of ~30 hours in mammalian cells. 
The peptide had neither motifs nor significant structural or sequence homology in the 
available databases of proteins and peptides.  
 
4.1.3.3  Sequence analysis of HEPN1 genomic DNA 
A BLAST search against the human genome database revealed that HEPN1 was 




FIGURE 4-7 Chromosomal localization of HEPN1 in human 
genome. HEPN1 is mapped to chromosome 11q24.2. 
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the genomic sequence of HEPN1 using the MatInspector program revealed a TATA 
box (TATTTAA) at position -57 upstream of the transcriptional start, indicative of a 
promoter. Comparative analysis revealed that HEPN1 cDNA was collinear to the 
genomic sequence, suggesting that gene HEPN1 is intronless.  
 
4.1.4  Subcellular localization of HEPN1 in HepG2 cells 
To localize HEPN1 gene product in living cells, the construct expressing HEPN1-V5 
fusion protein was transiently transfected into HEPN1-null HepG2 cells (Figure 4-3) 
for 48 hours and the distribution of the protein was detected by immunostaining with 
anti-V5 antibody. Cells transfected with pcDNA6B/V5-His vector served as control. 
Fluorescence microscopy showed that HEPN1 peptide was predominantly distributed 
in the cytoplasm (Figure 4-8).   
 
4.1.5  Growth suppression in HepG2 cells by HEPN1 
The biological role of HEPN1 was assessed in HepG2 cells. The construct HEPN1-
pcDNA was transiently transfected into HepG2 cells. Cells transfected with 
pcDNA3.1 vector served as control. At 48 hours after transfection, the cells were 
subjected to light microscopy, MTT assay, and real-time RT-PCR analysis. Cell 
viability detected by MTT assay was computed into percentage against the control. As 
shown in Figure 4-9, re-expression of HEPN1 (real-time RT-PCR) decreased cell 
density, altered cell morphology (light microscopy), and reduced cell viability to 





FIGURE 4-8 Subcellular localization of HEPN1 in HepG2 
cells. HepG2 cells were transiently transfected with either 
pcDNA6B/V5-His vector (pcDNA6) or HEPN1-V5 construct 
(HEPN1) for 48 hours. Immunostaining with anti-V5 antibody 


































FIGURE 4-9 Growth inhibition of HepG2 cells by HEPN1. 
Transient transfection for 48 hours. Light microscopic photographs 
demonstrate the density (100x) and morphology (400x) of HepG2 
cells transfected with HEPN1-pcDNA (right panel) in contrast to 
the control, cells transfected with pcDNA3.1 vector alone (left 
panel). Cell viability (mean ± SD, n = 12) was detected by MTT 
assay and computed into percentage against the control; * P = 
0.001. Real-time RT-PCR results show the expression level of 
HEPN1 in  the  transfected HepG2 cells. GAPDH was used as 
control. The RT-PCR products were analyzed by gel 
electrophoresis to verify the specificity. 
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Colony formation was performed to confirm the inhibitory effect of HEPN1 on cell 
growth. HepG2 cells transfected with HEPN1-EGFP and selected in 800 µg/ml of 
G418 antibiotic for 2 weeks were compared with those transfected with pEGFP-N2 
vector. Green fluorescent protein facilitated the visualization of cells in each colony. 
The results (Figure 4-10) demonstrated that, in addition to the significant reduction of 
the number of colonies formed, the number of fluorescent cells in the cells transfected 
with HEPN1-EGFP was extremely low as compared to that in the cells transfected 
with pEGFP-N2 vector alone.  
 
4.1.6  Apoptosis induction in HepG2 cells by HEPN1 
To explore if HEPN1 could promote cell death, HepG2 cells were transfected with 
either HEPN1-EGFP construct or pEGFP-N2 vector. Between 8 and 24 hours post-
transfection, cells were analyzed by fluorescence microscopy every 2 hourly. Figure 
4-11 showed the cell behaviour of HepG2 cells transfected with HEPN1 in contrast 
with the control cells. After transfection, 1) at hour 8, HEPN1 started being expressed 
predominantly in cytoplasm; 2) at hour 10, the expression level was increased and 
concentrated in granular structures; 3) at hour 12, HEPN1 was distributed more in the 
perinuclear region; 4) at hour 14, HEPN1 started translocating into cell nuclei; and 
from hour 16 onwards, typical apoptotic morphology including cytoplasm shrinking 
(16 h), cell blebbing (18 h), and nuclear fragmentation (20h and 22h) was observed. 
At hour 24, the number of cells transfected with HEPN1-EGFP was considerably 
reduced compared to that at hour 12 presented in the inset. The control cells 
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FIGURE 4-10 Inhibition of colony formation by HEPN1.
HepG2 cells transfected with the plasmid HEPN1-EGFP (right 
panel) or pEGFP-N2 vector (left panel) were cultured in the 
presence of 800 mg/ml of G418 for 2 weeks before confocal
microscopy. The density and morphology of cells in a colony were
visualized by green fluorescence. The number of colonies presented 
at the bottom of each picture was counted manually.
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FIGURE 4-11 Induction of apoptosis in HepG2 cells by 
HEPN1. HepG2 cells were transfected with either pEGFP-N2 
vector (EGFP) or HEPN1-EGFP construct. Between 8 and 24 hours 
after transfection, cells were analyzed by fluorescence microscopy 
every 2 hourly to visualize cell number, cell morphology and 
distribution of HEPN1. Microphotographs are presented at each 
time point and indicated as 8h, 10h, 12h, 14h, 16h, 18h, 20h, 22h, 
and 24h, respectively. An entire microscopic view at 24h is 
compared to that at 12h (inset), showing the reduction of cell 
number when HEPN1 was re-expressed. 
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In addition, Annexin V was used to determine if cells were indeed undergoing 
apoptosis. Since Annexin V detects changes in the position of PS in the cell 
membrane, one of the earliest changes of apoptotic cells, HepG2 cells were examined 
at 16 hours after transfection. As shown in Figure 4-12, positive Annexin V-PS 
binding on the cell membrane was observed in cells transfected with HEPN1-pcDNA 






FIGURE 4-12 Detection of HEPN1-induced apoptosis by 
Annexin V assay. The fluorescent rings represent positive binding 
of Annexin V with PS in the cell membrane, an early indication of 
apoptosis. A, HepG2 cells transfected with HEPN1-pcDNA 
construct; B, HepG2 cells transfected with the empty vector 
pcDNA3.1 (pcDNA). 
113
4.2  Gene hepaCAM 
4.2.1  Identification of hepaCAM  
As illustrated in Figure 4-13, an updated BLAST search with HEPN1 revealed an 
uncharacterized mRNA sequence of 2465 bp in the database (GenBank Accession no. 
AL834419). AL834419 contained the entire antisense strand of HEPN1 in its 3’ UTR 
and encoded an incomplete hypothetical protein of 165 amino acids at the 5’ terminus 
of the sequence. The lack of 5’ UTR and putative start codon (ATG) on AL834419 
implicated that the sequence was incomplete.  
 
4.2.2  Isolation of hepaCAM full-length cDNA 
The primer hCAM-RACE-R was designed at the 5’-end of HEPN1 antisense strand. 
Used in combination with adaptor primer AP1 in 5’ RACE (Figure 4-14), the 
complete cDNA of a novel gene, designated as hepaCAM, was isolated from human 
normal liver cDNA library. Q solution was added into the RACE-PCR reaction 
admixture as a PCR enhancer for amplifying the GC-rich template of hepaCAM. The 
cDNA was cloned into pGEM-T vector and sequenced. The full-length cDNA 
sequence of hepaCAM was submitted to the GenBank (Accession no. AY047587). 
 
4.2.3   Sequence characteristics of hepaCAM 
4.2.3.1  Sequence analysis of hepaCAM cDNA 
The full-length cDNA of hepaCAM was 3244 bp long (Figure 4-15). It contained a 5’ 
UTR of 44 bp, a deduced coding region of 1251 bp with ATG as start codon and TGA 
as stop codon, and a 3’ UTR of 1949 bp. An in-frame termination codon TAG was 
present at 24 nucleotides upstream of the putative initiating methionine, indicating the 
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FIGURE 4-13 Molecular cloning of hepaCAM. The full- length 
cDNA of hepaCAM was isolated from normal human liver cDNA
library by RACE. A forward primer on the adaptor (AP1) and a 
gene specific primer hCAM-RACE-R at the 5’-end of HEPN1
antisense strand were used in the RACE reaction. The cDNA
lengths of hepaCAM, HEPN1 and sequence AL834419 are given in 
the brackets. The indications of 5’ and 3’ correspond to the 
orientations of the cDNAs. The genomic DNA of hepaCAM
mapped to human chromosome 11q24 contains 7 exons indicated 
as I – VII and accompanied by their respective length in base pairs 
(bp). 
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FIGURE 4-14 Isolation of hepaCAM full-length cDNA by 5’
RACE. 5’ RACE product was generated by primers hCAM-RACE-
R and AP1. The RACE-PCR product was analyzed by gel 






FIGURE 4-15 The full-length cDNA sequence of hepaCAM. The 
full- length cDNA contains an ORF that begins from the start codon 
(ATG) and ends at the stop codon (TGA). A 5’-untranslated region 
containing a termination signal (TAG) indicates the completion of the 
ORF. A consensus Kozak (AAAATGA; bold) sequence surrounds the 
start codon. The polyadenylation signal (AATAAA; bold italic) is 
identified near the 3’-terminus. The full- length sequence of HEPN1
antisense strand (shaded) is localized within the 3’-untranslated region 
(1949 bp long). The GC-rich region is underlined and italicized. The 


















































as well as a polyadenylation sequence (AATAAA), which signals for poly-A addition, 
was identified in the sequence. Interestingly, CpG plot analysis predicted a short GC-
rich region of 176 bp (nucleotides 277-452) at the 5’ ORF of hepaCAM; and a long 
GC-rich region of 566 bp (nucleotides 966-1531) that spanned the 3’ ORF and 3’ 
UTR of hepaCAM cDNA. 
 
4.2.3.2  Protein sequence and structure of hepaCAM 
Gene hepaCAM was predicted by the SMART algorithm and SignalP server to encode 
a novel type I integral transmembrane Ig-like cell adhesion molecule of 416 amino 
acids (Figure 4-16). The protein contained an extracellular domain comprising a 
signal peptide (residues 1-33) and two Ig-like loops (residues 40-142; 159-224), a 
transmembrane segment (residues 241-263), and a cytoplasmic tail (residues 264-
416).  
 
Motif searches by the PROSITE and PSORT II programs identified a leucine zipper 
(residues 181-202), a proline-rich region (residues 325-385) with 6 SH3-binding 
domains, a nuclear localization signal (residues 265-271), a cAMP- and cGMP-
dependent protein kinase phosphorylation site (residues 237-240), a prokaryotic 
membrane lipoprotein lipid attachment site (residues 252-262), two tyrosine sulfation 
sites (residues 113-127; 274-288), two N-myristoylation sites (residues 33-38; 173-
178), four casein kinase II phosphorylation sites (residues 60-63; 125-128; 156- 159; 
331-334), six protein kinase C phosphorylation sites (residues 62-64; 90-92; 266-268; 
357-359; 371-373; 394-396), and six N-glycosylation sites (residues 35-38; 104-107; 




FIGURE 4-16 Predicted amino acid sequence of hepaCAM. 
Gene hepaCAM encodes a putative protein of 416 amino acids. The 
fragment highlighted in the box is the signal peptide (33 amino 
acids). The regions underlined with solid lines are the two 
immunoglobulin- like (Ig- like) domains (103 and 66 amino acids, 
respectively), while the one underlined with dashed line is the 
transmembrane domain (23 amino acids). Two cysteine residues 
(marked underneath the “·”) are identified in the second Ig- like 
domain, which may be needed for the formation of the disulfide 
bond in the domain. Six asparagines (marked underneath the “*”) 
are in the extracellular region, which represent the potential N-
linked glycosylation sites. The leucine zipper is italicized. The 
prokaryotic membrane lipoprotein lipid attachment site (shaded) is 
located in the transmembrane domain; and a proline-rich region 















Furthermore, scansite analysis of hepaCAM protein revealed binding sites for 14-3-3 
(residues 333, 376, 390), ATM kinase (residue 127), ITK kinase (residue 242), p85 
SH3 (residues 354; 365), Cbl-associated protein C-SH3 (residues 347; 385), 
Intersectin SH3 (residue 347), protein kinase C (residue 278), Akt kinase (residue 
392), Clk2 kinase (residue 392), GSK3 kinase (residue 384), Cdk5 kinase (residues 
377; 384), and Cdc2 kinase (residues 377; 384). 
 
Other potential motifs included eight dileucine motifs (residues 22-23; 23-24; 57-57; 
107-108; 108-109; 187-188; 194-195) distributed in the signal peptide, extracellular 
and transmembrane domains of hepaCAM. In addition, two potential palmitoylation 
sites were recognized in the transmembrane domain (Cys260; Cys262). The big-PI 
program predicted a potential C-terminal GPI-modification site at residue 399. 
 
A database search on the deduced protein of hepaCAM revealed sequence homology, 
mainly at the extracellular domain, between hepaCAM and other Ig-like cell adhesion 
molecules (Figure 4-17) such as coxsackie virus and adenovirus receptor (CAR; 
GenBank Accession no: AAX41267) and CEACAM3 (GenBank Accession no: 
AAQ88451). Furthermore, hepaCAM displayed structural similarities to Ig-like cell 
adhesion molecules like JAM1, CAR and ESAM (Figure 4-18). Typically, they 
contained an extracellular domain with two Ig-like domains (V and C2 domains), a 
transmembrane segment, and a cytoplasmic tail. Two cysteine residues flanking the 






FIGURE 4-17 Sequence comparison between hepaCAM
protein and other immunoglobulin-like adhesion molecules. A, 
Sequence homology between hepaCAM and coxsackie virus and 
adenovirus receptor (CAR; GenBank Accession no: AAX41267). 
B, Sequence homology between hepaCAM and CEACAM3 






























FIGURE 4-18 Structural comparison between hepaCAM
protein and other immunoglobulin-like adhesion molecules. 
hepaCAM owns the typical structure of cell adhesion molecules 
belonging to the immunoglobulin superfamily. Like JAM1, CAR 
and ESAM, hepaCAM contains a V-type and a C2-type Ig-domain 
on  i t s  extracellular domain,  a transmembrane segment, and a 
cytoplasmic tail. Putative N-linked glycosylation sites are marked 
by dots. Disulfide bridges and putative additional intramolecular 
disulfide bridges formed by cysteine residues in the C2-type Ig-
domain are indicated. The lengths of the intracellular domains are 
indicated at the bottom of each molecule (Modified from Ebnet et 
al., 2004).
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Alignment of the predicted amino acid sequence of human hepaCAM protein with 
those of chimpanzee (424 amino acids, GenBank Accession no. XP_522240), mouse 
(418 amino acids, GenBank Accession no. NP_780398), and dog (418 amino acids, 
GenBank Accession no. XP_852267) demonstrated an extremely conserved sequence 
with identities of 95%, 94% and 93%, respectively (Figure 4-19). 
 
4.2.3.3  Sequence analysis of hepaCAM genomic DNA 
A BLAST analysis was performed using the hepaCAM full-length cDNA sequence 
against the working draft sequences of the human genome in the NCBI database. 
Gene hepaCAM was mapped to the minus strand of the human chromosome 11q24.2 
and contained 7 exons ranging in sizes from 71 to 2252 bp (Figure 4-13). The start 
codon was located in exon 1 and the stop codon was positioned in exon 7. Intron sizes 
varied greatly from the longest intron 1 (10,851 bp) to the shortest intron 5 (285 bp). 
As listed in Table 4-2, all the exon/intron boundaries conformed to the GT-AG 
splicing signal rules.  
 
The MatInspector program predicted three binding sites for the tumor suppressor p53 
in hepaCAM genomic DNA. Two of the binding sites were situated in intron 1 at 
nucleotides 256-276 (aaacatgtcagggaattcagg) and nucleotides 8294-8314 
(caccatgcccggcctgtttct), while the other binding site was situated in intron 2 at 
nucleotides 11760-11780 (gttcatggcaaggcatttgga). No sequence pattern that resembled 
a promoter was detected in the genomic sequence of hepaCAM upstream of the 




FIGURE 4-19 Comparison of hepaCAM orthologues. Inverted 
shade indicates identity. The sequence data for human, chimpanzee, 
mouse and dog are available in GenBank Accession nos. 
















TABLE 4-2 Intron/Exon boundaries of hepaCAM  






5’ Splice donor Intron Size (bp) 
1 1-129 ggagaaATCATG 129 AGACAGgtagga 10,851 
2 130-471 tcacagACCCCC 342 TAGATGgtaaag 716 
3 472-753 gctcagTGCCCA 282 TATACAgtgagt 294 
4 754-847 ccctagGAAGAA 94 CAAAAGgtctgg 520 
5 848-921 tcacagGAAACA 74 CAGAAGgtgagc 285 
6 922-992 gtgcagCAGACA 71 GACAAGgtgagc 946 
7 993-3244 ttgcagGACTCC 2252   
Nucleotide sequences indicated at the intron (lowercase letters) and exon (uppercase 




4.2.4 Expression of hepaCAM in human tissues and cell lines 
4.2.4.1  Expression of hepaCAM in normal human tissues 
hepaCAM mRNA and protein were found to be widely expressed in normal human 
tissues. A search of hepaCAM cDNA sequence against the human EST databases 
retrieved a number of fragments identified in normal tissues of the liver, brain, breast, 
muscle, lung, retina, uterus, and etc. In addition, according to the GeneNote database 
of human genes and their expression profiles in healthy tissues 
(http://genecards.weizmann.ac.il), hepaCAM was expressed in all 12 human tissues 
tested, with the highest expression in spinal cord (Figure 4-20). A pair of primers 
hCAM-F and hCAM-R that was specific for hepaCAM and not associated with the 
HEPN1 sequence was used in semi-quantitative RT-PCR to detect the expression of 
hepaCAM in normal human liver tissues. The result showed that hepaCAM was 
ubiquitously expressed at a similar level in all the six normal liver tissues (Figure 4-
21). Furthermore, Western blot analysis with anti-hepaCAM polyclonal antiserum 
confirmed the protein expression of hepaCAM in all the 6 normal liver tissues (Figure 
4-22). 
 
4.2.4.2  Suppression of hepaCAM in HCC tissues 
Gene HEPN1 was frequently downregulated in HCC. To evaluate if hepaCAM was 
also differentially expressed in HCC, the mRNA levels of hepaCAM were examined 
in 23 paired liver samples obtained from HCC patients using primers hCAM-F and 
hCAM-R. Semi-quantitative RT-PCR results showed that hepaCAM was 
downregulated in 87% (20/23) of HCC tissues when compared to their non-tumorous 





FIGURE 4-20 Expression of hepaCAM transcript in normal 
tissues (GeneNote expression array). A, The expression level of 
hepaCAM in normal human tissues was calculated from the 
normalized signals and is presented in a graphical way. Tissues 
were grouped according to their origin and the groups colored 
accordingly. The range between the lower and higher measurements
was represented by a white box above the colored minimal 
measurement bar. The graph is presented on the y-axis with a 
special root scale Y = X(1/B) where B = log210 (Safran et al., 2003). 











FIGURE 4-21 Expression of hepaCAM transcript in normal 
liver tissues. Semi-quantitative RT-PCR using hepaCAM-specific 
primers hCAM-F and hCAM-R was performed to determine the 
mRNA expression of hepaCAM in 6 normal liver tissues obtained 
from 6 individuals. RT-PCR products were analyzed by gel 
electrophoresis. b-actin were included in the RT-PCR reaction as 
internal control. The samples are labeled from 1 to 6; NL, normal 
liver. L, 100 bp DNA ladder.
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FIGURE 4-22 Expression of hepaCAM protein in normal liver 
tissues. Western blot analysis with rabbit anti-hepaCAM polyclonal 
antiserum revealed the endogenous hepaCAM protein levels in 6 
normal liver tissues. GAPDH protein level indicates the loading 
quantity. The samples are labeled from 1 to 6; NL, normal liver.
hepaCAM
GAPDH
1NL 2NL 3NL 4NL 5NL 6NL
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FIGURE 4-23 Expression of hepaCAM transcript in 23 HCC 
patients. Semi-quantitative RT-PCR products generated using 
hepaCAM-specific primers hCAM-F and hCAM-R were analyzed 
by gel electrophoresis. b-actin was included as internal control. , 
sample that shows no clear difference in hepaCAM expression; L, 
100 bp DNA ladder; N, non-tumorous liver tissue; T, HCC liver 
tissue; Patient 23 had two HCC nodules (T1 and T2) in the liver. 
b-actin
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4.2.4.3  Suppression of hepaCAM in HCC cell lines 
In addition, semi-quantitative RT-PCR using primers hCAM-F and hCAM-R was 
carried out to analyze the expression of hepaCAM in 5 human HCC cell lines HepG2, 
Hep3B, Huh7, SK-Hep1 and PLC-5 (Figure 4-24). While hepaCAM mRNA was 
detected in the normal liver tissue that was included as a positive control, the 
transcript was undetectable in all the five HCC cell lines.  
 
4.2.4.4 Suppression of hepaCAM in cell lines derived from diverse tumors 
Furthermore, the expression of hepaCAM transcript was screened in six human cancer 
cell lines M14, HL60, NCI-H23, MCF7, Hs683, and HCT116 derived from 
melanoma, leukemia, lung cancer, breast cancer, glioblastoma and colorectal cancer, 
respectively (Figure 4-24). Semi-quantitative RT-PCR showed that hepaCAM mRNA 
was undetectable in all these cell lines. 
 
4.2.4.5 Suppression of hepaCAM in tissues derived from diverse tumors 
The Matched Tumor/Normal Expression Array from Clontech was used to examine 
the expression profile of hepaCAM transcript in a panel of human tumors derived 
from kidney, breast, prostate, uterus, ovary, colon, lung, stomach and rectum (Figure 
4-25). Dot blotting was performed on the membrane by using a DIG-labeled 
hepaCAM cDNA as a probe. Subsequently, the intensity of the dots obtained in the 
normal tissue as compared to its matched tumor was measured. Loading of the cDNAs 
was normalized for housekeeping gene ubiquitin to enable quantitative comparisons 
between gene expressions in different tissues. Downregulated expression of hepaCAM 
in tumor tissue as compared with the normal tissue was observed in 36.4% of the 




FIGURE 4-24 Expression of hepaCAM transcript in cancer 
ce l l  l ines .  Semi-quantitative RT-PCR was used to amplify 
hepaCAM mRNA and GAPDH mRNA (internal control). RT-PCR 
products were analyzed by gel electrophoresis. The expression 
levels of hepaCAM in the cancer cell lines were compared to that in 






































FIGURE 4-25 Expression of hepaCAM transcript in a panel of 
human tumors. hepaCAM mRNA expression was measured on the 
Matched Tumor/Normal Expression Array. Densitometric values 
were normalized to those for ubiquitin. The ratio obtained between 
normal and tumor tissue of each patient is shown. The broken line 
represents the standard deviation obtained from the 













































































































19.7% of tumors exhibited higher hepaCAM levels. The most striking examples were 
the ubiquitous decreased levels of hepaCAM mRNA in ovary tumor samples and the 
elevated levels of hepaCAM mRNA observed in all the lung tumor samples tested. 
 
4.2.5 Plasmid constructs of wildtype and truncated mutants of  
hepaCAM 
In order to investigate the function(s) and the structural significance of hepaCAM, a 
series of hepaCAM deletion mutants were constructed. Mutants with truncations at the 
cytoplasmic domain (Figure 4-26A) included hCAMU320 (deletion of residues 321-
416); hCAMU318 (deletion of residues 319-416); hCAMU290 (deletion of residues 
291-416); and hCAMU263 (deletion of the entire domain from residues 264-416); 
while those with truncations at the extracellular/transmembrane domains (Figure 4-
26B) included hCAMΔ1st Ig (deletion of the 1st Ig domain at residues 33-145); 
hCAMΔ2nd Ig (deletion of the 2nd Ig domain at residues 155-227); hCAMΔIgs 
(deletion of the 1st and 2nd Ig domains at residues 33-227); and hCAM_tail (deletion 
of the signal peptide, extracellular and transmembrane domains).   
 
Wildtype hepaCAM, hCAMU320, and hCAMU263 were fused in-frame at the N-
terminal of the green fluorescent protein (GFP) gene of the expression vector pEGFP-
N2. The resulting plasmids were named as hepaCAM-GFP, hCAMU320-GFP, and 
hCAMU263-GFP, respectively. In addition, wildtype hepaCAM, hCAMU318, 
hCAMU290, hCAMU263, hCAMΔ1st Ig, hCAMΔ2nd Ig, hCAMΔIgs, and 
hCAM_tail were inserted at the N-terminal of the V5 tag of the pcDNA6B/V5-His 
vector, and were designated as hepaCAM-V5, hCAMU318-V5, hCAMU290-V5, 




FIGURE 4-26 Schematic representation of wildtype hepaCAM 
and mutants. A, wildtype and cytoplasmic domain mutants of 
hepaCAM. B, wildtype and extracellular/transmembrane domain 
mutants of hepaCAM. EX, extracellular domain; TM, 
transmembrane domain (grey); CT, cytoplasmic domain; dotted 



















4.2.6   Establishment of stable clones of HepG2 and MCF7 transfectants 
4.2.6.1  HepG2 stable clones 
HepG2 cells were stably transfected with pcDNA6B/V5-His vector and hepaCAM-
V5. Two clones stably transfected with vector (V1 and V2) and 3 clones with 
hepaCAM-V5 (H1, H2 and H3) were screened. Cell lysates of these cells were 
subjected to Western blot analysis with anti-V5 antibody (Figure 4-27). The result 
showed that hepaCAM was absent in the vector clones V1 and V2, and expressed in 2 
(among 3) hepaCAM clones H1 and H3. Real-time RT-PCR using hepaCAM-specific 
primers hCAM-F and hCAM-R showed that hepaCAM mRNA was expressed in 
clones H1 and H3 but not overexpressed when compared to the normal liver tissues, 
and was expectedly absent in clones V1, V2 and H2 (Figure 4-28). Immunostaining 
with anti-V5 antibody confirmed the establishment of homogenous cell clones (Figure 
4-29). Clones V1, V2, H1, and H3 were therefore selected for the downstream 
functional exploration of hepaCAM. 
 
4.2.6.2  MCF7 stable clones 
MCF7 cells were stably transfected with pEGFP-N2 vector (MCF7/pEGFPN2), 
hepaCAM-GFP (MCF7/hepaCAM-GFP), hCAMU263-GFP (MCF7/hCAMU263-
GFP), hCAMU320-GFP (MCF7/hCAMU320-GFP), pcDNA6B/V5-His vector 
(MCF7/pcDNA6), hepaCAM-V5 (MCF7/hepaCAM-V5) and hCAMU263-V5 
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GAPDH
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FIGURE 4-27 Protein expression of HepG2 stable clones
transfected with pcDNA6B/V5-His vector or hepaCAM-V5. 
Anti-V5 antibody was used in the Western blot analysis to evaluate 
the protein levels of hepaCAM in 2 clones transfected with 
pcDNA6B/V5-His vector alone (V1 and V2) and 3 clones 
transfected with hepaCAM-V5 (H1, H2, and H3). The membrane 
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Blast_r hepaCAM
FIGURE 4-28 Real-time RT-PCR analysis of HepG2 stable 
transfectants. The mRNA levels of blasticidin resistant gene 
(Blast_r) and hepaCAM were determined in all the clones and 2 
normal liver tissues (1NL and 2NL), and converted into ratio 










FIGURE 4-29 Confocal microscopy of HepG2 stable 
transfectants. Immunostaining with ant i-V5 antibody was 
performed to visualize hepaCAM protein in both cells from the 
control clones V1 and V2 and cells from the clones expressing 
hepaCAM-V5 (H1 and H3). 400x, magnification.
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by Western blotting using anti-GFP (Figure 4-30) or anti-V5 antibody (Figure 4-31) 
to confirm expression.   
 
4.2.7  Subcellular localization of hepaCAM and mutants 
4.2.7.1  hepaCAM is localized predominantly on plasma membrane 
Two HCC cell lines Hep3B and HepG2 and a breast cancer cell line MCF7 (Figure 4-
32) were transiently transfected with hepaCAM-V5. After 48 hours of transfection, 
the cells were immunostained with anti-V5 antibody and the mitochondria of MCF7 
cells were labeled with Mitotracker-orange. Fluorescence microscopy showed that 
hepaCAM was scattered to punctuate structures in the cytoplasm, absent in the 
nucleus and predominantly localized on the plasma membranes of Hep3B, HepG2, 
and MCF7 cells. In addition, hepaCAM protein was not recruited to the mitochondria 
of MCF7 cells. 
 
4.2.7.2  Subcellular localization of hepaCAM is cell density-dependent 
The subcellular localization of hepaCAM appeared to be cell density-dependent 
(Figure 4-33). In well spread stable MCF7/hepaCAM-GFP cells, hepaCAM protein 
was localized to punctuate structures in the perinuclear membrane, cytoplasm, and at 
the tip of cell surface protrusions that were about to make contact with adjacent cell 
surfaces, forming zipper-like structures. Once cells became confluent, the protein was 
localized to a lesser extent in the perinuclear membrane and cytoplasm, and 







FIGURE 4-30 Protein expression of GFP-fused hepaCAM and 
cytoplasmic domain mutants in stable MCF7 cells. Proteins 
expressed by pEGFP-N2 vector as well as GFP-fused wildtype and 
cytoplasmic domain mutants of hepaCAM were detected by 
Western blot analysis with anti-GFP antibody. Positions of the 

















































FIGURE 4-31 Protein expression of V5-fused hepaCAM
and cytoplasmic domain mutant in stable MCF7 cells. 
Proteins expressed by pcDNA6B/V5-His vector (pcDNA6) as 
well as V5-fused wildtype hepaCAM and mutant hCAMr263 
were detected by Western blot analysis with anti-V5 antibody. 
Positions of the molecular size markers are shown on the left 
panel.
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FIGURE 4-32 Subcellular localization of hepaCAM protein in 
cancer cell lines. Two HCC cell lines Hep3B (A) and HepG2 (B) 
cells and a breast cancer cell line MCF7 (C1 and C2) were 
transiently transfected with hepaCAM-V5 plasmid. Anti-V5 
antibody was used for immunostaining to detect the expression and 
localization of hepaCAM. Confocal microscopy revealed that 
hepaCAM was scattered in the cytoplasm and predominantly 
localized on the plasma membrane (arrows). Mitochondria of 




FIGURE 4-33 The localization of hepaCAM in 
MCF7/hepaCAM cells is cell density-dependent. 
MCF7/hepaCAM-GFP cells were seeded at low density and 
cultured for a few days. Upper panel, well-spread cells with surface 






4.2.7.3  Colocalization of hepaCAM with E-cadherin 
The localizations of hepaCAM and E-cadherin were examined in confluent polarized 
MCF7/hepaCAM-GFP cells by confocal microscopy (Figure 4-34). The cells were 
seeded in low density and allowed to grow to confluence on 0.4-µm Transwell filters 
before immunostaining for E-cadherin, an adhesion molecule known to localize in the 
lateral cell surface. In the X-Y section, hepaCAM-GFP protein was distributed to 
honeycomb-like structures at cell-cell boundaries that significantly colocalized with 
E-cadherin. In the X-Z vertical cross-section, the distribution of E-cadherin along the 
entire lateral cell surface coincided with hepaCAM-GFP. Moreover, hepaCAM was 
also detected at the basal membrane in contact with the transwell membrane. Since 
hepaCAM and E-cadherin appeared to colocalize, coimmunoprecipitation was 
performed to investigate if there was any physical interaction between the two 
proteins (Figure 4-35). Cell lysate prepared from MCF7/hepaCAM-V5 cells was 
immunoprecipitated with anti-V5 antibody and subjected to Western blot analysis 
with either anti-E-cadherin or anti-V5 antibody. MCF7/pcDNA6 cell lysate was 
included in the experiment as control. No coimmunoprecipitation was observed, 
suggesting that E-cadherin and hepaCAM are not associated. 
 
4.2.7.4 Transmembrane domain is essential for plasma membrane 
localization of hepaCAM 
Deletion of the cytoplasmic domain did not affect plasma membrane localization of 
hepaCAM. Microscopic observation revealed that the cytoplasmic domain mutants of 
hepaCAM were clearly localized in the plasma membrane of MCF7/hCAMU320-
GFP and MCF7/hCAMU263-GFP (Figure 4-36A) cells. Moreover, immunostaining 








FIGURE 4-34 Colocalization of hepaCAM with E-cadherin. 
MCF7/hepaCAM-GFP cells grown to confluence on the Transwell 
filter unit were fixed, permeabilized, and immunostained with anti-
E-cadherin. Laser scanning confocal microscopy was performed 
with a filter set suitable for fluorescein and rhodamine detection. 
The representative sets of X–Y and X–Z sections are indicated. a, 
hepaCAM-GFP stained green; b, E-cadherin stained red; c, confocal 
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FIGURE 4-35 hepaCAM does not coimmunoprecipitate with 
E-cadherin. Equal amount of cell lysate prepared from 
MCF7/pcDNA6 or MCF7/hepaCAM-V5 cells was 
immunoprecipitated (IP) with anti-V5 antibody and analyzed by 
Western blotting using anti-E-cadherin (E-cadherin; top panel) or 
anti-V5 antibody (hepaCAM; bottom panel). The signals 
corresponding to E-cadherin and hepaCAM-V5 molecules are 
marked with arrowheads. Lane 1, cell lysate of MCF7/pcDNA6 
before IP; Lane 2, cell lysate of MCF7/hepaCAM-V5 before IP; 
Lane 3, cell lysate of MCF7/pcDNA6 after IP; Lane 4, cell lysate of 
MCF7/hepaCAM-V5 after IP; Lane 5, precipitate of 
MCF7/pcDNA6; Lane 6, precipitate of MCF7/hepaCAM-V5. 
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FIGURE 4-36 Plasma membrane localization of hepaCAM is 
independent of its cytoplasmic domain. A, The expressions of 
pEGFP-N2 (a), hCAMr263-GFP (b) and hCAMr320-GFP (c) in 
stable MCF7 cells were detected by fluorescence microscopy. B, 
MCF7/hepaCAM-V5 (a) and MCF7/hCAMr263 -V5 (b) cells 
were immunostained with anti-V5 antibody. The localizations of 
hepaCAM and mutant were detected under a fluorescence 
microscope. 320x, magnification. 




V5 antibody showed expression of wildtype and tailless hepaCAM on the plasma 
membrane, implicating that the extracellular/transmembrane domains hepaCAM may 
be responsible for its plasma membrane localization.  
 
MCF7 cells were transfected with the extracellular/transmembrane mutants 
hCAMΔ1st Ig-V5, hCAMΔ2nd Ig-V5, hCAMΔIgs-V5, and hCAM_tail-V5 (Figure 4-
37). Forty-eight hours post-transfection, the cells were immunostained with anti-V5 
antibody and the localization of these proteins was visualized by fluorescence 
microscopy. hCAMΔ1st Ig-V5, hCAMΔ2nd Ig-V5, and hCAMΔIgs-V5 were 
distributed, with varying intensities, on the plasma membrane as well as to the 
punctuate structures in the cytoplasm of MCF7 cells. On the contrary, hCAM_tail-V5 
was not distributed to the plasma membrane but localized in the cytoplasm in a 
punctuate pattern. The results suggested that the signal peptide and transmembrane 
domain of hepaCAM are essential for plasma membrane localization, although the 
extracellular Ig domains may participate in stabilizing the localization. 
 
4.2.8  N-linked glycosylation of hepaCAM 
Sequence analysis of hepaCAM predicted six N-linked glycosylation sites on its 
extracellular domain (Figure 4-16), indicating that hepaCAM protein might be 
glycosylated. To investigate if hepaCAM was indeed glycosylated, the cell lysate of 
MCF7/hepaCAM-GFP cells was enzymatically digested with PNGase F to cleave 
putative N-linked glycans (Figure 4-38A). An untreated sample was included as 
control. The molecular weight (MW) of hepaCAM-GFP was shown by Western blot 
analysis to be ~100 kDa. After deglycosylation, the MW shifted to ~75 kDa. 






FIGURE 4-37 Subcellular l o c a l i z a t i o n  o f  extracellular/ 
transmembrane domain mutants of hepaCAM in MCF7 cells.
MCF7 cells transiently transfected with hCAMD1st  Ig-V5(a), 
hCAMD2nd Ig-V5 (b), hCAMDIgs-V5 (c), and hCAM_tail-V5 (d) 
were immunostained with anti-V5 antibody and visualized under a 

















FIGURE 4-38 N-Linked glycosylation of hepaCAM. A, Cell 
lysate prepared from MCF7/hepaCAM-GFP cells (lanes 2 and 3) 
was treated without (-) or with (+) PNGase F. Cell lysate of 
untreated parental MCF7 cells (lane 1) was included as control. B, 
MCF7 cells transiently transfected with hepaCAM-GFP were 
treated with tunicamycin at the indicated concentrations for 24 
hours before lysis. Protein samples were resolved by SDS-PAGE 
and analyzed by Western blotting using anti-GFP antibody. Solid 
and open arrowheads indicate signals for glycosylated and non-
glycosylated proteins, respectively. Positions of the molecular size 




with different doses of tunicamycin (Figure 4-38B), an antibiotic that inhibits N-
linked glycosylation, also gave rise to a band at ~75 kDa. The results verified that 
hepaCAM is a glycoprotein. 
 
4.2.9 Homodimerization of hepaCAM occurs through cis-interaction on 
plasma membrane  
4.2.9.1  Dimerization of hepaCAM on cell surface  
The existing form of hepaCAM on cell surface was evaluated by incubating a 
monolayer of MCF7/hepaCAM-GFP cells with a noncleavable membrane-
impermeable crosslinker BS3 (Figure 4-39A). An untreated sample served as control. 
The cells were lysed and analyzed by Western blotting using anti-GFP antibody. In 
the presence of BS3, a band of ~200 kDa which seemed to represent the dimerized 
form of hepaCAM-GFP appeared, accompanied with the disappearance of the 
hepaCAM monomers. Similarly, treatment of MCF7/hepaCAM-V5 cells with BS3 
resulted in a loss of the ~75 kDa monomeric form of hepaCAM with a concomitant 
gain in the higher molecular weight species at ~150 kDa although no distinct band 
was noted (Figure 4-39B). It was possible that the anti-V5 antibody was unable to 
recognize the higher molecular weight species as efficiently as monomers. 
 
4.2.9.2 Homodimerization of hepaCAM  
To examine if hepaCAM could form homodimer on cell surface, MCF7/hepaCAM-
GFP cells were treated with DTSSP, a reducible membrane-impermeable crosslinker. 
In the absence of the reducing agent DTT, a significant increase in the 200-kDa 
species was observed. However, when DTT was included into the sample buffer, the 

















FIGURE 4-39 Dimerization of hepaCAM on plasma 
membrane. Crosslinking of hepaCAM-GFP (A) and hepaCAM-V5 
(B) on cell surface. A monolayer of MCF7/hepaCAM-GFP or 
MCF7/hepaCAM-V5 cells was untreated (-) or treated (+) with 3 
mM BS3 prior to cell lysate preparation using lysis buffer 
containing 10 mM iodoacetamide. Protein samples were subjected 
to Western blot analysis with anti-GFP or anti-V5 antibody, 
respectively. Solid and open arrowheads indicate signals for 
dimeric and monomeric proteins, respectively. The positions of the 
molecular size markers are shown on the left of each panel.
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closely comparable to that of the untreated sample (Figure 4-40). Interestingly, 
protein species that seemed to represent the dimeric form of the proteins were noted in 
the untreated sample of hepaCAM-GFP. This phenomenon could be caused by the 
existence of strong covalent bonds between the dimers of hepaCAM-GFP.  
 
A coimmunoprecipitation experiment further proved that hepaCAM homodimerized. 
An equal amount of cell lysate prepared from MCF7 cells transiently transfected with 
hepaCAM-GFP, hepaCAM-V5, or a combination of both was immunoprecipitated 
with anti-GFP antibody followed by Western blot analysis with anti-V5 or anti-GFP 
antibody. The result revealed coimmunoprecipitation of hepaCAM-V5 with 
hepaCAM-GFP (Figure 4-41), demonstrating that hepaCAM molecules dimerize 
through homophilic interaction.  
 
4.2.9.3  cis-Dimerization of hepaCAM 
To determine if hepaCAM-GFP formed cis- or trans-dimers on cell surface, an 
adherent monolayer and a single-cell suspension of MCF7/hepaCAM-GFP cells were 
treated with BS3 prior to Western blot analysis with anti-GFP antibody (Figure 4-42). 
The extent of dimerization was comparable in both adherent and suspension cells, 
suggesting that homodimerization of hepaCAM occurs predominantly through cis-






FIGURE 4-40 Homodimerization of hepaCAM on plasma 
membrane. A monolayer of MCF7/hepaCAM-GFP cells was 
untreated (-) or treated (+) with 3 mM DTSSP prior to cell lysis in 
lysis buffer containing 10 mM iodoacetamide. Protein samples were 
resuspended in Laemmli sample buffer in the presence (+) or 
absence (-) of 50 mM DTT, and analyzed by Western blotting using 
anti-GFP antibody. ‘*’, dimer in un-crosslinked sample. Solid and 
open arrowheads indicate signals for dimeric and monomeric 
proteins, respectively. The positions of the molecular size markers 
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FIGURE 4-41 Coimmunoprecipitation of hepaCAM-GFP and 
hepaCAM-V5. MCF7 cells were transfected with hepaCAM-GFP, 
hepaCAM-V5, or both. Protein samples were prepared, 
immunoprecipitated (IP) with anti-GFP antibody and analyzed by 
Western blotting (IB) using either anti-GFP (left panel) or anti-V5 
antibody (right panel). The signals corresponding to hepaCAM-GFP 








BS3          + +
Monolayer Single-cell 
suspension
FIGURE 4-42 Dimerization of hepaCAM through cis-
interaction. A monolayer or a single-cell suspension of 
MCF7/hepaCAM-GFP cells was incubated in the absence (-)  or 
presence (+) of 3 mM BS3. Protein samples were subjected to 
Western blot analysis with anti-GFP antibody. Solid and open 
arrowheads indicate signals for dimeric and monomeric proteins, 
respectively. The positions of the molecular size markers are shown 
on the left panel.
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4.2.9.4 Dimerization of hepaCAM is independent of its cytoplasmic 
domain  
MCF7/hCAMU263-GFP cells were treated with BS3 to explore if the cytoplasmic 
domain of hepaCAM was essential for dimerization. After Western blot analysis with 
anti-GFP antibody, the result showed that the monomeric form of hCAMU263-GFP 
was diminished and its dimeric form was accumulated at ~125 kDa in the BS3-treated 
sample, indicating that dimerization of hepaCAM is independent of its cytoplasmic 
domain (Figure 4-43). 
 
4.2.10  The cytoplasmic domain of hepaCAM is phosphorylated 
A polyclonal antiserum that recognizes hepaCAM cytoplasmic domain, but only in its 
non-phosphorylated form, was generated. The antiserum was generated by 
immunization of rabbits with a recombinant bacterial His-tagged fusion protein 
expressing the cytoplasmic domain of hepaCAM. Western blot analysis showed that 
this anti-hepaCAM antiserum could specifically detect the bacterial fusion protein, 
otherwise undetectable by the preimmune serum. However, when the antiserum was 
tested on the cell lysate of MCF7 transfected with hepaCAM-V5, hepaCAM could not 
be detected. This observation led to the suspicion that the cytoplasmic domain of 
hepaCAM might be post-translationally modified by phosphorylation. Evaluation of 
the cytoplasmic sequence of hepaCAM by the NetPhos 2.0 server showed that the 
domain was highly phosphorylated. Twenty-eight potential serine, threonine or 
tyrosine phosphorylated residues were scattered along the cytoplasmic domain, with 













FIGURE 4-43 Dimerization of hepaCAM is independent of its 
cytoplasmic domain. A monolayer of MCF7/hCAMr263-GFP 
cells was untreated (-) or treated (+) with 3 mM BS3. Cell lysates 
prepared in lysis buffer containing 10 mM iodoacetamide were 
subjected to Western blot analysis with anti-GFP antibody. ‘*’, 
dimer in un-crosslinked sample. Solid and open arrowheads indicate 
signals for dimeric and monomeric proteins, respectively. The 
positions of the molecular size markers are shown on the left panel. 
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FIGURE 4-44 Phosphorylation of hepaCAM cytoplasmic 
domain. A, The cytoplasmic domain (residues 260-416) of  
hepaCAM was used to generate rabbit polyclonal anti-hepaCAM 
antiserum. Potential serine/threonine and tyrosine kinase 
phosphorylation sites in the cytoplasmic region were identified 
using NetPhos 2.0 software. aa, amino acids. B, Cell lysate prepared 
from C3A cells expressing endogenous hepaCAM (lanes 1 and 2) or 
MCF7/hepaCAM-V5 cells expressing exogenous hepaCAM (lanes 
3 and 4) was either untreated (-) or treated (+) with calf intestinal 
alkaline phosphatase (CIP). After dephosphorylation, hepaCAM 
protein was detected by Western blot analysis with the rabbit anti-
hepaCAM polyclonal antiserum. 
B
260 – 416aa




Experimentally, cell lysates of C3A cells expressing endogenous hepaCAM and 
MCF7 cells expressing exogenous hepaCAM-V5 were dephosphorylated with calf 
intestinal alkaline phosphatase (CIP). Untreated cell lysates served as controls. As 
shown in Figure 4-44B, the CIP-treated endogenous and exogenous hepaCAM were 
detected by the rabbit anti-hepaCAM antiserum, confirming that the cytoplasmic 
domain of hepaCAM is phosphorylated. 
 
4.2.11   Anti-proliferative effect of hepaCAM 
The suppression of hepaCAM in a variety of human tumors implicated a possible 
involvement of hepaCAM in cell growth regulation. Therefore, colony formation was 
carried out while growth rate was determined in stable HepG2 clones to assess the 
anti-proliferative effect of hepaCAM. The results showed that the number of colonies 
formed after two weeks of blasticidin selection was reduced by 10-fold in the HepG2 
cells transfected with hepaCAM-V5 (P = 0.0022, Figure 4-45), and the growth rate 
was decreased by 14-fold (P < 0.001, on day 5, Figure 4-46) in cells expressing 
hepaCAM (H1 and H3). No clear cell death was observed in the course of examining 
growth arrest, suggesting that hepaCAM inhibits cell growth through suppressing 
proliferation rather than inducing apoptosis. 
 
4.2.12  hepaCAM induces p53 expression 
The expression of tumor suppressor p53 was tested in the HepG2 clones transfected 
with vector alone (V1 and V2) and expressing hepaCAM-V5 (H1 and H3). Western 
blot analysis with anti-p53 antibody (Figure 4-47) showed that while p53 was 
undetectable in both vector clones, it was clearly activated in the cells expressing 



























FIGURE 4-45 Inhibition of colony formation by hepaCAM. 
HepG2 cells transfected with pcDNA6B/V5-His vector (pcDNA6) 
or hepaCAM-V5 construct (hepaCAM) were selected with 
blasticidin for 2 weeks. The cell colonies formed at the end of the 
experiments were counted in 10 randomly selected fields and 
represented by the bar graph (means±SD, n = 6), ** P = 0.0022 as 
































FIGURE 4-46 Suppression of cell growth by hepaCAM. The 
growth rate of the cells from HepG2 clones H1 and H3 (stably 
transfected with hepaCAM-V5) was compared to that of the cells 
from V1 and V2 (stably transfected with pcDNA6B/V5-His vector 
alone) for 5 days by MTT assay. Data represent means±SD (n = 6), 
* P < 0.001 (on day 5) as assessed by ANOVA.
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FIGURE 4-47 Effect of hepaCAM on tumor suppressor p53.
The expression of p53 was detected in HepG2 clones transfected
with pcDNA6B/V5-His vector alone (V1 and V2) and expressing 
hepaCAM-V5 (H1 and H3) by Western blot analysis with anti-p53 
antibody. GAPDH, loading control.
V1 V2 H1 H3
GAPDH
p53
4.2.13   Modulation of cell adhesion by hepaCAM 
4.2.13.1 hepaCAM modulates cell-matrix interaction through its 
cytoplasmic domain 
The adhesive properties of hepaCAM were evaluated on the stable HepG2 clones 
through cell aggregation and spreading assays. Although hepaCAM did not clearly 
change cell aggregation (Figure 4-48), it was capable of modulating cell-matrix 
adhesion significantly on fibronectin (Figure 4-49). About 50 and 90% of the cells 
from both clones H1 and H3 exhibited spread morphology at 30 min and 2 h of 
incubation, respectively. In contrast, the majorities of the cells from clones V1 and V2 
remained round at the same time points. The number of cells showing spread 
morphology from clones H1 and H3 was about 5-fold higher than that from the 
control clones V1 and V2 (P < 0.001).  
 
To investigate if the adhesive properties of hepaCAM were mediated through its 
cytoplasmic domain, MCF7 cells stably transfected with pcDNA6B/V5-His vector, 
hCAMU263-V5 (lacked cytoplasmic domain) and hepaCAM-V5 were used in cell 
spreading and detachment assays. Figure 4-50 showed that about 60% and 79% of the 
MCF7/hepaCAM-V5 cells exhibited spread morphology on fibronectin at 30 minutes 
and 2 hours of incubation, respectively, in contrast to 40.8% and 58.2% of the 
MCF7/hCAMU263-V5 cells, and 7.3% and 18% of the MCF7/pcDNA6 cells (P < 
0.001). Similarly on matrigel, MCF7/hepaCAM-V5 cells showed the fastest 
spreading, followed by MCF7/hCAMU263-V5 cells, and then MCF7/pcDNA6 cells 
(P < 0.001). In cell detachment assay (Figure 4-51), MCF7/hepaCAM-V5 cells 
detached 18.9 times and 21.6 times slower than MCF7/pcDNA6 cells at 5 minutes 





FIGURE 4-48 hepaCAM does not induce cell aggregation.
Single cell suspension of HepG2 c lones  transfected with 
pcDNA6B/V5-His vector alone (V1) or expressing hepaCAM-V5 
(H1) was incubated in HBSS for 1 hour on a rotary shaker at 37°C. 
The microscopic photos were taken under 200x-magnification. No 
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FIGURE 4-49 Modulation of cell-matrix adhesion by 
hepaCAM. A, Cell morphology. HepG2 clones transfected with 
pcDNA6B/V5-His vector alone (V1 and V2) and expressing 
hepaCAM-V5 (H1 and H3) were allowed to spread on fibronectin-
coated plates for 30 min or 2 hours. The microscopic photos were
taken under 200x-magnification. B, The percentage of cell 
spreading. At 30 min or 2 hours after plating, total number of cells 
and cells showing spread morphology were counted in ten randomly
selected fields (>60 cell per field), and the percentage of cell
spreading was then computed. The data represent means±SD (n = 6), 














FIGURE 4-50 Cell spreading modulated by hepaCAM is 
dependent of its cytoplasmic domain. A, MCF7/pcDNA6 (left 
panel) ,  MCF7/hCAMr263-V5 (middle panel) and 
MCF7/hepaCAM-V5 (right panel) cells were allowed to spread on 
matrigel-coated coverslips for 30 min or 2 hours. Inset, cell 
morphology before spreading. The microscopic photos were taken 
under 200x-magnification. B, The percentage of spread cells on 
fibronectin and matrigel. At 30 min or 2 hours after plating, total 
number of cells showing spread morphology were counted in ten 
randomly selected fields, and the percentage of cell spreading was 
then computed. The data represent means±SD (n = 6), ** P < 0.001 










































FIGURE 4-51 Cell detachment modulated by hepaCAM is 
dependent of its cytoplasmic domain. A, MCF7/pcDNA6 (left 
panel) ,  MCF7/hCAMr263-V5 (middle panel) and 
MCF7/hepaCAM-V5 (right panel) cells were detached in 1 mM 
EDTA for 5 min or 15 minutes. The microscopic photos were taken 
under 200x- and 400x-magnifications. B, At 5 min or 15 min after 
incubation, total number of detached cells was counted in ten 
randomly selected fields, and the percentage of cell detachment was 
then computed. The data represent means±SD (n = 6), ** P < 0.001 





































detached approximately 4 times and 2.2 times slower than MCF7/pcDNA6 cells at 
time points 5 minutes and 15 minutes (P < 0.001). The results demonstrated that in 
addition to its extracellular and transmembrane domains, hepaCAM requires its 
cytoplasmic domain to mediate strong cell-matrix adhesion. 
 
4.2.13.2   hepaCAM modulates cell motility essentially through its 
cytoplasmic domain 
Assessment of cell motility of hepaCAM was carried out with the Boyden chamber 
and wound healing assays using HepG2 clones V1 (transfected with pcDNA6B/V5-
His vector) and H1 (expressing hepaCAM-V5). Both Boyden chamber (Figure 4-52) 
and wound healing assays (Figure 4-53) showed that the motility of HepG2 cells was 
increased (P = 0.0011) when transfected with hepaCAM. These results indicated that 
hepaCAM increases cell motility. 
 
Similar studies were performed on stable MCF7 cells transfected with pcDNA6B/V5-
His vector, hepaCAM-V5, and hCAMU263-V5 (lacked cytoplasmic domain). Barely 
any of these cells migrated through the 8-μm transwell membrane. This observation 
could be explained by the poorly invasive nature of MCF7 cells. Moreover, 
MCF7/hepaCAM-V5 cells compared to the vector transfected cells appeared 
enlarged, therefore retarding migration. Nevertheless, wound healing assay (Figure 4-
54) demonstrated that after 24 hours of incubation, MCF7/hepaCAM-V5 cells filled 
59.3% of the scratched area (P < 0.01), compared to 36.3% by MCF7/hCAMU263-
V5 cells (P > 0.05) and 33.1% by MCF7/pcDNA6 cells. After 48 hours, 
MCF7/hepaCAM-V5 cells closed 83.7% of the wound (P < 0.01), compared to 55.2% 

























FIGURE 4-52 Induction of cell migration by hepaCAM. Cell 
migration was examined by using the transwell chambers with 8-
mm pore size membranes coated with matrigel. HepG2 clones V1 
(pcDNA6) and H1 (hepaCAM) were allowed to migrate through the 
membrane for 24 hours. The migrated cells were harvested into new 
24-well plate and viewed by microscopy (100x-magnification). The 
migration was quantified by blind counting of the migrated cells in 
10 randomly selected fields and represented as mean±SD (n = 6) by 




FIGURE 4-53 Promotion of wound healing by hepaCAM. 
Wounds were made by pipette tip on confluent HepG2 clones V1 
(pcDNA6; left) and H1 (hepaCAM; right); and allowed to be healed 
by cell migration for 24 hours. The diameters of wounds were 
measured by microscopy (200x-magnification) at 0 hour and 24 
hours after wounding. Arrowheads show the diameters of the initial 
wounds. Changes in diameter were computed into ratio 
(means±SD%, n = 6) to represent wound closure. ** P = 0.0011 as 
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FIGURE 4-54 Wound healing modulated by hepaCAM is 
dependent of its cytoplasmic domain. A, Wounds were made by 
pipette tip on confluent MCF7/pcDNA6 (left panel), 
MCF7/hCAMr263-V5 (middle panel) and MCF7/hepaCAM-V5 
(right panel) cells; and allowed to heal for 24 and 48 hours. The 
microscopic photos were taken under 100x-magnification. B, The 
diameters of wounds were measured on the microscopic photos at 0 
hour, 24 hours and 48 hours after wounding. Changes in wound 
diameter were computed into percentage (means±SD%, n = 6) to 

























Hence, the cytoplasmic domain is important for cell motility modulated by hepaCAM. 
 
4.2.14    Partial resistance of hepaCAM to Triton X-100 solubilization 
Cell-matrix interactions are achieved by the coordinated interplay amongst cell 
adhesion molecules, actin cytoskeleton and lipid rafts. Detergent solubility assay is 
commonly used as a first step to study such interaction. Studies have shown that 
proteins that are interconnected to cytoskeletal proteins and lipid rafts are resistant to 
solubilization by non-ionic detergent e.g. Triton X-100, suggesting that proteins 
insoluble in non-ionic detergents interact with the cytoskeleton and/or lipid rafts 
(Simons and Ikonen, 1997; Tarone et al., 1984; Neame and Isacke, 1993; Stickney et 
al., 2004). 
 
Detergent solubility assays were performed on C3A cells expressing endogenous 
hepaCAM and MCF7 cells transiently transfected with hepaCAM. The cells were 
extracted in 1% Triton X-100, and equal volumes of the detergent-soluble and  
-insoluble lysates were analyzed by Western blotting using anti-hepaCAM antiserum 
or anti-V5 antibody as indicated in Figure 4-55. In both C3A and transfected MCF7 
cells, a fraction of hepaCAM remained resistant to Triton X-100 solubilization. 
 
The distribution of hepaCAM-insoluble protein in MCF7 cells was shown in Figure 4-
56. MCF7 cells transfected with hepaCAM-V5 construct were treated with 1% ice-
cold Triton X-100 to remove the detergent-soluble proteins before fixation. The cells 
were subsequently immunostained with anti-V5 antibody. For a control, the 
transfected cells were fixed prior to permeabilization with 1% ice-cold Triton X-100. 
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FIGURE 4-55 Partial resistance of hepaCAM to Triton X-100 
solubilization. The endogenous and exogenous hepaCAM proteins 
were extracted from C3A (left panel) and hepaCAM-V5-
transfected MCF7 (right panel) cells, respectively. Equal volumes 
of Triton X-100-soluble (S) and -insoluble (I) lysates were analyzed 
by Western blotting (IB) using anti-hepaCAM antiserum or anti-V5 
















FIGURE 4-56 Subcellular localization of detergent-insoluble 
hepaCAM. MCF7 cells transiently transfected with hepaCAM-V5 
were fixed either before (top panel) or after (bottom panel) 
extraction with ice-cold 1% Triton X-100, and immunostained with 
anti-V5 antibody. The cells were visualized by fluorescence (left 
panel) or phase contrast (right panel) microscopy. 320x, 
magnification.
176
localized predominantly to punctuate structures in the cytoplasm as well as weakly on 
the plasma membrane of MCF7 cells. 
 
4.2.15 Residues located within 319-416 of the cytoplasmic domain of 
hepaCAM confers Triton X-100 insolubility  
MCF7 and HeLa cells were transiently transfected with wildtype hepaCAM-V5 
construct and cytoplasmic domain truncated constructs hCAMU318-V5, 
hCAMU290-V5, and hCAMU263-V5 for 48 hours. The cells were lysed in 1% 
Triton X-100, and equal volumes of the detergent-soluble and -insoluble lysates were 
subjected to Western blot analysis with anti-V5 antibody. In contrast to wildtype 
hepaCAM, truncations of hepaCAM cytoplasmic domain after residues 263, 290 and 
318 completely abolished detergent insolubility of hepaCAM in MCF7 and HeLa 
cells (Figure 4-57). The results indicated that hepaCAM cytoplasmic domain, 
particularly residues located within 319-416, is responsible for conferring the 
detergent-resistant nature of the protein, implicating a critical role of the domain in 
interacting with the actin cytoskeleton and/or lipid rafts. 
 
4.2.16    Interaction of hepaCAM with actin cytoskeleton 
MCF7 cells transfected with hepaCAM-V5 were immunostained with anti-V5 
antibody to detect hepaCAM as well as labeled with TRITC-conjugated phalloidin to 
stain F-actin. Colocalization of hepaCAM and F-actin was observed mainly on the 
plasma membrane and, to a lesser extent, to the punctuate structures in the cytoplasm 
(Figure 4-58). When the transfected MCF7 cells were treated with 10 µM 
cytochalasin B, an agent that disrupts the actin filament, not only was the actin 
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FIGURE 4-57 Detergent solubility of hepaCAM and its  
cytoplasmic domain mutants. MCF7 and  HeLa cells were 
transiently transfected with V5-fused hepaCAM and its cytoplasmic
domain deleted mutants for 48 hours. The cells were extracted in
1% Triton X-100 in PBS. Equal volumes of Triton X-100-soluble 
(S)  and -insoluble (I) lysates were subjected to Western blot 

















FIGURE 4-58 Colocalization of hepaCAM with F-actin. MCF7 
cells transfected with hepaCAM-V5 were either treated (top panel) 
or untreated (bottom panel) with 10 mM cytochalasin B for 90 min 
to depolymerize F-actin. The cells were then immunostained with 
anti-V5 antibody (left panel). F-actin was labeled with TRITC-
conjugated phalloidin (middle panel) .  Confocal images of 
hepaCAM a n d  F -actin were merged to show regions of 
colocalization (right panel).
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membrane was also affected ― hepaCAM localized more dominantly to punctuate 
structures in the cytoplasm. Interestingly, translocated from the plasma membrane, 
both hepaCAM and actin appeared clustered in the cytoplasm. 
 
Furthermore, P100 fractions containing cellular membranes and cytoskeletal elements 
were prepared from both MCF7 and HeLa cells transfected with hepaCAM-V5. These 
fractions were resuspended in buffer containing 1% Triton X-100 and separated into 
soluble and insoluble components (Figure 4-59). In accord with Figure 4-55, 
hepaCAM remained partially insoluble in 1% Triton X-100. Stickney et al. showed 
that disruption of the F-actin network with 1 M potassium iodide (KI) resulted in the 
solubilization of merlin in Triton X-100, implying the direct association of merlin 
with F-actin (Stickney et al., 2004). Similar experiments were performed. 
Depolymerization of F-actin resulted in a significant shift of hepaCAM from the 
insoluble fraction to the soluble one. Notably, a small amount of hepaCAM remained 
insoluble although F-actin was completely solubilized, indicating the presence of 
another Triton X-100-insoluble pool of hepaCAM not associated with F-actin.  
 
4.2.17 Subcellular localization of hepaCAM affects its interaction with F-     
actin 
The cytoplasmic domain of hepaCAM was essential for cell-matrix adhesion, cell 
motility and detergent insolubility, implicating a possible interaction of the 
cytoplasmic domain with F-actin. The subcellular distributions of several hepaCAM 
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FIGURE 4-59 Depolymerization of  F -actin affects detergent 
solubility of hepaCAM. P100 fractions of MCF7 and HeLa cells 
transfected with hepaCAM-V5 were extracted in PBS containing 
1% Triton X-100 (TX) without or with 1 M potassium iodide (KI) 
to depolymerize F-actin. Equal volumes of soluble (S) and insoluble 
(I) lysates were subjected to Western blot analysis with anti-V5 
(hepaCAM) or anti-actin (actin) antibody. 
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domain of hepaCAM affected its interaction with F-actin. The localizations of 
hepaCAM’s extracellular/transmembrane mutants hCAMΔ1st Ig-V5, hCAMΔ2nd Ig-
V5, hCAMΔIgs-V5 and hCAM_tail-V5 were shown in Figure 4-37. hCAMΔ1st Ig-
V5, hCAMΔ2nd Ig-V5 and hCAMΔIgs-V5 were localized to the plasma membrane 
but hCAM_tail-V5 was localized to punctuate structures in the cytoplasm. MCF7 
cells were transiently transfected with these mutants, and the P100 fractions harvested 
from these cells were extracted with 1% Triton X-100 in the absence or presence of 
1M KI. Depolymerization of F-actin with KI showed an increased solubility of 
hCAMΔ1st Ig, hCAMΔ2nd Ig, and hCAMΔIgs proteins to 1% Triton X-100; however 
hCAM_tail remained unaffected (Figure 4-60), suggesting that the localization of 
hepaCAM cytoplasmic domain at the plasma membrane is necessary for its 
interaction with F-actin. 
 
In addition to the observation in Figure 4-57 that the cytoplasmic domain of 
hepaCAM conferred its detergent-resistant nature, Figure 4-60 revealed that the 
extracellular Ig domains regulated the insolubility of plasma membrane-bound 
hepaCAM to 1% Triton X-100. Deletion of the 1st Ig domain of hepaCAM rendered 
the protein more soluble in 1% Triton X-100 (without KI). Conversely, removal of the 
2nd Ig rendered the protein more insoluble in Triton X-100. In the absence of both Ig 
domains, an almost equivalent amount of hepaCAM was detected in both the soluble 











FIGURE 4-60 Relationship between hepaCAM structural 
domains and F-actin. P100 fractions of MCF7 cells transfected 
with hCAMD1st Ig-V5, hCAMD2nd Ig-V5, hCAMDIgs-V5 and 
hCAM_tail-V5 for 48 hours were extracted in 1% Triton X-100 
(TX) without or with 1 M potassium iodide (KI). Equal volumes of
soluble (S) and insoluble (I) lysates were analyzed by Western 
blotting using anti-V5 antibody.
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4.2.18   Recruitment of hepaCAM to lipid rafts  
The fraction of hepaCAM that remained insoluble in Triton X-100 after 
depolymerization of F-actin with KI could be associated with lipid rafts or its 
derivative, caveolae. For convenience, both structures are here referred to as lipid 
rafts. Lipid rafts are cholesterol- and sphingolipid-enriched microdomains important 
for numerous signal transduction processes. Like the actin cytoskeleton, lipid rafts are 
insoluble in cold nonionic detergents. However, they can be differentiated from the 
cytoskeleton by their low buoyant density (Brown and London, 1998). 
 
The putative connection between hepaCAM and the lipid rafts was examined by the 
detergent solubility assay. MCF7, HeLa, and NIH3T3 cells transiently transfected 
with hepaCAM-V5 for 48 hours were separated into cytosolic (S100) and 
membrane/cytoskeletal-bound (P100) fractions. The P100 pellet was further extracted 
into Triton X-100-soluble, n-OG (a detergent known to solubilize some lipid rafts)-
soluble, and detergent-resistant (DRM) fractions. An equal volume of each fraction 
was subjected to Western blot analysis with anti-V5 antibody (Figure 4-61). Virtually 
no hepaCAM was detected in the cytosolic fraction. In the P100 fraction, the bulk of 
hepaCAM was extracted by Triton X-100, while the remaining was distributed 
between the n-OG-soluble and DRM fractions. Most hepaCAM was retained in the 
DRM of NIH3T3 cells, as compared to a lower concentration in HeLa cells, and the 
least in MCF7 cells. 
 
NIH3T3 cells express a higher level of caveolin-1 than HeLa and MCF7 cells (Suzuki 






FIGURE 4-61 Association of hepaCAM with detergent-
resistant membrane. MCF7, HeLa and NIH3T3 cells transfected 
with hepaCAM-V5 were fractionated into S100 (cytoplasm) and 
P100 fractions. The Triton X-100-soluble (TX sol) proteins from 
the P100 fraction were extracted, and the insoluble pellet was 
resuspended in N-octyl-b-D-glucopyranoside to solubilize some 
lipid raft components (n-OG sol). The insoluble material that 
remained after n-OG treatment was the DRM (det. resistant). An 






















location of lipid rafts. Therefore, NIH3T3 cells were used to evaluate the relationship 
between hepaCAM and lipid rafts. The cells were transfected with hepaCAM-V5 and 
subjected to sucrose density gradient fractionation (Figure 4-62). Seven 0.5-ml 
fractions were subsequently collected and the proteins were concentrated by 
TCA/ethanol precipitation. An equal volume of the resuspended proteins in each 
fraction was subjected to Western blot analysis with anti-V5 (hepaCAM), anti-
caveolin-1 (caveolin-1), or anti-actin (actin) antibody. The result showed that 
hepaCAM was present in the low-density lipid raft fractions and copartitioned with 
caveolin-1. In addition, hepaCAM also cofractionated with actin in the high-density 
fractions. Because lipid raft organization is dependent on the presence of cholesterol, 
the depletion of cholesterol with methyl-β-cyclodextrin (MCD) will cause the lipid 
raft-associated proteins to lose their buoyancy (Ilangumaran and Hoessli, 1998). MCD 
treatment of hepaCAM-transfected NIH3T3 cells (Figure 4-63) led to a modest 
diminishment of hepaCAM in fraction 2 accompanied with an accumulation of 
hepaCAM in fractions 3 and 4 of the density gradient, when compared to the 
untreated samples. This shift was similar to that observed in the control caveolin-1. 
These results indicated that hepaCAM is associated with the lipid rafts. 
 
4.2.19  Colocalization of hepaCAM with lipid rafts and caveolae 
Colocalization studies were performed to distinguish if hepaCAM resided in the 
caveolae, lipid rafts, or both. NIH3T3 cells transfected with hepaCAM-V5 for 48 
hours were extracted with 0.5% ice-cold Triton X-100 prior to fixation and double-
staining with anti-V5 antibody and caveolae marker caveolin-1 or lipid raft marker 
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FIGURE 4-62 Partitioning of hepaCAM in lipid rafts. NIH3T3 
cells were transfected with hepaCAM-V5 for 48 hours before assay. 
The cells were lysed in 1% Triton X-100 in TNE buffer and 
subjected to sucrose density gradient ultracentrifugation. Seven 0.5-
ml fractions (numbered 1-7 from top to bottom) were collected, 
precipitated and analyzed by Western blotting using anti-V5 
(hepaCAM), anti-caveolin-1 (caveolin-1) or anti-actin (actin) 
antibody. Caveolin-1 served as a positive control for low-density 
lipid raft-associated proteins. In contrast, actin was only detected in 
high-density fractions.
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FIGURE 4-63 Disruption of cholesterol affects distribution of 
hepaCAM in lipid rafts. NIH3T3 cells transfected with hepaCAM-
V5 were either untreated (- MCD; top panel) or treated (+ MCD; 
bottom panel) with 10 mM methyl-b-cyclodextrin (MCD) for 
30 min to deplete membrane cholesterol. The cells were lysed in 
1% Triton X-100 in TNE buffer and subjected to sucrose density 
gradient ultracentrifugation. Seven 0.5-ml fractions (numbered 1-7 
from top to bottom) were collected, precipitated and analyzed by
Western blotting using anti-V 5  ( hepaCAM) or anti-caveolin-1 
(caveolin-1) antibody. Whereas comparable amount of hepaCAM
resided in fractions 2, 3 and 4 of the untreated sample, a loss of 
hepaCAM in fraction 2 and an accumulation of hepaCAM in 
fractions 3 and 4 were noted in the MCD-treated sample. A similar 
trend of shift was observed in lipid raft control caveolin-1 in the 
MCD-treated sample.












FIGURE 4-64 Colocalization of hepaCAM with lipid rafts and 
caveolae. NIH3T3 cells transfected with hepaCAM-V5 were 
detergent extracted with cold 0.5% Triton X-100 before fixing and 
immunostaining with anti-V5 antibody (left panel). Endogenous 
caveolin-1 (Cav) or fyn (Fyn) protein (middle panel) was also 
detected using either anti-caveolin-1 or anti- fyn antibody, 
respectively. Confocal images of the hepaCAM and caveolin-1 or 
fyn were merged to show regions of colocalization (right panel).
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insoluble hepaCAM aligned with both caveolin-1 and fyn on the plasma membrane as 
well as in the punctuate structures in the cytoplasm, indicating that in addition to the 
lipid rafts, a part of hepaCAM is also recruited to the lipid raft derivative, caveolae. 
 
4.2.20   Dimeric hepaCAM partitions to lipid rafts 
NIH3T3 cells were transiently transfected with hepaCAM-V5. Forty-eight hours post-
transfection, the cells were subjected to chemical crosslinking with BS3 prior to 
sucrose density gradient fractionation. An uncrosslinked sample was included as 
control. Seven 0.5-ml fractions were eventually collected and the proteins were 
concentrated by TCA/ethanol precipitation. An equal volume of the resuspended 
proteins in each fraction was analyzed by Western blotting using anti-V5 (hepaCAM) 
or anti-caveolin-1 (caveolin-1) antibody (Figure 4-65). The crosslinked dimeric 
hepaCAM was observed in fractions 1-4, demonstrating that the dimers are associated 




FIGURE 4-65 Partitioning of dimeric hepaCAM in lipid rafts.
NIH3T3 cells were transfected with hepaCAM-V5 for 48 hours. 
Post-transfection, the cells were incubated in the absence (- BS3; 
top panel) or presence (+ BS3; bottom panel) of 3 mM BS3 prior to 
lysis in 1% Triton X-100 in TNE buffer. After sucrose density 
gradient ultracentrifugation, seven 0.5-ml fractions (numbered 1-7 
from top to bottom) were collected, precipitated and analyzed by
Western blotting using anti-V5 (hepaCAM) or anti-caveolin-1 
(caveolin-1) antibody. Caveolin-1 served as a positive control for 
low-density lipid raft-associated proteins. Solid and open 
arrowheads indicate signals for dimeric and monomeric proteins, 
respectively. The positions of the molecular size markers are shown 
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4.3   Gene HEPT3 
4.3.1 Upregulated expression of HEPT3 in HCC 
4.3.1.1  Expression of HEPT3 in HCC patients 
Suppression subtractive hybridization revealed that gene HEPT3 was upregulated in 
HCC. The expression of HEPT3 was examined in the matched liver samples of 23 
HCC patients by semi-quantitative RT-PCR using gene-specific primers T3-F and T3-
R. An elevated expression of HEPT3 was observed in 87% of the HCC samples when 
evaluated against their adjacent non-tumorous liver tissues (Figure 4-66). Real-time 
RT-PCR was further performed on the same batch of liver specimens to quantitate the 
level of HEPT3 expression (Figure 4-67). In addition to obtaining reproducible results 
pertaining to the frequency of HEPT3 overexpression in HCC by both experimental 
approaches, real-time RT-PCR revealed a significant increase in the level of HEPT3 
expression in the tumor areas in comparison to the adjacent non-tumorous liver, 
which represented an average of 7-fold upregulation in mRNA expression, (P < 
0.0001). The data showed that HEPT3 overexpression was common in HCC tissues, 
suggesting its association with progression of tumorigenesis. 
 
4.3.1.2  Expression of HEPT3 in HCC cell lines 
Furthermore, the expression of HEPT3 was investigated in six liver cell lines by semi-
quantitative RT-PCR using primers T3-F and T3-R (Figure 4-68). Chang liver is a 
HeLa-contaminated immortalized non-tumor liver cell line, while HepG2, C3A, 
Hep3B, Huh7 and SK-Hep1 are HCC cell lines. The result showed that HEPT3 was 
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FIGURE 4-66 Expression of HEPT3 transcript in 23 HCC 
patients by semi-quantitative RT-PCR. RT-PCR products of 
HEPT3 generated by primers T3-F and T3-R were analyzed by gel 
electrophoresis.     , sample that shows no clear difference in 
HEPT3 expression; N, non-tumorous liver tissue; T, HCC liver 
tissue; GAPDH, internal control.
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FIGURE 4-67 Expression of HEPT3 transcript in 23 HCC 
patients by quantitative real-time RT-PCR. The expression level 
of HEPT3 in each sample was determined by real- time RT-PCR. 
Results were normalized and converted into percentage against the 
expression level of GAPDH. The average level of expression 
(mean ± SD, n = 23) is represented in the left inset, * P < 0.0001. 













































































FIGURE 4-68 Expression of HEPT3 transcript in 6 liver cell 
lines. Chang liver is a HeLa-contaminated immortalized non-tumor 
liver cell line, while HepG2, C3A, Hep3B, Huh7 and SK-Hep1 are 
HCC cell lines. Semi-quantitative RT-PCR was used to amplify 
HEPT3 mRNA and GAPDH (an internal control). RT-PCR 
products were analyzed by gel electrophoresis. 
4.3.2   Isolation of full-length HEPT3 cDNA 
5’ and 3’ RACE were employed to isolate the respective 5’ and 3’ ends of HEPT3 
cDNA from human normal liver cDNA library (Figure 4-69). Two successive rounds 
of 5’ RACE using gene-specific primer T3-RACE-R and adaptor primer AP1 
followed by nested primers T3-RACE-nR and AP2 yielded a band of ~1.7 kb. 
Concurrently, two consecutive rounds of 3’ RACE using primers T3-RACE-F and 
T3-RACE-nF in combination with adaptor primers AP1 and AP2, respectively, 
generated a ~750 bp long 3’ cDNA of HEPT3. The RACE fragments were cloned 
separately into the pGEM-T vector and sequenced. The overlapping sequences of the 
5’ and 3’ RACE products were aligned together to obtain a composite sequence of 
2839 bp, which represented the full-length cDNA of HEPT3 (Figure 4-70). Based on 
this sequence, primers T3ful-F and T3ful-R corresponding to both ends of HEPT3 
cDNA were synthesized and used in end-to-end PCR to amplify the complete cDNA 
of HEPT3. The cDNA was cloned into the pGEM-T vector and sequenced for 
verification. This sequence was deposited into GenBank (Accession no. AY374441). 
 
4.3.3   Genomic characteristics of HEPT3 
4.3.3.1 Sequence analysis of HEPT3 cDNA 
The full-length cDNA of HEPT3 contained a consensus polyadenylation signal, 
AATAAA, 23 bp upstream of the poly (A) tail at the 3’ terminus (Figure 4-70). It also 
contained 13 copies of the mRNA destabilization motif, ATTTA. 
 
A search of HEPT3 cDNA against the NCBI database revealed no significant 
sequence homology to any characterized genes. Interestingly, two entries that seemed 




FIGURE 4-69 Isolation of HEPT3 full-length cDNA by RACE. 
RACE-PCR products were analyzed by gel electrophoresis. A, 
Nested 5’ RACE product was generated by primers T3-RACE-nR 
and AP2; B, Nested 3’ RACE product was generated by primers 
T3-RACE-nF and AP2; C, Full- length HEPT3 cDNA was 
amplified by end-to-end PCR using primers T3ful-F and T3ful-R. 
L, 1 kb DNA ladder.
















AGGTTGCAGTGAGCCGAGATCACGCCACTGCACTCCAGCCTGGGGGACAGAGTGAGATTCTGTCTCAAAA   490 
AACAAAAAACAAAAAAGTCACCTTGTAACTCATCTCTTTTTATTGTAAGTTTATTAAAAATGAAGAGGAC   560 
AACAATGAGAAGGAACATAAAGGGTTAGCTAGCACTGTCTCCTGGTGCATGGGGCTGTGCAGATGTCCCG   630 
GCCACTTCTTCCTTCATACCTCCCTTAGAGAACTTGCTCTGCTACAAGCAGTGGGCTTGGACTAAAAGTG   700 
ATTAAAATACCACAGGCATAAGGAGAAAAGGAGTATATGTAGTAGTAATAATTACTAGTATAAATTATTT   770 
TCTTCACATGTTATGAGTAATAATATTAAAAAACTCATTTTACCATTAAGATTCCTTATGCTGAAGCTCT   840 
TCCATTTAGAATACTGTCAATGTCATTTACTGGTATGAACTAAAGTCCCCCTTCTTTTCCACTCACTGGG   910 
AACCTTAGTAAAACACCAGCATATCTTACCTCTCTTTCTGACTGGCCGATGCTTCCAGAGACTGAATGTT   980 
GGGAAAACCTAGTAGCCAAACAATTCTAGGACAGAATAACATTTTTATATTTGGTTCCACCATCTTATTA   1050 
CATTTAGTTATAGTTTTAAAAAAGAAATTCAAGCCCATTAAAATATGTCTGGTCAATGAAATGCTTCCTT 1120 
TTATTGTGTTGTGCTATTGTACTTTGTTTTTCAAAACATTGTAAAAATAGTATCTTTGGTTTAGTATTTT   1190 
GGATTATATATTATAATCTGAGGAGTGTTTGCTTATGTAGAATCCAGATATATTTCTGTTACCTAGGAGA   1260 
TGTTACTTACATATGTAATACTGTATCCTGCACGTGGAAATATTCAGAATTGTAGATAGCATAACTCTCC   1330 
CTGCTCCTATTCTTTTGAGCCTAGGTATAATTTTTTTTTTTTTTTTAGAAAAAGACATATTTAGCTTTAA   1400 
TTTCTATTTATGCTAAACATATTTATAAGTAGTCTGTCAATATAATACCAACTATTTTTATTTTTACATA   1470 
ATTCAATTATTTCATTTGACATGTCTGGCAGACTTAAGACATTAAGTAAAAAATTGGAACTATGATTTTT   1540 
CTTTGTCATTTTTTAAAAAAGAATTATTTTATTAACCTGCTGGCATATAATCTGGAGTTCTTTTCACAAC   1610 
CTTACTTTTTCTGATTTGCTTTATTGAATGATTGAATACTCATTTCTTTCTAAAAATATGTTGTAAATTC   1680 
TCCCTTGGCAAGATTTCTCCCTATGAGGGTAGTTATTATTTGAGTCTGCCAAGTGGTTACCATGGGGCAA   1750 
GGTGCCATGATGTATTCTTGGGTGCATTGGTTTTTTGCGCATTGTAAATTTAAGACACTTATAGTAAGTG   1820 
GACTCATTCATAGATGAGTTTCAGAACCTTTTACGTTCTCGGTGGAGGCTTCTGTCGGACAGGCAGAAGA   1890 
GTGTATTCCTCACTTTTTTTTTTTTGTCTTCAAATTCCAGTAAGGCATAGCACTTTTAAGAAATTAGAAT   1960 
TTTTCTATCATCTATGCAAATGATATTTATGTTAATATTAAATATCTTATGTTACACTGGGAGTAATTTG   2030 
AGGTGCAATTATTTTTATTACTACTTTGAATAGAGGACCATTATCCTTCTTTCTTCAGAAAACTAAGAAG   2100 
TAAGTGTAACTTTTAAAGTAAGTATATATCAGTGAGAGTAGGCTTGTTTTACAACTATTTCTAGCCAGTG   2170 
AGTTGTGTTTTCATGTCTCATCAAAAGACAATACCACATTGCATCATTTTACAAAATATGTTGTCATTTT   2240 
CATTTCAGTTGTAACATAGGAAAATAGATATTTCCTAGATGATTTCTGAGTTTCTTACTGCAAAGAACAG   2310 
TTATAAATTGGTATACATGTGTCTCTGTAATAGGGATAATATTGATATATCTGTTGCTACATATTTAAGA   2380 
ATCATTCTATCTTATGTTGTCTTGAGGCCAAGATTTACCACGTTTGCCCAGTGTATTGAATTGGTGGTAG   2450 
AAGGTAGTTCCATGTTCCATTTGTAGATCTTTAAGATTTTATCTTTGATAACTTTAATAGAATGTGGCTC   2520 
AGTTCCGGTCCTTCAAGCCTGTATGGTTTGGATTTTCAGTAGGGGACAGTTGATGTGGAGTCAATCTCTT   2590 
TGGTACACAGGAGGCTTTATAAAATTTCATTCACGAATCTCTTATTTTGGGAAGCTGTTTTGCATATGAG   2660 
AAGAACACTGTTGAAATAAGGAACTAAAGCTTTATATATTGATCAAGGTGATTCTGAAAGTTTTAATTTT   2730 
TAATGTTGTAATGTTATGTTATTGTTAATTGTACTTTATTATGTATTCAATAGAAAATCATGATTTATTA 2800 
ATAAAAGCTTAAATTCTCATCTAAAAAAAAAAAAAAAAA                              2839 
FIGURE 4-70 The full-length cDNA sequence of HEPT3. A 
polyadenylation signal (bold) was identified near the 3’-terminus. The 
mRNA destabilization motif, ATTTA, is in bold and italic. The ALU 
repetitive element is underlined. The sequence data for HEPT3 is 
available in GenBank Accession no. AY374441.
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CR599670  (1743 bp)

















FIGURE 4-71 Genomic structure and isoforms of HEPT3. A,
HEPT3 is located on human chromosome 6q13-14. B, The genomic 
DNA of HEPT3 (GenBank Accession no. AL591480) lacks intron. C, 
Isoforms of HEPT3 retrieved from database. D, Northern blot analysis 
of HEPT3. Total RNA extracted from normal liver was separated on a 
1% formaldehyde/MOPS gel, blotted onto membrane and probed with 
DIG-labeled HEPT3 probe. Three transcripts with different sizes were 
detected. 
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3211 bp Homo sapiens cDNA FLJ26594 fis (GenBank Accession no. AK130104) that 
contained the entire HEPT3 cDNA in its 3’ region, and the other was a 1743 bp full-
length cDNA clone CS0DF031YL13 of Fetal brain of Homo sapiens (GenBank 
Accession no. CR599670) that corresponded to the 3’ end of HEPT3 cDNA. 
Additionally, extensive homologies of HEPT3 to a cluster of ESTs from various 
tissues were detected. The ESTs were derived from normal tissues of liver, lung, 
brain, uterus, prostate, adipose, and etc. More strikingly, ESTs were also identified in 
tumor tissues of kidney, bladder, breast, parathyroid, lung, testis, skin, and etc. These 
results indicated that HEPT3 is widely expressed in diverse tissues, particularly high 
in tumors. It is noteworthy that gene HEPT3 appeared to be exclusive to human 
because significant matches were not found between HEPT3 and ESTs of other 
organisms.  
 
The homologous ESTs revealed the presence of an Alu repetitive sequence in HEPT3 
cDNA. To confirm, the RepeatMasker program (Takeda et al., 1998) that screens 
DNA sequences for interspersed repetitive sequences was employed; and a 300 bp 
long Alu repetitive element located at nucleotides 140-439 of the HEPT3 cDNA was 
identified. 
 
The region on HEPT3 cDNA that encompassed the Alu repetitive element, located at 
nucleotides 208-505, was shown by the BLAST program to be extensively 
complementary to multiple sites on the Alu-containing cDNA of the AD7c-NTP gene 
(GenBank Accession no. AAC08737). AD7c-NTP encoded a ~41 kDa neuronal thread 
protein that induced apoptosis and neuritic sprouting in transfected neuronal cells. The 




79-94% (Figure 4-72), suggesting a possible sense-antisense interaction between the 
two genes.  
 
4.3.3.2 HEPT3 lacks coding potential 
A prominent feature of HEPT3 cDNA sequence was the high density of stop codons 
in the three theoretical reading frames, causing a lack of extensive open reading 
frames (Figure 4-73), suggesting that HEPT3 lacks coding capacity. Nevertheless, the 
possibility that HEPT3 might encode a small protein could not be excluded. NCBI 
ORFinder analysis of HEPT3 cDNA revealed multiple small open reading frames 
distributed throughout the gene. In the plus frames, the longest ATG-initiated ORF 
predicted was a 69 amino acid peptide which contained a protein kinase C 
phosphorylation site (residues 63-55). Other putative open reading frames included a 
65 amino acid peptide that contained two putative protein kinase C phosphorylation 
sites (residues 7-9; 11-13) and a 62 amino acid peptide with no recognizable motifs. 
These predicted peptides shared no significant similarities with proteins and peptides 
deposited in the databases. In addition, the sequence surrounding the potential ATG 
start codon of each peptide did not contain a strong Kozak initiation sequence (Kozak, 
1996).  
 
Interestingly, the minus frame of HEPT3 cDNA encoded a putative 103 amino acid 
protein, in which the entire protein had 55% identity to an unknown protein (GenBank 
Accession no. AAH01284), 94 of the 103 residues had 62% sequence match to an 
unnamed protein product (chromosome 9; GenBank Accession no. BAB15071), and 
~70 of the 103 residues had about 60% homology to Alu subfamily sequence. Other 




FIGURE 4-72 Possible sense-antisense interaction between 
HEPT3 Alu element and AD7c-NTP. The full- length cDNA 
sequence of AD7c-NTP is 1128 bp long. As revealed by paired 
comparison between HEPT3 and AD7c-NTP cDNA sequences, the 
ALU sequence of HEPT3 is complementary to various regions on 
the AD7c-NTP cDNA. The location of each complementary site on 
AD7c-NTP is depicted by a box and the nucleotide positions are 



























FIGURE 4-73 Coding potential of HEPT3. HEPT3 cDNA 
sequence contains a high density of stop codons in the six reading 
frames and lacks extensive open reading frames. The location of each 
start codon is indicated by a green bar, and the location of each stop 
codon is indicated by a pink bar. 
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NP_060312), zinc finger protein HZF9 (GenBank Accession no. Accession no. 
NP_060312), zinc finger protein HZF9 (GenBank Accession no. XP_290171), 
neuronal thread protein (GenBank Accession no. NP_055301), topoisomerase II 
alpha-4 (GenBank Accession no. AAG13405), seven transmembrane helix receptor 
(GenBank Accession no. BAC05890), alpha-1A-adrenergic receptor isoform 2 
(GenBank Accession no. NP_150646), seven transmembrane helix receptor 
(GenBank Accession no. BAC45260), and etc. Structural motifs identified by 
PROSITE algorithm included a N-glycosylation site (residues 34-37), two protein 
kinase C phosphorylation sites (residues 15-17; 38-40) and three N-myristoylation 
sites (residues 45-50; 69-74; 70-75).  
 
4.3.3.3 Sequence analysis of HEPT3 genomic DNA 
A BLAST homology search was performed using the HEPT3 full-length cDNA 
sequence against the human genome database of NCBI algorithm to determine the 
location of HEPT3 on human chromosomes. HEPT3 was mapped specifically to the 
human chromosome 6q13-14 (GenBank Accession no. AL591480; Figure 4-71). 
Comparative analysis revealed that HEPT3 cDNA was collinear to the genomic 
sequence, indicating that gene HEPT3 is intronless.  
 
4.3.4 Northern blot analysis 
Northern blot analysis was performed on total RNA extracted from normal liver to 
confirm that the isolated HEPT3 cDNA was indeed full-length. The DIG-labeled 
HEPT3 probe recognized three differently-sized transcripts ⎯ ~3.3 kb, ~2.5 kb and 




length HEPT3 product, while the 3.3 kb and 2 kb signals seemed to correspond to the 
two isoforms identified in the database.   
 
4.3.5   Anti-proliferative effect of antisense HEPT3 
An antisense approach was employed to examine the effect of HEPT3 on HCC cell 
growth by inhibiting the expression of endogenous HEPT3. The antisense expression 
plasmid of HEPT3 (HEPT3 (AS)-pcDNA3.1) was constructed by cloning a partial 
cDNA of HEPT3 in the reverse orientation into vector pcDNA3.1 (Figure 4-74). 
Colony formation was carried out while growth rate was determined in stable C3A 
cells to assess the anti-proliferative effect of antisense HEPT3. In colony formation 
assay, HEPT3 (AS)-pcDNA3.1 was transfected into C3A cells and the cells were 
selected in 800 µg/ml of G418 for two weeks. Cells transfected with vector 
pcDNA3.1 served as control. As shown in Figure 4-75, antisense HEPT3 significantly 
reduced the number of colonies formed as compared to the control. Moreover, the 
growth rate of the stable C3A cells expressing antisense HEPT3 was 4-fold slower 
than cells transfected with empty vector (Figure 4-76). Semi-quantitative RT-PCR 
using the endogenous HEPT3-specific primer pair T3frag-f and T3frag-r 
demonstrated a moderately diminished expression of endogenous HEPT3 in the C3A 











FIGURE 4-74 Schematic representation of HEPT3 antisense 
construct. A cDNA fragment comprising of nucleotides 68-2025 of 
HEPT3 cDNA was cloned in the reverse order into pcDNA3.1 
vector to create the HEPT3 (AS)-pcDNA3.1 construct. Endogenous 
HEPT3-specific primers T3frag-f and T3frag-r were synthesized to 
amplify nucleotides 2320 to 2582 of endogenous HEPT3.
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FIGURE 4-75 Inhibition of colony formation by antisense
HEPT3. C3A cells  transfected with either antisense plasmid 
HEPT3 (AS)-pcDNA3.1 or pcDNA3.1 were cultured in the 
presence of 800 mg/ml of G418 for 2 weeks.
pcDNA3.1 HEPT3 (AS)-pcDNA3.1
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FIGURE 4-76 Inhibition of cell growth by antisense HEPT3.
The growth rate of HEPT3 (AS)-pcDNA3.1-transfected C3A cells 
(AS) was compared to that of cells transfected with pcDNA3.1 



























FIGURE 4-77 Suppression of endogenous HEPT3 by antisense
HEPT3. The expression levels of endogenous HEPT3 in C3A cells 
stably transfected with HEPT3 (AS)-pcDNA3.1 (AS) and 
pcDNA3.1 alone (V) were examined by semi-quantitative RT-PCR 
using primers T3frag-f and T3frag-r. RT-PCR products were 





CHAPTER 5 DISCUSSIONS 
 
5.1  Gene HEPN1 
5.1.1  Downregulation of HEPN1 in HCC and other tumors  
Gene HEPN1, downregulated in HCC, was identified in non-tumorous liver through 
the technique of suppression subtractive hybridization (SSH). Screening against 23 
HCC patients, it was found that HEPN1 mRNA was downregulated in 95.7% (22/23) 
of HCC and the average expression level was 5.7-fold lower in HCC tissues than that 
in non-tumorous liver tissues (P < 0.0001), suggesting that silencing of HEPN1 is 
associated with carcinogenesis of hepatocytes. In addition, HEPN1 was also 
significantly suppressed in 100% (4/4) of the HCC cell lines tested, further implying 
that loss of HEPN1 expression is of generality in HCC of different etiologies. 
However, no correlation was identified between the loss of HEPN1 expression and 
the events related to the development and progression of HCC, including hepatitis B 
viral infection, hepatitis C viral infection, liver cirrhosis, and the differentiation of 
HCC. This may be due to the ubiquitous downregulation of HEPN1 in the HCC 
samples tested. The suppression of HEPN1 seems to be applicable to diverse types of 
cancer. Evaluation of HEPN1 expression in human cancer cell lines derived from 
blood, colon, breast, brain, and lung demonstrated a loss of expression in 83.3% 
(10/12) of the cell lines. 
 
The mechanism responsible for the abrogation of HEPN1 expression is still elusive. 
However, the reduced mRNA level in tumors implicates that silencing of HEPN1 may 




LOH (Largaespada, 2001; Cavenee et al., 1983) or transcriptional repression at the 
mRNA level such as epigenetic silencing through hypermethylation (Issa et al., 1994).  
 
5.1.2  Genomic organization and characteristics of HEPN1 
5.1.2.1  HEPN1 encodes a protein of 88 amino acids 
Gene HEPN1 codes for a 1448 bp transcript. A probable functional TATA box resides 
upstream of the transcriptional start site at position -57. The predicted HEPN1 product 
is a 10-kDa peptide consisting of 88 amino acids. The peptide neither has significant 
homology to any of the known proteins and peptides nor discloses substantial 
sequence and structural motifs in the available databases. The functionality of HEPN1 
gene is supported by the fact that HEPN1 mRNA is translatable in transfected cells. 
Subcellular localization revealed that the encoded protein accumulated in the 
cytoplasm of HepG2 cells. It is certainly conceivable that small proteins that lack 
apparent functional domains may exert their effect primarily through interactions with 
other proteins. For example, Brd (Drosophila gene Bearded) encodes a novel small 
protein of 81 amino acids that interacts with and regulates genes of the Notch pathway 
(Leviten et al., 1997). Nevertheless, the novelty of HEPN1 sequence led to the 
difficulty of understanding its biological role. 
 
5.1.2.2  HEPN1 is an intronless gene 
A comparison between HEPN1 cDNA sequence and the genomic sequence available 
in the database revealed a lack of intervening sequence in the genomic DNA, 
indicating that HEPN1 is an intronless gene. In human, naturally intronless genes 
account for less than 6% of the genes in contrast to 96% in S. cerevisiae and 17% in 




transcriptional splicing, they can be transcribed more efficiently leading to a 
potentially faster rate of expression, greater abundance and higher fidelity. In essence, 
these intronless genes may react instantly to cellular signals. Families of intronless 
genes encode G-protein-coupled receptors and histones (Gentles and Karlin, 1999; 
Kedes, 1979). In the context of tumorigenesis, there are a few examples of intronless 
putative tumor suppressor genes. They include TUSC1 (tumor suppressor candidate 1; 
Shan et al., 2004), MORF4 (mortality factor 4; Bertram et al., 1999), and BRCC2 
(breast cancer cell 2; Broustas et al., 2004).  
 
5.1.2.3  HEPN1 maps to chromosome 11q24.2 
HEPN1 is mapped to the human chromosome 11q24.2. Abnormalities of chromosome 
11q including chromosome breakage, rearrangement, and loss on the long arm have 
been reported in a number of human tumors, including HCC (Walker et al., 1991; 
Wang and Rogler, 1988), colorectal cancer (Connolly et al., 1999), breast cancer 
(Gentile et al., 2001), melanoma (Goldberg et al., 2000), acute lymphoblastic 
leukemia (Mathew et al., 2001), and ovarian cancer (Launonen et al., 1998), 
signifying the presence of tumor suppressor genes in this region. The existence of 
important tumor suppressor genes is further supported by the observation that 
introduction of a normal chromosome 11 via microcell-mediated chromosome 
transfer can suppress tumorigenicity in Wilms’ tumor, lung, rhabdomyosarcoma, 
ovarian, breast and melanoma cell lines (Weissman et al., 1987; Satoh et al., 1993; 
Loh et al., 1992; Stronach et al., 2003; Negrini et al., 1994; Robertson et al., 1996). 
Several tumor suppressor genes have been identified on 11q22-qter. They include the 
cell cycle regulatory and DNA repair genes, ATM at 11q23 (Rasio et al., 1995), and 




replication and normal cell division. In response to DNA damage, ATM and ATR 
phosphorylate CHK1, which in turn inactivates Cdc25, and blocking the transition of 
the cell cycle. The p53 target genes, PIG8 and P53AIP1, both involved in mediating 
p53-dependent apoptosis, are also located in 11q23 and 11q24, respectively (Gu et al., 
2000; Matsuda et al., 2002).  
 
5.1.3   HEPN1 inhibits cell growth and induces apoptosis 
The frequent downregulation of HEPN1 mRNA expression and its localization on 
chromosome 11 suggest a role of HEPN1 in tumor suppression. To study its 
functional significance, HEPN1 was expressed into a HEPN1-null HCC cell line, 
HepG2, in three phases. Firstly, transient transfection was performed on HepG2 cells. 
Forty-eight hours after transfection, the results showed that re-expression of HEPN1 
inhibited cell growth by about 62.5±2.5% (P = 0.001). Secondly, colony formation 
was performed on cells transfected with the HEPN1-pEGFP construct and the 
pEGFP-N2 vector. The results showed that exogenous HEPN1 reduced both the 
number of colonies and the number of fluorescent cells. Furthermore, attempts to 
establish stable clones of HEPN1 from these colonies were unsuccessful; supporting 
that HEPN1 is indeed capable of suppressing cell growth in HepG2 cells. Finally, 
time-course transfection with GFP-fused HEPN1 visualized the dynamics of the 
distribution of HEPN1 and cell behaviour after transfection. Together with Annexin V 
assay, the results showed that HEPN1 promotes apoptosis in HepG2 cells. These data 





5.2  Gene hepaCAM 
5.2.1  hepaCAM is antisense to HEPN1 
A growing number of naturally occurring antisense RNAs has been identified in 
prokaryotes and eukaryotes over the last several years (Dolnick, 1997; Simons, 1988; 
Vanhee-Brossollet and Vaquero, 1998). Antisense transcripts are believed to 
constitute a general mechanism that regulates the expression of their sense target 
genes through transcription, nuclear processing, nuclear transport, translation, and 
mRNA stability (Green et al., 1986; Van der Krol et al., 1988). Numerous examples 
of antisense transcripts complementary to their sense counterparts have been 
documented. They include a native antisense RNA to Hoxa11 (Chau et al., 2002), an 
antisense RNA to Msx1 (Blin-Wakkach et al., 2001), and an antisense RNA to basic 
fibroblast growth factor (bFGF; Asa et al., 2001). 
 
In this study, a previously unstudied gene antisense to HEPN1 was identified. 
Containing the complete sequence of HEPN1 in the reverse orientation in its 3’ UTR, 
this gene was predicted to encode an incomplete ORF of 165 amino acids. Sequence 
extension by RACE revealed a 3244 bp long cDNA that contains a putative ORF of 
416 amino acids. This novel gene was designated as hepaCAM. Gene hepaCAM is 
highly conserved in vertebrates. A search of the database revealed hepaCAM 
orthologues in chimpanzee, mouse and dog, with an overall 93-95% amino acid 
identity relative with the human sequence. 
 
The fact that most of the antisense transcripts studied are non-translatable RNAs 
makes it difficult to establish if there might be a reciprocal relationship between the 




similar transcriptional expression profiles of HEPN1 and hepaCAM in tissues and cell 
lines of HCC and other tumors, it is least likely for HEPN1 and hepaCAM to have 
repressive effects on each other. 
 
5.2.2 Gene hepaCAM encodes a new member of the immunoglobulin 
superfamily  
5.2.2.1   hepaCAM exhibits the typical sequence and structure of 
immunoglobulin-like cell adhesion molecule 
Gene hepaCAM was predicted to encode a type I integral transmembrane 
immunoglobulin (Ig)-like cell adhesion molecule. The novel protein displays the 
typical structure of members of the immunoglobulin superfamily (IgSF), especially to 
JAM1, CAR and ESAM. Specifically, they contain an extracellular domain 
comprising of a membrane-distal V type Ig-domain and a membrane-proximal C2-
type Ig-domain, a single transmembrane region, and a cytoplasmic tail. They also 
share a common feature of possessing conserved cysteine residues in the C2-type Ig 
domain that form intrachain disulfide bridges (Williams and Barclay, 1998). In 
addition, the extracellular domain of hepaCAM exhibits sequence homology to a 
cluster of cell adhesion molecules such as CEACAM3 and CAR. Collectively, these 
sequence and structural predictions suggest that hepaCAM may encode a new cell 
adhesion molecule belonging to the IgSF. 
 
5.2.2.2   hepaCAM is localized predominantly on plasma membrane 
Adhesion molecules such as TSLC1 (Masuda et al., 2002), CAR (Ashbourne 
Excoffon et al., 2003), and nectins (Satoh-Horikawa et al., 2000; Miyahara et al., 




Similar characteristic pattern of distribution was also observed in hepaCAM. Analysis 
of the subcellular localization of hepaCAM revealed that the molecule was recruited 
predominantly to the plasma membrane, particularly in the areas of cell-cell contact 
when cells were confluent. Plasma membrane localization of many transmembrane 
proteins such as endothelial cell nitric oxide synthase (Sessa et al., 1993) has been 
attributed to myristoylation. Two putative myristoylation sites were recognized in 
hepaCAM.  
 
In addition to its distribution to the plasma membrane, hepaCAM was also localized 
to the cytoplasm in a punctuate pattern. However, Western blot analysis of the 
membrane (P100) and cytosolic (S100) fractions revealed that hepaCAM was weakly 
present in the cytoplasm but abundant in the membrane. These findings imply that 
hepaCAM may reside in small membrane-bound vesicles in the cytoplasm. The 
identity of these structures has not been defined, but they are unlikely to be 
mitochondria because hepaCAM did not colocalize with mitochondria when 
examined in MCF7 cells. 
 
In polarized cells, hepaCAM was accumulated at the basolateral plasma membranes, 
and lacking physical interaction, hepaCAM was shown to colocalize with E-cadherin 
at the lateral domain. Previous studies on adhesion molecules have defined a dileucine 
signal that functions in the basolateral targeting of the Lutheran glycoprotein (El 
Nemer et al., 1999) and E-cadherin (Miranda et al., 2001). Excluding those found in 
the signal peptide, hepaCAM contains 6 putative dileucine motifs ⎯ five in 
ectodomain and one in transmembrane domain. Although the exact functional 




hepaCAM to the basolateral membrane. Dileucine signals that typically contain an 
acidic residue at the -4 position (D/EXXXLL) are also known to participate in 
endocytosis (Pond et al., 1995; Simonsen et al., 1998; Dietrich et al., 1997). Among 
the dileucine patterns in hepaCAM, three of them have the defined acidic residue in 
the -4 position. Therefore, it is possible that these sequences may also function as an 
endocytosis motif. 
 
A potential GPI-binding site was identified near the COOH-terminal of hepaCAM. In 
contrast to the basolateral localization of hepaCAM in polarized cells, it has been 
reported that GPI-linked proteins are selectively sorted to the apical domain of many 
polarized epithelial cells, but preferentially excluded from the basolateral membrane. 
For example, a role of GPI in apical targeting has been demonstrated in Madin-Darby 
canine kidney (MDCK) cells and intestinal cells by attaching a GPI anchor to proteins 
not originally destined to the apical surface (Soole et al., 1985; Brown et al., 1989; 
Lisanti et al., 1989). Replacement of the GPI anchor of placental alkaline phosphatase 
with the transmembrane and cytoplasmic domains of vesicular stomatitis virus 
(VSV)-G switched its targeting from the apical to the basolateral surface (Brown et 
al., 1989). However, the role in apical targeting of the GPI-anchor has been 
challenged. It is now realized that GPI-anchored proteins may also contain 
basolateral-sorting signals. Clearly, in Fischer rat thyroid cells, six out of nine 
endogenously expressed GPI-linked proteins are directly delivered to the basolateral 
domain, the other three being apically disposed (Zurzolo et al., 1993). It was also 
observed that 50% of the native, GPI-anchored decay-accelerating factor (DAF) was 




sequence of DAF to the herpes simplex gD-1 protein exclusively targeted the 
molecule to the basolateral domain. 
 
Deletion mutagenesis of hepaCAM revealed that the extracellular and transmembrane 
domains, but apparently not the cytoplasmic domain, are needed for plasma 
membrane localization of the molecule in mammalian cells. Nevertheless, it is to be 
clarified if the cytoplasmic domain of hepaCAM may play a role in the basolateral 
targeting of the protein. As exemplified by the two isoforms of adhesion molecule 
CEACAM1, both proteins are localized to the plasma membrane despite having 
different lengths of cytoplasmic domain. However, a recent study in polarized cells 
demonstrated that these isoforms, in fact, exhibit unequal plasma membrane 
localization. CEACAM1-S with the shorter cytoplasmic domain is exclusively 
distributed to the apical cell surface while CEACAM1-L is recruited to both the apical 
and lateral cell surfaces (Sundberg and Obrink, 2002). In addition, Neame and Isacke 
showed that the cytoplasmic tail of CD44 is required for its basolateral localization. 
Deletion of the domain resulted in the relocalization of the molecule onto the apical 
cell surface (Neame and Isacke, 1993). 
 
5.2.2.3  hepaCAM is a glycoprotein  
N-glycosylation in the endoplasmic reticulum (ER) is an essential protein 
modification critical for proper folding of the newly synthesized glycoproteins as they 
pass from one chaperone to another. In the ER, N-linked glycans attached to 
asparagines residues of newly synthesized glycoproteins provide binding sites for the 
lectin-like molecular chaperones, calreticulin and calnexin. The interactions between 




or unassembled proteins are initially retained in the ER, after which, they are 
translocated to cytoplasm for ubiquitination and degradation by proteasomes (Parodi, 
2000).  
 
Like most membrane proteins, hepaCAM is also modified by N-linked glycosylation. 
In addition to the six predicted N-glycosylation sites on hepaCAM’s extracellular 
domain, the observation of a difference between the calculated MW and the MW 
identified by Western blot analysis suggests that hepaCAM protein may be 
glycosylated. Enzymatic deglycosylation with PNGase and inhibition of glycosylation 
with tunicamycin confirmed that hepaCAM is a glycoprotein. 
 
N-glycosylation has been reported to regulate the trafficking of proteins to the plasma 
membrane. Yan et al. showed that treatment of transfected podocyte and HEK-293 
cells with tunicamycin led to the retention of non-glycosylated nephrin molecules in 
the ER. This result implies that nephrin depends on N-linked glycosylation for 
transport to the plasma membrane (Yan et al., 2002). Although it is still unclear if N-
glycosylation affects the plasma membrane localization of hepaCAM, truncation of 
the extracellular domain of hepaCAM, which contains the N-glycosylation sites, 
clearly decreased the distribution of hepaCAM to the plasma membrane. 
 
5.2.3   hepaCAM modulates cell-matrix adhesion  
Cell adhesion is essential in all aspects of cell growth, cell migration and cell 
differentiation. It is mediated by cell adhesion molecules that are responsible for 
adhesion of cells to neighbouring cells or to the ECM components in the extracellular 




implicated in a wide variety of processes including organogenesis, cell growth, 
immunity, wound healing, and signal transduction. 
 
In polarized cells, hepaCAM was distributed to the basal membrane, suggesting an 
interaction of the molecule with the substratum. In favour of this notion, cell adhesion 
assays demonstrated that hepaCAM increased cell spreading on matrices fibronectin 
and matrigel, and delayed cell detachment. Deletion of the cytoplasmic domain 
reduced, but did not completely inhibit hepaCAM-mediated cell-matrix adhesion, 
implicating that, to a considerable extent, the extracellular and transmembrane 
domains may be needed to initiate and strengthen adhesion. Interestingly, hepaCAM 
was predicted to contain binding sites for Cdk5. Negash et al. demonstrated that Cdk5 
promotes cell-matrix adhesion in lens epithelial cells when overexpressed (Negash et 
al., 2002). 
 
The accelerated cell-matrix adhesion mediated by hepaCAM raises the possibility that 
loss of hepaCAM may ultimately lead to the disruption of tissue architecture by the 
loss of a tumor cell’s ability to communicate with its extracellular environment.  
 
5.2.4   hepaCAM is a candidate tumor suppressor gene 
5.2.4.1  hepaCAM is frequently downregulated in tumors 
It is evident that alterations in the adhesive properties play a vital role in the 
development and progression of cancer. Perturbation of cell adhesion to the ECM or 
to neighboring cells is a prominent feature of cancer cells. It allows malignant cells to 
escape from their site of origin, degrade the ECM, gain a more motile and invasion 




context of IgSF adhesion molecules such as CEACAM1 that is normally widely 
expressed in epithelia, vessel endothelia, and leukocytes (Odin et al., 1988), a loss of 
expression had been observed in numerous malignancies in humans including HCC 
(Tanaka et al., 1997), colon (Neumaier et al., 1993; Nollau et al., 1997), endometrial 
(Bamberger et al., 1998), breast (Huang et al., 1998), and prostate (Hsieh et al., 1995) 
cancers. Likewise, hepaCAM was expressed in a wide variety of normal human 
tissues, but frequently suppressed in tissues and cell lines of HCC and tumors derived 
brain, breast, lung, kidney, stomach, colon, rectum, prostate, uterus, ovary, skin and 
blood.  
 
The mode of hepaCAM suppression in tumors is unelucidated. It may be inactivated 
by genetic modifications such as LOH (Largaespada, 2001; Cavenee et al., 1983) or 
epigenetic silencing through CpG methylation (Issa et al., 1994). Two potential CpG 
sites were recognized in the coding region and 3’ UTR of hepaCAM transcript. 
Whether these sequences participate in the silencing of hepaCAM is unknown. Riggs 
and Jones proposed that methylation of the coding regions, introns or untranslated 
regions is relatively insignificant as compared to methylation of the promoter regions. 
Methylation of the promoter region could be the primary switching mechanism while 
methylation of the other regions could provide only fine-tuning (Riggs and Jones, 
1983). Nevertheless, Malumbres et al. demonstrated that CpG methylation of the cell 
cycle inhibitor p15INK4b at the 3' UTR decreases its transcription in primary 





5.2.4.2 hepaCAM is localized on chromosome 11 in a region where other 
adhesion molecules/tumor suppressors exist 
Gene hepaCAM is mapped to the human chromosome 11q24.2. Molecular genetic and 
cytogenetic studies have indicated that the long arm of chromosome 11 is one of the 
most common targets for chromosomal aberrations during the progression of human 
malignancies. Several tumor suppressor genes encoding cell adhesion molecules of 
the IgSF have been identified on 11q22-qter. An Ig-like adhesion molecule TSLC1 is 
a tumor suppressor at 11q23 and its downregulated expression through promoter 
hypermethylation has been reported in the development of many human cancers such 
as cancers of the lung, cervix, breast and prostate (Pletcher et al., 2001). Truncation of 
the cytoplasmic domain of TSLC1 in a primary NSCLC tumor suggests that this 
domain is important for tumor suppression activity (Kuramochi et al., 2001). Another 
example is the OPCML in 11q25, which is a member of the IgLON family of Ig 
domain-containing GPI-anchored cell adhesion molecules. The gene is frequently 
somatically silenced in epithelial ovarian carcinoma by allele loss and by CpG island 
methylation (Sellar et al., 2003).  
 
5.2.4.3  hepaCAM inhibits cell proliferation 
Importantly, transfection studies revealed that hepaCAM reduced cell colony 
formation and inhibited cell growth in HCC cell line HepG2 through suppression of 
cell proliferation. The frequent loss of hepaCAM expression in HCC and other tumors 
together with its anti-proliferative effect meets the most important criteria widely used 





5.2.4.4  Possible mechanism of cell growth regulation by hepaCAM 
Several interesting motifs identified in the sequence of hepaCAM allowed us to 
deduce a possible pathway in which hepaCAM may exert cell growth control in 
response to DNA damage. Three putative DNA binding sites for the tumor suppressor 
p53 were detected in the genomic DNA of hepaCAM, indicating that hepaCAM may 
be a p53-responsive gene. Some of the common targets of p53 are p21waf1/cip1, Bax, 
gadd45, and 14-3-3σ genes whose overexpression induces cell growth arrest and/or 
apoptosis (Kaghad et al., 1997; Jost et al., 1997; Yang et al., 1998; Zhu et al., 1998). 
Strikingly, an elevated expression of p53 protein was observed in HepG2 cells 
expressing hepaCAM. Cell cycle regulatory motifs were also recognized on 
hepaCAM protein. They include binding sites for ATM kinase, 14-3-3, Cdk5 and 
Cdc2.   
 
It is attractive to speculate that upon DNA damage, hepaCAM may be activated 
through two pathways. p53 may act as a transcription factor that binds to hepaCAM 
genomic DNA to drive the expression of gene. In response, the gene product of 
hepaCAM may further stimulate the activity of p53. Alternatively, the existing 
hepaCAM protein may be activated through phosphorylation by ATM kinase. The 
activated hepaCAM molecule may, in turn, induce 14-3-3 that can subsequently 
sequester cyclin-dependent kinases such as Cdc2 and Cdk5 in the cytoplasm, causing 
cell cycle arrest. Otherwise, hepaCAM may directly interact with the cyclin-







5.2.5  hepaCAM modulates cell motility  
Cell-matrix adhesion is a key aspect of cell migration. Cell migration is a complex 
and integrated phenomenon that plays a central role in normal physiological processes 
such as embryonic development, wound healing, regeneration and immune 
surveillance, as well as in pathological processes such as angiogenesis, tumor 
invasion and metastasis (Gilbert, 2003; Ridley et al., 2003). To assess if hepaCAM is 
capable of modulating cell motility, Boyden chamber and wound healing assays were 
employed. Cells expressing hepaCAM exhibited increased motility through the 
transwell membrane. Furthermore, the cells had an increased ability to migrate into 
the mechanical scratch wound. The migratory effect of hepaCAM was almost 
completely abolished when lacking the cytoplasmic domain, indicating that hepaCAM 
modulates cell motility mainly via its cytopasmic domain.  
 
hepaCAM was predicted to contain binding sites for Cdc2. It is of interest that Cdc2 is 
capable of promoting cell migration through αvβ3 integrin (Manes et al., 2003). In 
addition, the accumulation of p53 in hepaCAM-expressing cells further supports 
hepaCAM’s ability to mediate cell migration since a loss of p53 activity was shown to 
decrease cell motility under physiological conditions (Sablina et al., 2003). 
 
Adhesion molecules that stimulate cell migration have been associated with tumor 
spreading. A classic example is integrin which is the well established mediator of cell 
migration (Hynes, 1999). The αvβ3 integrin is predominantly, although not 
exclusively, found in cancer cells and neovessels (Byzova et al., 1998; Seftor et al., 
1999). Overexpression of αvβ3 integrin in tumor cells alters cell-ECM interactions and 




1992). αvβ3 integrin has been shown to contribute to the establishment and growth of 
pulmonary metastatic melanoma lesions (Filardo et al., 1995). Additionally, it 
increases invasiveness of melanomas from the epidermis to the dermis (Hsu et al., 
1998) and of human breast cancer cells in nude mice (Felding-Habermann et al., 
2001). 
 
Gene hepaCAM is widely expressed in normal tissues. Therefore, it is believed that, in 
physiology, hepaCAM-mediated cell migration stimulates tissue remodeling and 
wound healing. Nevertheless, it remains in question if hepaCAM, in contrast to its 
tumor suppressor activity, plays a role in promoting tumor invasion and metastasis in 
pathology. The notion of two opposing roles for a protein is not uncommon. A recent 
study showed that fibroblasts deficient of p27Kip1 exhibit a dramatic decrease in cell 
motility as compared to the wildtype cells. Gene p27Kip1 is a well characterized tumor 
suppressor and is frequently inactivated in malignancies. However, in subsets of 
tumors, high p27Kip1 levels correlate with high tumor grade and increased metastasis. 
Besson et al. proposed that the overexpression of p27Kip1 in these tumors might result 
in a switch of role from a cell cycle-inhibitor to an inducer of tumor progression and 
metastasis (Besson et al., 2004). 
 
5.2.6  hepaCAM – a signal transducer? 
5.2.6.1  hepaCAM resides in the lipid rafts and caveolae 
Interaction of cell adhesion molecules with ECM components allows the transmission 
of signals directly or indirectly to second messengers that in turn unravel a cascade of 
events leading to the coordinated expression of a variety of genes involved in cell 




Lipid rafts and its derivative, caveolae, are platforms for signal transduction. They are 
most abundant on the plasma membrane, but can also be found in intracellular 
membrane compartments, such as the endocytotic pathway or the Golgi apparatus; 
and are formed by the dynamic assemblies of cholesterol and sphingolipids. There is 
ample evidence suggesting that association of transmembrane receptors and signaling 
molecules with the lipid rafts provides a cellular mechanism for the concentration of 
receptor and signaling proteins to the microdomains of the cell surface (Simons and 
Ikonen, 1997; Brown and London, 1998; Jacobson and Dietrich, 1999). For example, 
ephrinB1, which is involved in embryonic patterning, is localized in lipid rafts where 
it recruits and interacts with signaling molecules such as the glutamate receptor-
interacting protein (GRIP). Stimulation of ephrinB1 with its ligand causes the 
formation of large raft patches that contain GRIP and induces serine/threonine kinase 
activity (Bruckner et al., 1999). 
 
Several lines of evidence demonstrate that hepaCAM is associated with both lipid 
rafts and caveolae. Firstly, the membrane-spanning domain of hepaCAM contains a 
membrane lipoprotein lipid attachment site and two potential palmitoylation sites. It 
has been shown that disruption of the palmitoylation sites of NCAM140 by mutation 
destroys its raft association (Niethammer et al., 2002). In addition, the dileucine 
signals of hepaCAM that may serve as endocytosis motifs implicate an interaction 
with lipid rafts/caveolae in the endocytotic pathway. Furthermore, hepaCAM was 
predicted to be a GPI-anchored protein and such proteins are found abundantly in the 
lipid rafts (Simons and Ikonen, 1997). Experimentally, a pool of insoluble hepaCAM 
remained after Triton X-100 solubilization and F-actin depolymerization, indicating 




solubility assays performed on MCF7, HeLa and NIH3T3 cells unmasked a possible 
association between hepaCAM and caveolae. Caveolin-1, the essential structural 
component of caveolae, is known to be highly expressed in NIH3T3 cells but lowly 
expressed in HeLa cells and deficient in MCF7 cells (Suzuki et al., 1998; Engelman et 
al., 1999). The level of caveolin-1 expression correlated with the level of hepaCAM 
in the detergent-resistant membranes (DRMs) of these three cell lines. The retention 
of hepaCAM was the highest in the DRM of NIH3T3, followed by HeLa, and then 
MCF7 cells. Furthermore, sucrose density gradient ultracentrifugation partitioned 
hepaCAM to the lipid rafts/caveolae fractions, and this buoyant density of hepaCAM 
could be altered by cholesterol dispersion. Finally, colocalization studies of hepaCAM 
with caveolae marker caveolin-1 and lipid raft marker fyn showed that hepaCAM 
colocalized in part with caveolae as well as lipid rafts.  
 
A substantial amount of hepaCAM also resides in the high density fractions, 
suggesting that hepaCAM molecules either do not all reside in lipid rafts or shift 
between raft-associated and -unassociated states. A number of proteins are known to 
be functionally modified by a partial association with lipid rafts. For example, GRIP 
variably associates with lipid rafts via its interaction with ephrinB (Bruckner et al., 
1999). A similar phenomenon may occur via binding to a linker protein that is 
variably associated with rafts. As demonstrated in CD44, the adhesion molecule 
associates with rafts through its interaction with annexin II, which partitions into the 
rafts in a calcium-dependent manner. In addition, disruption of the actin cytoskeleton 
results in the flotation of CD44-containing-lipid rafts, indicating that the interaction of 
CD44 with the heavy cytoskeleton restricts the buoyancy of raft-associated CD44 




5.2.6.2  hepaCAM forms cis-homodimers on cell surface 
Dimerization is fundamental to the activation of transmembrane receptors. It is 
common that signaling through cell surface receptor proteins containing a single 
transmembrane domain is transduced by dimerization of the proteins in response to 
ligand binding (Schlessinger, 2000; Heldin, 1995). It has also been postulated that 
oligomerization of transmembrane proteins may regulate their association with lipid 
rafts (Simons and Toomre, 2000). 
 
The role of leucine zipper in mediating homo- or heterodimer formation is well 
established. Dimerization within the family or with other leucine zipper proteins is 
considered to mediate DNA binding specificity (Kouzarides and Ziff, 1988; Vinson et 
al., 1989). Protein analysis of hepaCAM revealed a leucine zipper on its extracellular 
domain, implicating that hepaCAM may dimerize through its ectodomain. As 
demonstrated by chemical crosslinking, hepaCAM is capable of forming cis-
homodimers on the cell surface. Deletion of the cytoplasmic domain did not interfere 
with dimer formation, indicating that dimerization of hepaCAM is mediated by the 
extracellular and/or transmembrane domains independent of the cytoplasmic domain. 
This finding concurs with reports indicating that the ectodomains of N- and E-
cadherins support their lateral interactions (Nagar et al., 1996; Pertz et al., 1999; 
Shapiro et al., 1995; Tamura et al., 1998; Tomschy et al., 1996). Moreover, sucrose 
density gradient ultracentrifugation of crosslinked hepaCAM showed that dimeric 
hepaCAM partitioned exclusively in the lipid rafts/caveolae, suggesting that 
dimerization regulates the association of hepaCAM with lipid rafts/caveolae as well 





Notably, crosslinking of hepaCAM or its cytoplasmic domain deleted mutant showed 
the presence of high molecular weight proteins, indicating that hepaCAM may form 
large complexes with other endogenously expressed cellular proteins through its 
extracellular and/or transmembrane domains. Alternatively, it may represent higher 
order homo-oliogomers of hepaCAM or its mutant. Growing evidences indicate that 
most adhesion molecules transduce signaling by associating with other adhesion 
molecules and/or receptors for a soluble ligand (Kamiguchi and Lemmon, 2000; Aplin 
et al., 1999; Yamada and Geiger, 1997). Hence, identification of hetero-interacting 
partners for hepaCAM may lead to finding novel signaling pathways underlying its 
biological functions. It is interesting to observe the seemingly dimeric form of 
hepaCAM and its mutant in their respective un-crosslinked samples. Although the 
mechanism resulting in such interaction is unknown to us, Hunter et al. (Hunter et al., 
1996) and others (Greenberg et al., 1991) have observed a similar phenomenon in 
CEACAM and raised the possibility that CEACAM dimers become covalently linked, 
perhaps through the action of transglutaminase, an enzyme which catalyzes the 
formation of γ-glutamyl-ε-lysine bonds in a restricted number of cellular proteins. 
 
5.2.6.3  Cytoplasmic domain of hepaCAM is phosphorylated 
Dimerization of extracellular domains results in the juxtaposition of the cytoplasmic 
domains which may lead to subsequent autophosphorylation on residues such as 
tyrosine in the cytoplasmic domains. These phosphorylated residues either trigger the 
intrinsic catalytic activity of the receptor or serve as recruitment sites for downstream 





Investigations need to be carried out to determine if the cytoplasmic domain of 
hepaCAM is capable of undergoing autophosphorylation upon dimerization. 
Nevertheless, the cytoplasmic domain of hepaCAM was predicted to contain potential 
serine/threonine and tyrosine kinase phosphorylation sites. Enzymatic 
dephosphorylation of hepaCAM revealed that the intracellular domain of hepaCAM is 
indeed phosphorylated. Although the sites of phosphorylation have not been 
identified, the results obtained suggest an important role of hepaCAM cytoplasmic 
domain in signal transduction. 
 
Furthermore, sequence analyses showed that the cytoplasmic domain of hepaCAM 
contains phosphorylation sites for casein kinase II and protein kinase C, suggesting 
that hepaCAM may be a substrate for casein kinase II and/or protein kinase C. 
Additionally, the cytoplasmic domain also contains a proline-rich region with 6 SH3-
binding domains. The amino acids of the proline-rich region may be capable of 
forming a polyproline type II helix and mediating interactions with SH3 binding 
domains (Pawson, 1995). Some adapter proteins containing SH3 domains may 
associate with the cytoplasmic domain of hepaCAM and induce intracellular 
signaling. Recently, the CD2-interacting adapter protein CD2AP was shown to bind 
to the proline-rich cytoplasmic sequence of CD2 and induce clustering of CD2 as well 
as cytoskeletal polarization (Dustin et al., 1998).  
 
5.2.6.4  hepaCAM interacts with F-actin 
Cell adhesion and migration require the coordinated interactions amongst the plasma 
membrane, cell adhesion molecules and actin cytoskeleton. These interactions are 




cytosolic proteins and membrane lipids. The signaling complexes are thought to 
participate in the polymerization of actin filaments leading to the formation of 
membrane protrusions, or in the contraction of the actomyosin network leading to 
membrane retraction (Pollard and Borisy, 2003; Gumbiner, 1996). Many adhesion 
molecules interact with the actin cytoskeleton, some directly, such as beta-
dystroglycan (Chen et al., 2003), and others indirectly, such as Ep-CAM that interacts 
with the actin cytoskeleton via α-actinin (Balzar et al., 1998). 
 
Detergent solubility is a widely accepted technique that is routinely used in the 
analysis of actin cytoskeleton and lipid microdomains. Cold Triton X-100 extraction 
of endogenous and exogenous hepaCAM showed a portion of hepaCAM to be 
resistant to detergent solubilization. Extensive deletion mutagenesis of hepaCAM 
revealed that while the cytoplasmic domain, specifically residues located within 319-
416, confers the detergent-resistant nature of the molecule, the extracellular Ig 
domains regulate the insolubility. Notably, further truncations of hepaCAM within 
residues 319-416 were not feasible because of the high GC content that restricted 
suitable primer design as well as the lack of unique restriction enzyme sites in the 
cDNA sequence. 
 
In addition to the detergent solubility assay, the interaction between hepaCAM and 
the actin cytoskeleton was evidenced by the distribution of hepaCAM to the high 
density sucrose gradient where the actin cytoskeleton resides. Disassembly of F-actin 
by potassium iodide resulted in an increased solubility of hepaCAM. Moreover, the 
subcellular localization of hepaCAM seemed to be mediated by interaction with the 




B, a filamentous actin-disrupting agent, not only affected the actin cytoskeleton, but 
also disorganized the subcellular localization of hepaCAM. Intriguingly, hepaCAM 
protein, previously localized on cell periphery, was redistributed into clusters 
containing the polymerized actin. These findings indicate that the subcellular 
localization of hepaCAM is influenced by the integrity of F-actin.  
 
Furthermore, the localization of hepaCAM on plasma membrane seemed necessary to 
establish an interaction with F-actin. When the cytoplasmic domain of hepaCAM was 
cloned and transfected into cells, the protein was no longer localized on the plasma 
membrane, and its solubility could not be affected by F-actin depolymerization. 
Whether variations in post-translational modifications of the mutant, if any, influence 
the interaction with F-actin requires further investigation. The cytoplasmic domain of 
hepaCAM does not contain any consensus actin-binding sites such as the LKXXES/T 
motif (Prekeris et al., 1996; Howard et al., 1998) and I/LWEQ module (McCann and 
Craig, 1997), indicating that the interaction with the actin cytoskeleton may be 




5.3  Gene HEPT3 
5.3.1  HEPT3 is upregulated in HCC 
HEPT3 was identified by SSH as a novel gene that was upregulated in HCC. RT-PCR 
revealed an average 7-fold increase in the expression of HEPT3 in 87% (20/23) of the 
HCC patients. In addition, the expression of HEPT3 was elevated in 100% (5/5) of the 
HCC cell lines tested. The frequent transcriptional activation of HEPT3 indicates a 
gain in function favoring liver cell proliferation/survival. Although the expression 
profile of HEPT3 in other tumors has not been established, it is noteworthy that a 
cluster of HEPT3-homologous ESTs derived from a variety of human tumors can be 
retrieved from the public databases.  
 
5.3.2 Genomic organization and characteristics of HEPT3 
5.3.2.1 HEPT3 is localized on chromosome 6q13-14 
The full-length cDNA of HEPT3 was isolated by RACE and constitutes 2839 bp. 
HEPT3 is mapped to the long arm of human chromosome 6 at q13-14. Chromosome 6 
is best recognized for the Major Histocompatibility Complex (MHC) that is critical to 
the human immune response. Additionally, it was documented to carry genes related 
to genetic diseases such as arthritis (Jawaheer et al., 2003), diabetes (Metz et al., 
2002), schizophrenia (Lindholm et al., 1999), cancers, and etc. Abnormalities in 
chromosome 6 have been implicated in a wide spectrum of human neoplasms 
including melanoma (Trent et al., 1990; Das et al., 2000), ovarian cancer (Wan et al., 
1999) and breast cancer (Rodriguez et al., 2000), with allelic deletions in the long arm 
being a commonplace. Microcell-mediated transfer of normal chromosome 6 into 
melanoma (Trent et al., 1990) and ovarian (Wan et al, 1999) cell lines was 




reported in HCC (Zimmermann et al., 1997), gastric, (Cavalho et al., 2001) and breast 
cancers (Rodriguez et al., 2000). Overall, these genetic aberrations highlight the 
importance of chromosome 6 in controlling the progressive transformation of normal 
cells into malignant derivatives. 
 
5.3.2.2  HEPT3 and isoforms are encoded by an intronless gene 
Further molecular characterization revealed several unusual characteristics of gene 
HEPT3. Firstly, HEPT3 represents an intronless gene. The cDNA of HEPT3 was 
found to be collinear to its genomic DNA. In human, naturally intronless genes 
account for less than 6% of the genes in contrast to 96% in S. cerevisiae and 17% in 
D. melanogaster (Lewin, 2000). Since intronless genes do not require post-
transcriptional splicing, they can be transcribed more efficiently leading to a 
potentially faster rate of expression, greater abundance and higher fidelity. In essence, 
these intronless genes may react immediately to cellular signals. Families of intronless 
genes encode G-protein-coupled receptors and histones (Gentles and Karlin, 1999; 
Kedes, 1979). There are also examples of proto-oncogenes that are intronless, the 
classic being myc (Sugiyama et al., 1999) and c-jun (Hattori et al., 1988) genes, and a 
recent addition, the human pituitary tumor transforming gene (PTTG) homologs 
(Prezant et al., 1999). 
 
The lack of intron/exon boundaries in the genomic sequence implies that alternative 
splicing of HEPT3 is unlikely to occur. Surprisingly, Northern blot analysis revealed 
three differently sized signals of approximately 3.3 kb, 2.5 kb and 2.0 kb, suggesting 
that HEPT3 has isoforms. Indeed, database analysis revealed two uncharacterized 




is a ~3.2 kb long transcript obtained from human lung and the other is a ~1.7 kb 
transcript derived from human fetal brain. Like HEPT3, both transcripts are 
synthesized by intronless genomic DNA. These findings indicate that HEPT3 and its 
‘alternatively spliced’ variants are transcribed from the same genomic DNA. 
However, the mechanism of generating these differently sized transcripts by the DNA 
machinery remains puzzling.  
 
5.3.2.3  HEPT3 may encode a natural noncoding RNA 
Another striking feature of HEPT3 is the high density of stop codons in all the reading 
frames. The lack of extensive open reading frames suggests that HEPT3 may be an 
example of noncoding RNA (ncRNA) termed as “riboregulator” which may function 
solely through its RNA. The theory of central dogma defines that DNA that carries 
the genetic information is transcribed to RNA and subsequently translated to protein; 
and proteins have been perceived as the functional outputs of genes. However, there is 
a growing class of ncRNA genes, which constitute about 98% of the transcriptional 
output of the human genome, that do not conform to this well-accepted paradigm of 
post-translational function. Rather, they produce functional transcripts that directly 
regulate important processes such as gene splicing nucleotide modification, protein 
transport, cell cycle progression, gene expression, protein degradation, and 
translocation through mechanisms such as RNA-RNA base pairing, RNA-protein 
interactions and intrinsic RNA activity (Mattick, 2001; 2003). Consequently, 
identification of ncRNAs is important. However, conventional protein gene-finding 
softwares such as Genscan are not designed to support the detection of ncRNAs, thus 




The identification of an Alu repetitive element in the HEPT3 transcript portrayed 
another characteristic of ncRNA, in which the presence of short interspersed repetitive 
sequences (SINEs) and other repeats is a frequent event (Michel, 2002), but rare in 
translated transcripts (Yulug et al., 1995). Alu sequences are short interspersed 
repetitive DNA elements distributed throughout the genomes of primates (Singer, 
1982), and have been implicated to be involved in recombination and evolution of the 
genome as well as contribute to about 0.1% of human genetic diseases (Deininger and 
Batzer, 1999). Although Alu sequences were initially thought to be ‘junk DNA’, 
evidence suggests that Alu repeats have a function. A study by Norris et al. 
demonstrated that Alu sequences possess the ability to function as estrogen receptor-
dependent enhancers (Norris et al., 1995).  
 
The polyadenylated transcript of HEPT3 contains 13 copies of the mRNA 
destabilization motif, AUUUA. Such motifs have been reported in lymphokines, 
cytokines and proto-oncogene mRNAs; and have been proposed to interact with the 
AU-binding factor that destabilizes mRNA. Therefore, the RNA levels of HEPT3 
may be regulated by mechanisms involving RNA stability (Shaw and Kamen, 1986). 
Collectively, the atypical structural features of the cDNA suggest that HEPT3 may 
function as a noncoding RNA. 
 
Two examples of relatively well-studied mammalian genes that act at the RNA level 
are XIST (X (inactive)-specific transcript) and H19 (Szymanski et al., 2003; Askew 
and Xu, 1999). XIST gene produces a 17-kb noncoding, spliced, polyadenylated 
transcript exclusively expressed from the inactivated X chromosome (Avner and 




randomly coats one of the two chromosome X in female, resulting in transcriptional 
silencing of the chromosome in order to achieve dosage compensation. This process 
of X inactivation is critical for the maintenance of equivalent levels of X-linked gene 
expression in XX females and XY males. H19 is implicated in imprinting of the 
insulin-like growth factor 2 (IGF-II) gene (Okamoto et al., 1997). The silencing of 
H19 by methylation results in a loss of IGF-II/H19 imprinting, leading to biallelic 
expression of both paternal and maternal IGF-II, and predisposing individuals to 
Wilms tumor and other embryonal tumors. Restoration of H19 into embryonal tumor 
cell lines suppressed cell growth and induced morphological changes. Furthermore, 
clonogenicity in soft agar and tumorigenicity in nude mice were inhibited, indicating 
that H19 may function as a tumor suppressor RNA (Hao et al., 1993).  
 
5.3.3  HEPT3 promotes tumorigenesis 
To determine if HEPT3 mRNA is involved in cell growth regulation of liver cells, an 
antisense inhibition approach was employed to interfere with the biological function 
of HEPT3. A plasmid that expressed a partial cDNA of HEPT3 in the antisense 
orientation was constructed. The introduction of the antisense plasmid into C3A cells 
led to a modest suppression of endogenous HEPT3 mRNA level. Colony formation 
assay showed that antisense HEPT3 reduced the incidence of colonies that were 
resistant to antibiotic selection as compared to cells transfected with vector alone. In 
addition, C3A cells stably expressing antisense HEPT3 displayed a 4-fold decrease in 
the rate of cell proliferation. These results demonstrated that antisense HEPT3 exerts 
anti-proliferative effect on the liver cells that express endogenous HEPT3 gene, 
implying that transcriptional activation of the HEPT3 gene may stimulate the 




5.3.4 Possible sense-antisense interaction between HEPT3 and AD7c-
NTP 
Sequence analysis revealed that the region encompassing the Alu repetitive sequence 
of HEPT3 is remarkably complementary to multiple sites on the Alu-containing 
cDNA of the AD7c-NTP gene. AD7c-NTP encodes a ~41 kDa neuronal thread protein 
that induces apoptosis and neuritic sprouting in transfected neuronal cells (Monte et 
al., 1997). This observation suggests a possible sense-antisense relationship between 
HEPT3 and AD7c-NTP. Interestingly, HEPT3 (chromosome 6q13-14) and AD7c-NTP 
(chromosome 1p36) are localized on different chromosomes.  
 
Antisense RNAs may regulate expression of the corresponding sense genes, at the 
nuclear, transcriptional, post-transcriptional, or translational level. Gene regulation by 
naturally occurring antisense RNA has been initially documented in prokaryotes 
(Simons, 1988; Wagner and Simons, 1994), which later progresses to eukaryotes 
(Kumar and Carmichael, 1998; Vanhee-Brossollet and Vaquero, 1998) like plants 
(Terryn and Rouze, 2000) and animals (Erdmann et al., 2001). A recent study by 
Chen et al. predicted 22% of natural sense-antisense transcripts in the human genome 
(Chen et al., 2004). Endogenous antisense RNAs in eukaryotes may be grouped into 
cis-encoded antisense molecules that are transcribed from the opposite strand of the 
same genomic locus as the sense RNA and form a long or perfect RNA duplexes with 
the sense transcript; and trans-encoded antisense molecules that are transcribed from 
the genomic locus different from the sense RNA and form short or imperfect RNA 
duplexes with the sense transcript. The presence of highly repetitive sequences within 
the genome provides the potential for transcripts from different strands to yield RNAs 




examples of naturally occurring transcripts have been reported to date, no general rule 
of antisense RNA in the regulation of gene expression has been verified. Potentially, 
HEPT3 RNA and AD7c-NTP transcript may form trans-RNA duplexes and degrade 
through double-stranded RNA formation, thus impeding the gene function. However, 






CHAPTER 6 CONCLUSION 
 
6.1  Conclusion 
The present study embraces three novel genes, HEPN1, hepaCAM and HEPT3 that 
are genetically altered in human hepatocellular carcinoma (HCC). Aiming to 
characterize these three novel genes, in this study, their full-length cDNAs were 
cloned and their expression and biological functions were investigated in HCC and 
other malignant cells.  
 
Gene HEPN1 is frequently silenced in HCC and in cell lines derived from various 
tumor types. HEPN1 maps to human chromosome 11q24.2; and its gene product, a 
10-kDa peptide, is distributed predominantly in the cytoplasm. Exogenous HEPN1 is 
capable of suppressing cell growth and inducing apoptosis of HepG2 cells. The data 
suggest that silencing of HEPN1 may be associated with carcinogenesis of 
hepatocytes.  
 
Gene hepaCAM is expressed in a wide variety of normal human tissues, but 
frequently silenced in HCC and in other human tumors. Gene hepaCAM maps to 
human chromosome 11q24.2 and contains 7 exons; and the gene product of 416 
amino acids encodes a cell adhesion molecule of the immunoglobulin superfamily. 
The hepaCAM protein is glycosylated, phosphorylated and forms cis-homodimers on 
cell surface. The molecule is distributed predominantly to the plasma membrane and 
is recruited to the basolateral membrane of polarized cells. The 
extracellular/transmembrane domains of hepaCAM are important for its dimerization 




proliferative effect on cell growth and activates tumor suppressor p53. In addition, 
hepaCAM modulates cell-matrix adhesion and cell motility mainly through its 
cytoplasmic domain. The detergent-resistance nature of hepaCAM is conferred by 
residues located within 319-416 of the cytoplasmic domain and regulated by the 
extracellular immunoglobulin domains. hepaCAM interacts with the actin 
cytoskeleton and resides in the lipid rafts. Taken together, hepaCAM is a new 
immunoglobulin-like cell adhesion molecule that plays important roles in cell growth 
regulation, cell-matrix interaction, and signal transduction. 
 
Gene HEPT3 exhibits a frequent upregulated expression in HCC tumors and cell 
lines. HEPT3 maps to chromosome 6q13-14 and its transcript contains sequence 
characteristics typical of the emerging class of noncoding RNA including the lack of 
extensive ORF and the presence of an Alu sequence. Antisense studies revealed that 
HCC cell growth was significantly suppressed when HEPT3 expression level was 
reduced. The data indicate that HEPT3 may function as a noncoding RNA and may 
participate in the malignant transformation of hepatocytes. 
 
In conclusion, the data presented to date indicate that HEPN1, hepaCAM and HEPT3 
may serve as promising markers for the early diagnosis of HCC and other 
malignancies. Understanding the molecular mechanisms of tumor suppression by 
HEPN1 and hepaCAM as well as tumor promotion by HEPT3 will provide insight 





6.2  Future work 
The work presented in this thesis has laid the foundation for further studies. Along 
with the particularly interesting findings obtained for hepaCAM, several lines of 
research may be pursued. 
 
Firstly, the frequent downregulation of hepaCAM in diverse human tumors and its 
ability to negatively regulate cell growth suggested an important role for hepaCAM in 
carcinogenesis. To date, the mode of silencing, the events leading to hepaCAM 
expression and its mechanism of regulation remain to be elucidated. The putative 
binding sites for cell cycle regulatory proteins on hepaCAM may provide a clue to the 
pathway(s) in which the molecule may exert anti-proliferative effects on cells. 
Identification of the functional domain of hepaCAM responsible and sufficient for 
tumor suppression may allow the synthesis of a peptide for use in cancer therapy. 
 
Secondly, through in vitro studies, hepaCAM was shown to modulate cell-matrix 
adhesion and cell migration. It will be worthwhile to explore the in vivo role of 
hepaCAM in cell adhesion and migration in development, physiology and pathology. 
It is not uncommon for tumor suppressor genes to promote metastasis and invasion, 
depending on the stage of tumor progression and level of gene expression. Profiling 
the expression of hepaCAM in tumors of different grades may reveal if the molecule 
plays contrasting roles. 
 
Last but not least, signaling through cell adhesion molecules are critical for the 
regulation of many cellular processes including embryonic development, homeostasis, 




domain of hepaCAM was shown to be phosphorylated. Although the sites of 
phosphorylation have not been identified, hepaCAM may be the substrate of kinases 
such as casein kinase II and protein kinase C. Recent experiments confirmed the 
physical interactions of hepaCAM with actin and the structural protein of caveolae, 
caveolin-1. Delineating the signaling pathways of actin and caveolin-1 may unravel 
the mechanisms of hepaCAM-mediated cell adhesion, cell migration, and tumor 
suppression. Furthermore, microarray- and proteomics-based technologies may be 
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100 mg/ml in H2O 
 
Kanamycin 30 mg/ml in H2O 
 
Blasticidin 10 mg/ml in H2O  
 
All water-soluble antibiotics were filter-sterilized. 
 






0.5g Yeast Extract 
1% NaCl 
 
LB agar 1% Tryptone 




CaCl2 solution 60 mM CaCl2, 
15% Glycerol 
10 mM PIPES [piperazine-N,N’-bis(2-hydroxypropane-
sulfonic acid)] 
Adjust pH to 7.0 
 
0.1 M IPTG 1.2 g IPTG (isopropyl-beta-D-thiogalactopyranoside) in 50 
ml of H2O 
 
X-gal (2 ml) 100 mg X-Gal (5-bromo-4-chloro-3-indolyl-β-D-









Add 1 ml of DEPC (diethylpyrocarbonate) per liter of 
solution. Shake vigorously and leave overnight at room 
temperature. Autoclave at 121°C for 15 min 
 
10X MOPS buffer 200 mM MOPS (3-[N-Morpholino] propanesulfonic acid) 
50 mM Sodium acetate 
20 mM EDTA 





1% Formaldehyde/MOPS gel 
(50 ml) 
Melt 0.5 g of agarose in 47.3 ml of 1X MOPS buffer, and add 
2.7 ml of 37% formaldehyde and 2.5 µl of ethidium bromide. 
 
Running buffer Dilute 10X MOPS to 1X with DEPC-treated H2O 
 
Loading buffer (500 µl) 250 µl 100% formamide, 83 µl 37% formaldehyde, 50 µl of 
10X MOPS, 50 µl 100% glycerol, 10 µl 2.5% bromophenol 
blue, 57 µl DEPC-treated H2O 
 
20X SSC 3M NaCl 
0.3 M Sodium citrate 
Adjust pH to 7.2 
 
Low Stringeny buffer 2X SSC containing 0.1% SDS 
 
High Stringency buffer 0.1X SSC containing 0.1% SDS 
 
Maleic Acid buffer 0.1 M Maleic acid 
0.15 M NaCl 
Adjust pH to 7.5 
 
Blocking solution Dilute 10X Blocking solution to 1X with Maleic Acid buffer 
 
Washing buffer Dissolve 0.3% (v/v) Tween-20 in Maleic Acid buffer 
 
Antibody solution Dilute Anti-Digoxigenin-AP 1:10,000 in Blocking solution 
 
Detection buffer 0.1 M Tris-HCl 
0.1 M NaCl 
Adjust pH to 9.5 
 
Wash solution 1  2X SSC, 1% SDS 
 
Wash solution 2 0.1X SSC, 0.5% SDS 
 
   
 
Solutions for agarose gel electrophoresis and DNA purification from gel 
Solution Concentration 
 
1X TAE buffer 
 
40 mM Tris 
20 mM Acetic acid 
1 mM EDTA 
Adjust pH to 7.8 
 
6X Loading dye 0.25% (w/v) Xylene Cyanol FF   
15% (w/v) Ficoll 400  
0.25% (w/v) Bromophenol Blue  
 
3 M sodium acetate Dissolve 123g of sodium acetate in 500 ml of H2O 





Solutions for immunocytochemistry 
Solution Concentration 
 
1X PBS (1 liter) 
 
 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 • 7H2O, 0.24 g KH2PO4  
Adjust pH to 7.2 
 
3.7% Paraformaldehyde (50 ml) Add 1.85 g of paraformaldehyde into 40 ml of 1X PBS. 
Warm to dissolve. Add 5M NaOH dropwise until solution 
clears. Adjust pH to 7.4 and increase volume to 50 ml. Filter-









20 mM Tris-HCl, pH 7.4 
1 mM EDTA 
0.01% β-mercaptoethanol  
 
RIPA buffer 50 mM Tris pH8.0 
150 mM NaCl 











25 mM Tris-HCl, pH 7.5 
150 mM NaCl 
5 mM EDTA 
1% Triton X-100 
 
TNE buffer 25 mM Tris-HCl, pH 7.5 
150 mM NaCl 
5 mM EDTA 
 
80% (w/v) sucrose (50 ml) Add 40 g of sucrose into 40 ml of TNE buffer. Warm to 
dissolve and increase volume to 50 ml 
 
30% (w/v) sucrose (10 ml)  Dilute 3.75 ml of 80% sucrose in 6.25 ml of TNE buffer 
 






Solutions for Western blot 
Solution Concentration 
 
2X Laemmli sample buffer 
 




0.01% bromophenol blue 
 




0.05% Bromophenol blue 
 
10% separating gel (10 ml)  2.72 ml H2O, 3.75 ml Tris-HCl pH 8.8, 3.33 ml 30% 
acrylamide/bis solution (29:1; Biorad), 100 μl 10% SDS, 100 
μl 10% APS (ammonium persulfate), 4 μl TEMED 
 
4% stacking gel (4 ml)  2.75 ml H2O, 0.5 ml Tris-HCl pH 6.8, 0.67 ml 30% 
acrylamide/bis solution, 40 μl 10% SDS, 40 μl 10% APS, 4 
μl TEMED 
 
1X SDS-PAGE running buffer 25 mM Tris-HCl 
0.2 M Glycine 
0.1% SDS 
Adjust pH to 8.3 
 
Stripping buffer 25 mM Glycine 
Adjust pH to 2.0  
1% SDS 
 
Towbin transfer buffer 25 mM Tris 
192 mM Glycine 
20% v/v Methanol 
Adjust pH to 8.3 
 
10X TBS 0.2M Tris base 
1.37M NaCl 
Adjust pH to 7.6 
 
1X TBS 20 mM Tris base 
137 mM NaCl 
Adjust pH to 7.6 
 
1X TBS-T  
  
0.1% Tween-20 in 1X TBS 








HEPN1, a novel gene that is frequently down-regulated in
hepatocellular carcinoma, suppresses cell growth and induces
apoptosis in HepG2 cells
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Background/Aims: Examining genes associated with human hepatocellular carcinoma (HCC) by subtractive
hybridisation, we identified a novel transcript, designated as HEPN1, in non-tumorous liver. In this study, we aimed to
evaluate HEPN1 gene expression in HCC patients, to characterise and to explore the functional significance of HEPN1
in vitro.
Methods: One-step reverse transcription-polymerase chain reaction (RT-PCR) and real-time RT-PCR were
employed to determine HEPN1 expression in 23 paired (HCC and the adjacent non-HCC) liver specimens. Sequence
analyses were performed by bioinformatics. Transfection studies were carried out by expressing HEPN1, V5-fused
HEPN1, and green fluorescent protein-fused HEPN1, individually, in HepG2 cells.
Results: Significant downregulation of HEPN1 (P < 0.0001) was detected in 22/23 of HCC patients tested. Gene
HEPN1 maps to chromosome 11q24.2; and the predicted gene product, a 10-kDa peptide with 88 amino acids, has no
homology to known proteins. When transfected into HepG2 cells, HEPN1 reduced cell viability to 37.5 6 2.5%
(P 5 0.001), and induced apoptosis with typical morphological changes as demonstrated by microscopy and Annexin V
assay.
Conclusions: Our data show that HEPN1 is frequently silenced in HCC, and that exogenous HEPN1 exhibits
antiproliferative effect on HepG2 cells, suggesting that silencing of HEPN1 may be associated with carcinogenesis of
hepatocytes.
q 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Keywords: Novel gene; Hepatocellular carcinoma; HepG2; Apoptosis; Growth inhibition
1. Introduction
Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide, with significantly
higher incidence rates in Africa, Southeast Asia and
China. Despite a few improvements made in diagnosis
and treatment, prognosis of HCC remains extremely poor
leading to almost one million deaths annually [1]. The
causes of HCC have been associated with chronic liver
diseases due to hepatitis virus infections [2,3] and/or
aflatoxin exposure [4]. Although it has been shown that
genetic changes occur in hepatocytes following exposure
to various viral or chemical carcinogens [5], the
underlying mechanisms of the hepatocarcinogenesis are
still largely unknown.
Genetic alterations have been defined as the hallmark of
cancers. A widely accepted approach to study genetic
instability is to identify cancer-related genes, in
particular, the two major groups of growth regulatory
genes – oncogenes and tumour suppressor genes. Notice-
ably, studies on genetic alterations in HCC have recently
increased, reporting genes that are either up- or down-
regulated or lost in hepatocellular carcinoma [6–11].
Among genes that are down-regulated in HCC, DRH1
[11] is one of the few genes that have directly been linked to
carcinogenesis and progression of hepatocellular carci-
noma; however, its biological role in cell growth/death of
hepatocytes remains to be examined.
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To explore genes associated with HCC, we compared the
gene expression between HCC and its adjacent non-
tumorous liver using the technique of suppression sub-
tractive hybridisation. With this approach, we identified a
novel transcript, HEPN1, which was suppressed in HCC
liver tissue. In this report, we demonstrate the frequency of
HEPN1 downregulation in human hepatocellular carci-
noma, the characteristics and the functional significance of
this gene in HepG2, a cell line derived from HCC.
2. Materials and methods
2.1. Isolation of HEPN1 full-length cDNA
A fragment about 400 bp of HEPN1 was identified by subtractive
hybridisation. Based on the known sequence, gene-specific primers 1 and 2
were generated. The full-length cDNA of HEPN1 was obtained by the
technique of rapid amplification of cDNA ends (RACE). RACE reactions
were prepared using the SMARTe RACE cDNA Amplification Kit
(Clontech, Palo Alto, CA, USA) and total RNA extracted from normal liver
tissue. To confirm the sequence information, RACE was repeated using the
Human Liver Marathon-Readye cDNA (Clontech, Palo Alto, CA, USA).
Briefly, the gene-specific primer 1 (GSP1, 50CTC CTA AAC TCC AGC
TCT GAT 30) was used in combination with the adapter primer to amplify
the 50-end of the gene. PCR amplification was performed for 35 cycles of
948C for 30 s and 688C for 4 min with a reaction volume of 50 ml. Similarly,
the gene-specific primer 2 (GSP2, 50ATC CAA GTC CTG CTG CCT CTT
30) was used together with the adaptor primer to generate the 30-end. The
overlap between 50- and 30-RACE products was about 300 bp. RACE
products were cloned into the pGEM-T system (Promega, Madison, WI,
USA) and sequenced by ABI PRISM 377 DNA sequencer (Applied
Biosystems, Foster City, CA, USA). Two primers at 50- and 30-end were
then designed to isolate the full-length HEPN1 cDNA by PCR. The full-
length cDNA was cloned into pGEM-T and sequenced.
2.2. Liver specimens and cell culture
A total of 23 liver specimens (Table 1) were collected from the No. 3
Hospital of Chongqing in China. Each sample was snap-frozen and stored
in liquid nitrogen before experiment. The final diagnosis of HCC was
confirmed by histological examination. Four HCC cell lines, HepG2,
Hep3B, Huh7 and SK-Hep1 were maintained in the recommended media
and culture conditions.
2.3. RNA purification and reverse transcription-polymerase
chain reaction (RT-PCR)
RT-PCR was performed to screen the expression of HEPN1 in 23 HCC
patients and in four HCC cell lines. Total RNA was extracted from either
liver tissues or cells by the RNeasy Kit (Qiagen, Hilden, Germany) and
treated with DNase I (Promega, Madison, WI, USA). RT-PCR reactions
were prepared by using the OneStep RT-PCR kit (Qiagen, Hilden,
Germany) and 0.2 mg of total RNA. Primers GSP1 and GSP2 were used
in the reactions to generate a HEPN1 fragment about 300 bp. Beta-actin or
GAPDH was included as an internal control. The One-step RT-PCR
conditions were: (1) 508C for 30 min (RT); (2) 958C for 15 min
(inactivation of reverse transcriptase); and (3) for PCR amplification, 35
cycles of 30 s at 948C, 30 s at 558C, and 1 min at 728C; and ended with 10
min at 728C. RT-PCR products were analysed by electrophoresis on 1%
agarose gels.
2.4. Real-time RT-PCR
The expression level of HEPN1 in HCC patients, as well as in
transfected HepG2 cells, was quantitated by Real-time RT-PCR with
LightCycler (Roche, Basel, Switzerland). Each product was amplified from
0.2 mg of total RNA. Reactions were prepared in 20-ml volumes using
the LightCycler RNA Amplification Kit SYBR Green I (Roche, Basel,
Switzerland) in thin-walled glass capillaries. The Real-time RT-PCR
conditions were programmed as follows: 558C for 10 min for RT followed
by PCR initial denaturation at 958C for 10 s and 45 cycles of 5 s at 958C, 10 s
at 558C, and 12 s at 728C. Primers GSP1 and GSP2 were used in
quantitative RT-PCR. RT-PCR products were evaluated on agarose gels to
ascertain the specificity of the experiments. The results were normalised
and presented as percentage against the expression level of the internal
control GAPDH.
2.5. Plasmid constructs
The open reading frame (ORF) of HEPN1 was generated by PCR and
cloned into three types of expression vectors, including: (1) pcDNA3.1/þ
(Invitrogen, Carlsbad, CA, USA) promoting high level expression of
HEPN1; (2) pcDNA6/V5-His (Invitrogen, Carlsbad, CA, USA) allowing
HEPN1 to be fused with V5/His for detection by anti-V5 or anti-His
antibody; and (3) pEGFP-N2 (Clontech, Palo Alto, CA, USA) allowing
HEPN1 to be fused with the green fluorescent protein (GFP) for
visualisation. The constructed plasmids were named as HEPN1-pcDNA,
HEPN1-V5, and HEPN1-EGFP, respectively. The empty vectors were used
as controls in the respective experiments.
2.6. Transfection studies
Monolayers of exponentially growing HepG2 cells were transfected
with desired plasmids using Lipofectamine Plus (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Transfection efficiency,
approximately 40% in this study, was detected by transfecting HepG2 cells
with the pEGFP-N2 vector and calculated based on the number of
fluorescent cells against the total number of cells in the test. For transient
transfection, HepG2 cells were transfected with either HEPN1-pcDNA or
pcDNA3.1 vector alone and analysed by microscopy, MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, and real-
time RT-PCR at 48 h after transfection. Transient transfections were
performed in triplicates and repeated four times. For colony formation,
Table 1
Clinical data of 23 patients with HCC
Case Sex Age (years) HBsAg HCV Ab Cirrhosis Grade
1 M 67 þ 2 þ 3
2 F 66 2 2 þ 2
3 M 46 þ 2 2 2
4 M 36 þ 2 þ 3
5 M 55 þ 2 þ 2
6 M 69 þ 2 þ 1
7 M 63 2 2 þ 1
8 F 72 2 2 2 2
9 F 73 þ þ þ 2
10 M 24 þ 2 2 3
11 M 39 þ 2 þ 3
12 M 69 þ 2 þ 2
13 M 32 þ 2 þ 3
14 M 68 þ 2 þ 1
15 M 70 þ 2 þ 2
16 M 58 þ 2 þ 2
17 M 56 þ 2 þ 2
18 M 64 2 þ þ 2
19 F 75 2 2 2 2
20 M 60 þ 2 þ 2
21 F 66 þ 2 þ 2
22 M 48 þ 2 þ 2
23 M 33 þ þ þ 3
HBsAg, hepatitis B virus surface antigen in serum; HCV Ab, anti-
hepatitis C virus antibodies in serum; Cirrhosis, HCC accompanied by liver
cirrhosis; þ , positive; 2 , negative. Grade, histological differentiation of
HCC: 1, well; 2, moderate; and 3, poor.
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HepG2 cells had been transfected with either HEPN1-EGFP or vector
pEGFP-N2 and selected in medium with 800 mg/ml of G418 for 2 weeks
before colonies were counted and cells were analysed by confocal
microscopy. For transfections with time-course, HepG2 cells were
transfected with either HEPN1-EGFP or vector pEGFP-N2 and examined
by fluorescent microscopy between 8 and 24 h after transfection with 2-h
interval.
2.7. Cell behaviour analyses
2.7.1. MTT assay
Cell viability was assessed by MTT dye conversion. At 48 h after
transfection in six-well culture plate, a volume of 100 ml MTT (5 mg/ml
in phosphate buffered saline) was added into each well. After 3 h of
incubation at 378C, cells were lysed and formazan crystals were
dissolved in 1 ml of isopropanol with 0.4 N HCl. Optical density









where TE ¼ transfection efficiency, i.e. 40% in this study; ODe ¼ OD
reading of experiment; ODc ¼ OD reading of control. Cell viability of
control was regarded as 100%.
2.7.2. Light microscopy
Cells were observed under an inverted microscope (Carl Zeiss,
Germany) to examine cell density and morphology. Cell behaviour
was recorded by microscopic photography with magnifications 100 £
and 400 £ .
2.7.3. Fluorescent or confocal microscopy
Cells were cultured on cover slips and transfected with
either HEPN1-EGFP or pEGFP-N2 alone. At desired times, cells
were fixed in 3.7% paraformaldehyde at 378C for 10 min, and
then examined by either Leica DM RXA2 fluorescent microscopy
(Heerbrugg, Switzerland) or Confocal Laser Scanning Microscope LSM
510 (Carl Zeiss, Germany).
2.8. Detection of V5-fused HEPN1 protein
Anti-V5 antibody was purchased from Invitrogen (Carlsbad, CA, USA)
and the secondary antibody (biotin-conjugated goat anti-mouse IgG) was
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The experimental
protocols provided by the manufacturers were therefore combined. Briefly,
HepG2 cells were cultured on coverslips and transfected with either
HEPN1-V5 construct or the empty vector pcDNA6/V5-His. At 12 h after
transfection, cells were fixed in2108C methanol for 5 min and incubated in
succession with blocking serum (for 20 min), primary antibody (anti-V5,
1:200 dilution, for 60 min), secondary antibody (3 mg/ml, for 45 min), and
streptavidin-fluorescein (15 mg/ml, for 15 min in dark). Finally, the
coverslips were mounted onto slides and cells were examined by
fluorescent microscopy.
2.9. Detection of apoptosis by Annexin V
ApoAlertw Annexin V (Clontech, Palo Alto, CA, USA) was used to
detect changes in the position of phosphatidylserine (PS) in the cell
membrane. HepG2 cells cultured on cover slips were transfected with either
HEPN1-pcDNA or vector pcDNA3.1 alone. At 16 h after transfection, cells
were rinsed with binding buffer, incubated with 5 ml of Annexin V for 10
min and observed under a fluorescent microscope using a filter for FITC
(fluorescein isothiocyanate).
2.10. Bioinformatics and statistics
Database searches were carried out using BLAST and Swiss-Prot. Motif
searches were performed with PROSITE program. Statistics was performed
by paired t-test and Mann–Whitney test for HEPN1 expression in liver
tissues and the reduction of cell viability in transfection studies,
respectively. Software InStat 3.0 (GraphPad, San Diego, CA, USA) was
employed and P , 0:05 was considered as significant.
3. Results
3.1. Identification of HEPN1 and isolation
of its full-length cDNA
Using the technique of subtractive hybridisation, we
compared mRNA populations of HCC and its adjacent non-
tumorous liver tissue obtained from a randomly chosen
HCC patient (No. 15 in Fig. 1). With this approach, we
identified 272 genes that were either up- or down-regulated
in HCC. Several novel genes were screened against a panel
of HCC patients by RT-PCR. A novel transcript, designated
as HEPN1, was chosen for further studies as it appeared to
be constantly down-regulated in HCC.
The full-length cDNA of HEPN1 was isolated from
normal liver tissue by the technique of RACE (Rapid
Amplification of cDNA Ends). The complete length and
sequence information were confirmed by the second set of
RACE reactions performed on the full-length cDNA of
normal liver from Clontech.
3.2. Loss of HEPN1 expression in human
hepatocellular carcinoma
To determine the frequency of its suppression in liver
cancer, we examined the expression of HEPN1 against 23
Fig. 1. Expression of HEPN1 in 23 HCC patients. (A) One-step RT-
PCR products were analysed by gel electrophoresis. (B) The expression
level of HEPN1 in each sample was determined by Real-time RT-PCR.
Results were normalised and converted into percentage against the
expression level of GAPDH. The average level of expression (mean 6
SD, n 5 23) is represented on the right, *P < 0.0001. N, non-tumorous
liver tissue; T, HCC liver tissue; and b-actin, internal control.
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HCC patients using both RT-PCR and real-time RT-PCR.
RT-PCR results (Fig. 1A) showed that HEPN1 was
ubiquitously expressed in 23 non-tumorous liver tissues,
but either down-regulated or lost in 22 HCC tissues (except
for sample 16), demonstrating suppression of HEPN1 in
95.7% of 23 HCC samples tested. Real-time RT-PCR
(Fig. 1B) detected a significant reduction of HEPN1
expression in 22 of 23 HCC and the average expression
level in HCC (7.2 ^ 10.4) was 5.7 folds lower than that in
non-tumorous liver tissues (40.8 ^ 10.0), P , 0:0001.
Furthermore, in four HCC cell lines tested, RT-PCR
showed that the expression of HEPN1 was significantly
suppressed in Hep3B, Huh7 and SK-Hep1, and completely
lost in HepG2 cells as compared to a non-tumorous liver
tissue (Fig. 2). However, silencing of HEPN1 in HepG2
cells was not resulted from gene mutation as direct
sequencing failed to reveal any alterations in HEPN1
genomic DNA.
3.3. Characteristics of HEPN1
The full-length cDNA of HEPN1 (Fig. 3A) is approxi-
mately 1.4 kb long containing an ORF of 267 base pairs.
The start codon ATG, the stop codon TGA, and the Kozak
sequence [12] were identified (GenBank Accession No.
AY275431). Searching HEPN1 against human EST
(expressed sequence tag) databases yielded a number of
aligned fragments identified mainly in the brain. The
predicted HEPN1 peptide consisted of 88 amino acids
with a molecular weight about 10 kDa. The peptide had no
significant homology in the available databases of proteins
and peptides. BLAST search against the human genome
database revealed that HEPN1 was mapped to human
chromosome 11 at q24.2 (Fig. 3B); however, the promoter
region remained to be identified. To localise HEPN1 gene
product in living cells, the construct expressing HEPN1-V5
fusion protein was transfected into HepG2 cells. Fluorescent
microscopy showed that HEPN1 peptide was predominately
distributed in the cytoplasm (Fig. 3C).
3.4. Growth suppression in HepG2 cells by HEPN1
To determine the biological role of HEPN1, we
expressed HEPN1 in a HEPN1-null HCC cell line,
HepG2. The construct HEPN1-pcDNA was transiently
transfected into HepG2 cells. Cells transfected with
pcDNA3.1 vector served as control. At 48 h after
transfection, cells were subjected to light microscopy,
MTT assay, and real-time RT-PCR analysis. As shown in
Fig. 2. Expression of HEPN1 in four HCC cell lines. One-step RT-PCR
was used to amplify HEPN1 mRNA and GAPDH (an internal control).
The expression of HEPN1 in four HCC cell lines, HepG2, Hep3B, Huh7
and SK-Hep1, was compared to that in the non-tumorous liver tissue
from patient number one (N1).
Fig. 3. Characteristics of HEPN1. (A) Sequences of HEPN1 cDNA and the predicted amino acid (GenBank Accession No. AY275431). The full-length
cDNA of HEPN1 is approximately 1.4 kb long. The ORF, start codon, stop codon, and the Kozak sequence are highlighted. The predicted peptide has
88 amino acids with molecular weight about 10 kDa. (B) Localisation of HEPN1 in human genome. HEPN1 is mapped to chromosome 11q24.2. (C)
Subcellular localisation of HEPN1 in HepG2 cells. HepG2 cells transfected with HEPN1-V5 construct. Anti-V5 immunostaining visualised that
HEPN1 is predominantly distributed in the cytoplasm.
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Fig. 4A, re-expression of HEPN1 (real-time RT-PCR)
decreased cell density, changed cell morphology (light
microscopy), and reduced cell viability to 37.5 ^ 2.5%
(P ¼ 0:001).
Colony formation was performed to confirm the
inhibitory effect of HEPN1 on cell growth. HepG2 cells
transfected with HEPN1-EGFP were compared with those
transfected with pEGFP-N2 vector alone. Green fluor-
escent protein facilitated the visualisation of cells in each
colony. The results showed (Fig. 4B) that, in addition to
the significant reduction of the number of colonies
formed, the number of fluorescent cells in the cells
transfected with HEPN1-EGFP was extremely low
compared to that in the cells transfected with pEGFP-
N2 vector alone.
3.5. Apoptosis induction in HepG2 cells by HEPN1
To explore if HEPN1 could promote cell death, we
transfected HepG2 cells with either HEPN1-EGFP con-
struct or pEGFP-N2 vector alone. Between 8 and 24 h post-
transfection, cells were analysed by fluorescent microscopy
at every 2 h. Fig. 5 shows the cell behaviour of HepG2 cells
transfected with HEPN1 in contrast with the control cells.
After transfection: (1) at hour 8, HEPN1 started being
expressed predominately in cytoplasm; (2) at hour 10, the
expression level was increased and concentrated in
granules; (3) at hour 12, HEPN1 was distributed more in
the perinuclear region; and (4) at hour 14, HEPN1 started
translocating into cell nuclei; and from hour 16 onwards,
typical apoptotic morphology including cytoplasm shrink-
ing (16 h), cell blebbing (18 h), and nuclear fragmentation
(20 and 22 h) was observed. At hour 24, the number of cells
transfected with HEPN1-EGFP was considerably reduced
compared to that at hour 12 presented in the inset.
The control cells transfected with pEGFP-N2 vector alone
remained unchanged throughout.
Annexin V was used to determine if cells were indeed
undergoing apoptosis. Since Annexin V detects changes in
the position of PS in the cell membrane, one of the earliest
changes of apoptotic cells, HepG2 cells were examined at
16 h after transfection. As shown in Fig. 6, positive Annexin
V-PS binding on the cell membrane was observed in cells
transfected with HEPN1-pcDNA but not in the cells
transfected with pcDNA3.1 vector alone.
4. Discussion
We report here the characterisation of a novel gene,
HEPN1, and its functional significance in HepG2 cells. Gene
HEPN1, suppressed in HCC, was identified in non-tumorous
liver through the technique of subtractive hybridisation.
Screening against 23 hepatocellular carcinoma patients, we
found that HEPN1 was down-regulated in 95.7% (22/23) of
HCC and the average expression level was 5.7 folds lower in
HCC tissues than that in non-tumorous liver tissues,
suggesting that silencing of HEPN1 is associated with
carcinogenesis of hepatocytes (P , 0:0001). Additionally,
HEPN1 is also significantly suppressed in all the HCC cell
lines tested, further implying that loss of HEPN1 expression
is of generality in HCC. However, we failed to identify any
correlation between the loss of HEPN1 expression and the
events related to the development and progression of HCC,
including hepatitis B viral infection, hepatitis C viral
infection, liver cirrhosis, and the differentiation of HCC.
This may be due to the ubiquitous downregulation of HEPN1
in the HCC samples tested.
Fig. 4. Growth inhibition of HepG2 cells by HEPN1. (A) Transient
transfection for 48 h. Light microscopic photographs demonstrate the
density (100 3 ) and morphology (400 3 ) of HepG2 cells transfected
with HEPN1-pcDNA (right) in contrast to the control, cells transfected
with pcDNA3.1 vector alone (left). Cell viability (mean 6 SD, n 5 12)
was detected by MTT assay and computed into percentage against the
control; *P 5 0.001. Real-time RT-PCR results show the expression
level of HEPN1 in the transfected HepG2 cells. GAPDH was used as
control. The RT-PCR products were analysed by gel electrophoresis to
verify the specificity. (B) Colony formation. HepG2 cells transfected
with the plasmid HEPN1-EGFP (right) and pEGFP-N2 vector (left)
were cultured in the presence of 800 mg/ml of G418 for 2 weeks before
confocal microscopy. The density and morphology of cells in a colony
were visualised by green fluorescence. The number of colonies
presented at the bottom of each picture was counted manually.
M.C. Moh et al. / Journal of Hepatology 39 (2003) 580–586584
HEPN1 is mapped to the human chromosome 11q24.
Abnormalities of chromosome 11q including chromosome
breakage, rearrangement and loss on the long arm have been
reported in a number of human tumours, such as, colorectal
cancer [13], breast cancer [14], melanoma [15], acute
lymphoblastic leukemia [16], and ovarian cancer [17],
signifying the presence of tumour suppressor genes in this
region. However, HEPN1 does not resemble any of the
tumour suppressor genes identified to date; and, moreover,
no known alterations of chromosome 11q24 have been
found in HCC. Therefore, the mechanisms that suppress the
expression of HEPN1 in HCC remain to be explored.
The predicted HEPN1 product is a 10-kDa peptide (p10)
consisting of 88 amino acids. The peptide neither has
significant homology to any of the known proteins and
peptides nor discloses substantial sequence motifs in
the available databases. Unlike gene PTEN, whose structure
provided important clues to the function of the protein when
it was first discovered [18], the novelty of HEPN1 sequence
led to the difficulty of understanding its biological role.
To study its functional significance, we expressed
HEPN1 into a HEPN1-null HCC cell line, HepG2, in
Fig. 5. Induction of apoptosis in HepG2 cells by HEPN1. HepG2 cells were transfected with either pEGFP-N2 vector alone (labeled as EGFP) or
HEPN1-EGFP construct. Between 8 and 24 h after transfection, cells were analysed by fluorescent microscopy at every 2 h. Green fluorescence
visualised cell number, cell morphology and distribution of HEPN1. Microphotographs are presented at each time point and indicated as 8, 10, 12, 14,
16, 18, 20, 22, and 24 h, respectively. An entire microscopic view at 24 h is compared to that at 12 h (inset), showing the reduction of cell number when
HEPN1 was re-expressed.
Fig. 6. Results of Annexin V assay. The fluorescent rings represent
positive binding of Annexin V with PS in the cell membrane, an early
indication of apoptosis. (A) HepG2 cells transfected with HEPN1-
pcDNA construct; and (B) HepG2 cells transfected with the empty
vector pcDNA3.1.
M.C. Moh et al. / Journal of Hepatology 39 (2003) 580–586 585
three phases. Firstly, transient transfection was performed
on HepG2 cells. Forty-eight hours after transfection, the
results showed that re-expression of HEPN1 inhibited
cell growth by about 62.5 ^ 2.5% (P ¼ 0:001). Secondly,
colony formation was performed on cells transfected with
the HEPN1-pEGFP construct and the EGFP-N2 vector.
The results showed that exogenous HEPN1 reduced both
the number of colonies and the number of fluorescent
cells, supporting that HEPN1 is indeed capable
of suppressing cell growth in HepG2 cells. Finally,
time-course transfection with GFP-fused HEPN1 visual-
ised the dynamics of the distribution of HEPN1 and
cell behaviour after transfection. Together with Annexin
V assay, the results showed that HEPN1 promotes
apoptosis in HepG2 cells. These data indicate that the
predicted HEPN1 peptide does exhibit biological
functions.
In conclusion, gene HEPN1 is frequently silenced in
hepatocellular carcinoma. HEPN1 maps to chromosome
11q24.2; and its product, a 10-kDa peptide, is distributed
predominantly in the cytoplasm. Exogenous HEPN1 is
capable of suppressing cell growth and inducing apoptosis
in HepG2 cells. Our data suggest that HEPN1 is involved
in the growth control of hepatocytes; however, the
mechanisms of its antiproliferative effect are to be
determined.
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Cloning and characterization of hepaCAM, a novel Ig-like cell
adhesion molecule suppressed in human hepatocellular carcinoma
Mei Chung Moh, Lay Hoon Lee, Shali Shen*
Laboratory of Hepato-Oncogenetics, Department of Physiology, Faculty of Medicine, National University of Singapore,
2 Medical Drive, Singapore 117597
Background/Aims: Previously, we reported on gene HEPN1 that was silenced in hepatocellular carcinoma (HCC) and
its capability of arresting cell growth. In this study, we identified another novel gene hepaCAM from the liver, which
contains the full-length HEPN1 on its antisense strand in the 3 0-noncoding region, and assessed its expression,
characteristics and functions in HCC.
Methods: Full-length hepaCAM cDNA was isolated by rapid amplification of cDNA ends. The gene expression was
examined by semi-quantitative RT-PCR in 23 paired HCC liver specimens and 5 HCC cell lines. Transfection studies,
coupled with immunocytochemistry, cellular interaction analyses, colony formation and microtetrazolium assay, were
employed to elucidate the localization and functions of hepaCAM.
Results: The expression of hepaCAM decreased in 20/23 of HCC samples and was undetectable in 5 HCC cell lines
tested. The gene product consisting of 416 amino acids displayed the typical structure of Ig-like cell adhesion molecules.
The protein was glycosylated and predominantly localized on the cytoplasmic membrane. When re-expressed in
HepG2, hepaCAM accelerated cell spreading (P!0.001), increased cell motility (PZ0.0011), reduced colony formation
(PZ0.0022), and inhibited cell growth (P!0.001).
Conclusions: Gene hepaCAM, frequently silenced in HCC, encodes an Ig-like transmembrane glycoprotein and is
involved in cell adhesion and growth control.
q 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Keywords: Hepatocellular carcinoma; hepaCAM; Ig-like cell adhesion molecule; Cell growth arrest; Cell–matrix
interaction; HEPN11. Introduction
Cell adhesion is crucial not only for the formation and
maintenance of cellular architecture but also for the normal
biological processes including adhesion, migration, pro-
liferation and survival [1]. Such specialized recognition and
adhesion are mediated by cell adhesion molecules (CAMs)
expressed on the cell surface. Generally classified into
cadherins [2,3], selectins [4], integrins [5], and immuno-
globulin superfamily (IgSF) [6], these glycoproteins
recognize and interact either with other cell adhesion
molecules on the adjacent cell surface or with proteins0168-8278/$30.00 q 2005 European Association for the Study of the Liver. Pub
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E-mail address: phsssl@nus.edu.sg (S. Shen).deposited in the extracellular matrix. In addition to the
adhesive properties of these molecules, an exciting concept
that has emerged from recent cell biological research is that
cell adhesion complexes are not simply static architectural
entities. Rather, they are dynamic units that are critical in
modulating cytoplasmic signaling cascades by capturing
and integrating signals from the extracellular
environment [2].
Cell organization and tissue architecture of the liver are
well defined. Approximately, 80% of the adult liver consists of
hepatocytes that are arranged as single-cell annastomosing
plates extending from the portal region of the liver lobule
towards the central vein [7]. Proper liver architecture is crucial
for hepatic function [8] and is commonly disrupted in disease/
injury state, including hepatitis, cirrhosis [9] and hepatocel-
lular carcinoma [10]. Disruption of normal cell–cell adhesion
in transformed cells may contribute to tumor cells’ enhancedJournal of Hepatology 42 (2005) 833–841www.elsevier.com/locate/jheplished by Elsevier B.V. All rights reserved.
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tasis. Although the underlying mechanism of how these
phenotypes are resulted remains elusive, such disruption has
been related to inactivation of cadherin, or the catenin family
members, and activation of signaling pathways that prevent
the assembly of adherens junctions [11].
Extensive studies have shown that the disruption of cell
adhesion plays a causal role in tumor progression and
metastasis [12]. Alterations of several IgSF tumor suppres-
sors have been implicated in tumor malignancies. One such
intriguing Ig-containing protein is the neural cell adhesion
molecule (NCAM), a cell surface sialoglycoprotein, which
is involved in neural development, signal transduction and
synaptic plasticity and is downregulated during tumorigen-
esis [13–17]. A correlation between reduced NCAM
expression and poor prognosis has been reported in several
cancer types, including gastrointestinal neoplasia, colorectal
cancer, and pancreatic cancer [18–20]. Another IgSF
adhesion protein implicated in carcinogenesis is the
carcinoembryonic antigen cell adhesion molecule-1
(CEACAM1), an epithelial cell adhesion molecule, which
is frequently downregulated in liver, colorectal and prostate
cancers [21–24]. Consistently, ectopic restoration of its
expression in colorectal and prostate carcinoma cells
significantly suppressed their tumorigenicity in vitro and
in vivo [24–26], suggesting that CEACAM1 functions as a
tumor suppressor gene. Moreover, CEACAM1 is an
angiogenic factor and an effector of vascular endothelial
growth factor in endothelial cells; and has been implicated
in cell invasion and metastasis [27,28].
In our previous study, examining genes associated with
human hepatocellular carcinoma (HCC) by suppression
subtractive hybridization, we identified a novel gene,
HEPN1, frequently silenced in HCC [29]. Interestingly, an
updated BLAST search revealed that an mRNA sequence in
the database (GenBank AL834419), encoding a partial open
reading frame (ORF) at the 5 0 terminus, contained the entire
antisense strand of HEPN1 in its 3 0 noncoding region. This
finding led us to isolate a new gene with a full-length cDNA
approximately 3.2 kb. The gene encodes a putative Ig-like
cell adhesion molecule with 416 amino acids, designated as
hepaCAM. In this report, we demonstrate the expression,
characteristics and functions of hepaCAM in hepatocellular
carcinoma.2. Materials and methods2.1. Isolation of hepaCAM full-length cDNA
Rapid amplification of cDNA ends was performed with the Human
Liver Marathon-Readye cDNA Kit (Clontech) according to
the manufacturer’s instructions. The gene-specific primer (GSP, 5 0-
GCTAGGCACTCTGCTGGATGCTAGTA-30) designed at the 5 0-end on
the antisense strand of HEPN1 was used with the adapter primer 1
(provided) to amplify the full-length cDNA of hepaCAM. The cDNA was
cloned and sequenced.2.2. Liver specimens and cell lines
A total of 23 paired liver specimens and 6 normal liver tissues were
surgically collected at the No. 3 Hospital of Chongqing in China through
Dr Yang Xiaodong. The final diagnosis of HCC was confirmed and
classified by histological examination. Five human HCC cell lines, HepG2,
Hep3B, Huh7, SK-Hep1 and PLC-5, were maintained in the recommended
conditions.2.3. RT-PCR
Semi-quantitative RT-PCR reactions were performed with the OneStep
RT-PCR kit (Qiagen) while real-time RT-PCR was performed with the
LightCycler RNA Amplification Kit SYBR Green I (Roche). A forward
primer (5 0-TGTACAGCTGCATGGTGGAGA-3 0) and a reverse primer
(5 0-TCTGGTTTCAGGCGGTCATCA-3 0) were used to generate a
hepaCAM fragment of 235 bp from 0.2 mg of DNase-treated total RNA.
Beta-actin or GAPDH was included as control.2.4. Plasmid construct
The open reading frame of hepaCAM was generated by PCR from the
full-length cDNA with the forward primer 5 0-GAAGCTT(HindIII)-
CAAAATGGAGAGAGAAAGGGGAGCC-3 0 and the reverse primer
5 0-AGGATCC(BamHI)-GGCCCAGGCGCTGATCTCCACC-3 0. The
PCR product was cloned into the HindIII/BamHI restriction sites of
pcDNA6/V5-His (Invitrogen). The construct, namely hepaCAM-V5,
facilitated the expression of hepaCAM-V5 fusion protein and the detection
by anti-V5 antibody.2.5. Transfection
Transient transfections were carried out with Lipofectamine Plus
(Invitrogen). Hep3B and HepG2 cells grown on coverslips were transfected
with either hepaCAM-V5 or pcDNA6/V5-His (pcDNA6) vector for 48 h
before immunocytochemistry. Stable transfections were performed on
HepG2 cells. Transfected cells were selected in the presence of 10 mg/ml of
blasticidin (Invitrogen) for 3 weeks and then cloned.2.6. Immunocytochemistry
Cells cultured on coverslips were washed with PBS, fixed with 2%
paraformaldehyde, and permeabilized with 0.2% Triton-X 100. Nonspecific
sites were blocked in 10% normal goat serum (Santa Cruz). Protein
expression of hepaCAM was detected using mouse anti-V5 antibody
(Invitrogen) diluted at 1:200, biotin-conjugated goat anti-mouse IgG
antibody (3 mg/ml), and subsequently streptavidin-fluorescein (15 mg/ml).
Fluorescence was visualized by Fluorescence Microscope and Confocal
Microscope LSM 510 (Carl Zeiss).2.7. Western analysis
Total protein (50 mg) from HepG2 or liver tissue was resolved by
SDS-PAGE, transblotted onto membrane, and detected by either rabbit
anti-hepaCAM polyclonal antibody (generated following the procedure
described in the Current Protocol) or mouse anti-V5 monoclonal
antibody. The membranes were stripped and reprobed with mouse
anti-GAPDH antibody (Chemicon) to assess loading quantity.2.8. Deglycosylation
Cell lysate was deglycosylated with peptide N-glycosidase F
(PNGase F) (New England Biolabs) according to the manufacturer’s
instructions. Equal amount of cell lysate without PNGase F treatment
served as control. These samples were then subjected to western analysis.
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Cells were seeded in plates coated with 10 mg/ml-fibronectin (Santa
Cruz) and incubated under standard conditions. Cell morphology was
observed by microscopy (Carl Zeiss). Unspread cells were defined as round
cells, while spread cells were defined as cells with extended processes [30].
The percentage of cells demonstrating spread morphology was quantified in
10 randomly selected fields (O60 cells/field).
2.10. Matrigel invasion assay
Cell migration was assessed using the transwell chambers with 8-mm
pore size membranes coated with matrigel (BD Biosciences) in 24-well
plates. Cells (5!104) were loaded into the upper volume of the chambers
and allowed to migrate through the membrane for 24 h. Non-migrated cells
were removed with a cotton swab, and the migrated cells were harvested by
trypsinizing the lower surface of the membrane and collected into new 24-
well plate. The migration activity was quantified by blind counting of the
migrated cells in 10 randomly selected microscopic fields (O40 cells/field).
2.11. Wound closure assay
Cell motility was also assessed by the wound healing experiment on
monolayer cells. Cells were seeded in 35-mm culture plates at high density
and allowed to form monolayers overnight. Wounds were made by pipette
tip on confluent cells and allowed to be healed by cell migration for 24 h.
The changes in diameter (D) of each wound were measured by microscopy
and computed into ratio (D24 h/Dinitial!100%) to represent wound closure.
2.12. Colony formation
HepG2 cells transfected with either hepaCAM-V5 or vector pcDNA6
were selected in 10 mg/ml of blasticidin (Invitrogen) for 3 weeks without
trypsinization while medium was refreshed every 2 days. The cell colonies
formed at the end of experiment were visible, and the size and thickness of
the colonies were analyzed by microscopy. The number of colonies was
counted in 10 randomly selected fields.
2.13. Growth curve
The growth rate of HepG2 stable cell lines were monitored for 5 days.
Cells were seeded in triplicates and cultured under standard conditions. At
every 24 h, cell viability was determined by MTT assay. The growth rate of
each cell line was presented as folds of increase in cell viability against the



















Fig. 1. Molecular cloning of hepaCAM. (A) Reconstitution scheme of hepaCAM
liver cDNA library by RACE. A forward primer on the adaptor (AP1) and a
antisense strand were used in the RACE reaction. The cDNA lengths of hepa
indications of 5 0 and 3 0 correspond to the orientations of the cDNAs. The genom
exons indicated as I–VII and accompanied by their respective length in base2.14. Bioinformatics and statistical analysis
Sequence analyses were carried out through database searches
(facilitated by the NCBI, Ensembl and ExPASy). Mann–Whitney test
was performed to compare two means of samples with small sample size
(nZ6). Fisher’s exact test was used to assess the correlation between two
parameters. Nonparametric ANOVA was performed to compare the
differences between more than two means. Software InStat 3.0 (GraphPad)
was employed and P!0.05 was considered as significant.3. Results
3.1. Identification of hepaCAM
As illustrated in Fig. 1, the cDNA sequence AL834419
(GenBank) containing the antisense strand of HEPN1 in its
3 0-noncoding region was deficient in the 5 0-noncoding
region. The gene specific primer (GSP) at the 5 0-end of
HEPN1 antisense strand and the adaptor primer (AP1)
enabled us to isolate a new gene, hepaCAM, from a human
normal liver cDNA library. Gene hepaCAM was mapped to
human chromosome 11q24 and its genomic DNA sequence
contained 7 exons ranging in sizes from 71 to 2252 bp. The
full-length cDNA sequence of hepaCAM (3244 bp) has
been submitted to the GenBank (AY047587).
3.2. Suppression of hepaCAM in HCC
Semi-quantitative RT-PCR revealed that hepaCAM was
expressed at a similar level in all the normal liver tissues
tested (Fig. 2A). To evaluate if hepaCAM expression was
downregulated in HCC, we examined hepaCAM mRNA
levels in 23 paired liver samples from HCC patients using a
pair of hepaCAM specific primers that were not associated
with the HEPN1 sequence. The results showed that
hepaCAM was reduced in 87% (20/23) of HCC tissues
(Fig. 2B). The expression of hepaCAM was not detectable















. The full-length cDNA of hepaCAM was isolated from normal human
gene specific primer (GSP, the reverse primer) at the 5 0-end of HEPN1
CAM, HEPN1 and sequence AL834419 are given in the brackets. The
ic DNA of hepaCAM mapped to human chromosome 11q24 contains 7
pairs (bp). [This figure appears in colour on the web.]
Fig. 2. Expression of hepaCAM in liver specimens and HCC cell lines. (A) Expression of hepaCAM in normal liver tissues. Semi-quantitative RT-PCR
was performed to determine the mRNA expression of hepaCAM in 6 normal liver tissues obtained from 6 individuals. Two pairs of gene specific
primers were included in one RT-PCR reaction to generate the fragments of genes b-actin (720 bp, as the internal control) and hepaCAM (235 bp),
respectively. The samples are labeled from 1 to 6; NL, normal liver. (B) Expression of hepaCAM in 23 HCC patients. Semi-quantitative RT-PCR
products were analyzed by gel electrophoresis. %, samples that show clear differences in hepaCAM expression; N, non-tumor liver tissue; C, HCC
liver tissue; b-actin, internal control. Patient 23 had two HCC nodules (C1 and C2) in the liver. (C) Expression of hepaCAM in five hepatic cell lines.
Semi-quantitative RT-PCR was used to amplify hepaCAM mRNA and GAPDH mRNA (internal control). The expression level of hepaCAM in 5 HCC
cell lines, HepG2, Hep3B, Huh7, SK-Hep1 and PLC-5, was compared to that in the normal liver tissue 1NL. (D) Protein levels of hepaCAM in normal
liver tissues and HepG2 cells. Western analysis with rabbit anti-hepaCAM polyclonal antibody revealed the endogenous hepaCAM protein levels in 6
normal liver tissues and the exogenous protein in hepaCAM-transfected HepG2 cells (H). No hepaCAM protein was detectable in both the parental
(P) and the vector-transfected (V) HepG2 cells. GAPDH protein level indicates the loading quantity.
Table 1
Correlation between hepaCAM suppression and the clinicopathologic








Total number 20 3 87
Sex
Male 16 2 89 NS
Female 4 1 80 NS
Grade
Well 3 0 100 NS
Moderate 12 2 86 NS
M. Chung Moh et al. / Journal of Hepatology 42 (2005) 833–841836Huh7, SK-Hep1 and PLC-5 (Fig. 2C). Furthermore, western
analysis with anti-hepaCAM polyclonal antibody confirmed
the protein expression of hepaCAM in all the normal liver
tissues, as well as in HepG2 cells transfected with
hepaCAM, but neither in the parental HepG2 cells nor in
the cells transfected with vector alone (Fig. 2D). These data
implied the association between the loss of hepaCAM and
hepatocarcinogenesis. No correlations between hepaCAM
and the clinicopathologic parameters could be detected.
This could be due to the high rate of hepaCAM suppression
in the HCC samples tested (Table 1).Poor 5 1 83 NS
Cirrhosis 16 3 84 NS
Hepatitis virus
HBV 18 2 90 NS
HCV 3 0 100 NS
HBVCHCV 2 0 100 NS
Grade, histological differentiation of HCC; NS, not significant; P was
revealed by the Fisher’s exact test.3.3. Characterization of hepaCAM protein sequence
Gene hepaCAM encoded a 46-kDa protein of 416
amino acids consisting of an extracellular region,
a transmembrane segment, and a cytoplasmic tail
(Fig. 3A). The extracellular region comprised a signal
M. Chung Moh et al. / Journal of Hepatology 42 (2005) 833–841 837peptide and 2 Ig domains (Ig-like and C2 domains) as
predicted by SignalP [31] and SMART [32], respectively.
Two cysteine residues flanking the C2 domain contributed
to the formation of intrachain disulfide-linked loop. Six N-
glycosylation sites were identified in the extracellular
region, which may contribute to the glycosylation of
hepaCAM protein. The transmembrane segment was
found to contain a prokaryotic membrane lipoprotein
lipid attachment site (LLVTLVTVCAC). At the cyto-
plasmic tail, two potential class III PDZ domain-binding
motifs were predicted. Overall, the structure of hepaCAM
closely resembles Ig-like cell adhesion molecules.Fig. 3. The characteristics of hepaCAM protein sequence.
(A) Predicted amino acid sequence of human hepaCAM. The fragment
highlighted in the box is the putative signal peptide (34 amino acids).
The regions underlined with solid lines are the two immunoglobulin-
like (Ig-like) domains (103 and 66 amino acids, respectively) while the
one underlined with dashed line is the transmembrane domain (23
amino acids). Two cysteine residues (marked underneath the ‘C’) are
identified in the second Ig-like domain, which may be needed for the
formation of the disulfide bond in the domain. Six asparagines (marked
underneath the ‘*’) are in the extracellular region, which represent the
potential N-linked glycosylation sites. The class III PDZ domain
binding motifs (in the inverted shades) are present in the cytoplasmic
region. (B) Illustration of the secondary structure of hepaCAM protein.
hepaCAM owns the typical structure of proteins in the immunoglobu-
lin superfamily, including an extracellular segment consisting of an N-
terminal-proximal Ig-like domain and a membrane-proximal C2-type
Ig-domain with a disulfide bond formed between two cysteine residues
(S S), a transmembrane region, and a cytoplasmic tail. The six putative
N-linked glycosylation sites are indicated by the signs of ‘ ’.
(C) Deglycosylation of hepaCAM. HepG2 cells transfected with
hepaCAM were lysed and treated with (lane II) or without (lane I)
peptide N-glycosidase F. The cell lysates were resolved by SDS-PAGE
and subjected to western blotting with anti-V5 antibody.3.4. Deglycosylation of hepaCAM protein
The molecular weight of the epitope-tagged hepaCAM
shown by western analysis was approximately 75 kDa,
larger than the predicted size (46 kDa). The six N-glycosy-
lation sites identified on hepaCAM protein within the
extracellular region (Fig. 3B) implied that hepaCAM
protein might be glycosylated. The cleavage of N-linked
glycans on hepaCAM by PNGase F indeed shifted the
molecular weight from 75 to 60 kDa (Fig. 3C), indicating
hepaCAM a glycoprotein. Noticeably, the molecular weight
of the deglycosylated protein was still higher than the
predicted one, suggesting the involvement of additional
post-translational modifications.
3.5. Cellular localization of hepaCAM
Two hepatic cell lines Hep3B and HepG2, in which
hepaCAM was undetectable (Fig. 2C), were transiently
transfected with hepaCAM-V5. Immunofluorescence stain-
ing with anti-V5 antibody showed that hepaCAM was
scattered in the cytoplasm, absent in the nucleus and
predominantly localized on the plasma membrane of both
Hep3B and HepG2 cells (Fig. 4A). Interestingly, the
cellular localization of hepaCAM appeared to be cell
density-dependent in HepG2 with stable transfection. In
well-spread cells (Fig. 4B upper), hepaCAM was dis-
tributed in the cytoplasm and at the cell surface protrusions
that were about to make cell contacts. In confluent cells
(Fig. 4B lower), hepaCAM was predominantly localized on
the cytoplasmic membrane, particularly in the areas of
cell–cell contacts.
3.6. Evaluation of stable transfection
Two clones stably transfected with vector (V1 and V2) and
3 clones with hepaCAM-V5 (H1, H2 and H3) were screened.
Western analysis showed that hepaCAM was absent in the
vector clones V1 and V2, and expressed in 2 (among 3)
hepaCAM clones H1 and H3 (Fig. 5A). Real-time RT-PCR
showed that hepaCAM was expressed in clones H1 and H3 but
not overexpressed when compared to the normal liver tissues,
and was expectedly absent in clones V1, V2 and H2 (Fig. 5B).
Immunofluorescence staining and confocal microscopy con-
firmed the establishment of cell clones (Fig. 5C). Clones V1,
V2, H1 and H3 were therefore selected for the downstream
functional exploration of hepaCAM.
3.7. Cell–matrix interaction and cell motility
modulated by hepaCAM
As hepaCAM displayed the typical structure of cell
adhesion molecules, we evaluated the adhesive properties of
hepaCAM on the stable HepG2 clones through cell
aggregation and spreading assays. Although hepaCAM did
not clearly change cell aggregation (data not shown), it was
Fig. 4. Cellular localization of hepaCAM. (A) Through transient
transfection and immunocytochemistry, hepaCAM protein was loca-
lized in 2 HCC cell lines. Fused with V5 in vector pcDNA6/V5-His,
hepaCAM was transfected into Hep3B and HepG2 cells. Anti-V5
antibody was used for immunostaining to detect the expression and
localization of hepaCAM. Confocal microscopy revealed that hepa-
CAM was scattered in the cytoplasm and predominantly localized on
the cell membrane (arrows). (B) The localization of hepaCAM in
HepG2 cells with stable transfection was cell density-dependent. Upper
panel, well-spread cells with surface protrusions (arrow heads); lower
panel, confluent cells with clear cell-cell contacts. [This figure appears
in colour on the web.]
Fig. 5. Stable transfection of hepaCAM in HepG2. HepG2 cells stably
transfected with vector or hepaCAM-V5 construct were cloned.
(A) Western analysis. Anti-V5 antibody was used in the western
analysis to evaluate the protein levels of hepaCAM in two clones
transfected with vector alone (V1 and V2) and three clones transfected
with hepaCAM-V5 (H1, H2, and H3). The membrane was stripped and
reprobed with anti-GAPDH antibody for loading control. (B) Real-
time RT-PCR analysis. The mRNA levels of blasticidin resistant gene
(Blast_r) and hepaCAM were determined in all the clones and two
normal liver tissues (1NL and 2NL), and converted into ratio against
GAPDH mRNA levels. (C) Confocal microscopy. Immunofluorescence
staining through anti-V5 antibody was used to visualize hepaCAM
protein in both cells from the control clones V1 and V2 and cells from
the clones expressing hepaCAM (H1 and H3). 400!, magnification.
[This figure appears in colour on the web.]
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(Fig. 6A). About 50% and 90% of the cells from both clones
H1 and H3 exhibited spread morphology at 30 min and 2 h
of incubation, respectively (Fig. 6B). In contrast, the
majorities of the cells from clones V1 and V2 remained
round at the same time points. The number of cells showing
spread morphology from clones H1 and H3 was about
5 folds higher than that from the control clones V1 and V2
(P!0.001). Furthermore, HepG2 cell motility was
increased (PZ0.0011) when transfected with hepaCAM
as determined by matrigel invasion (Fig. 7A) and wound
healing assays in culture dish (Fig. 7B). These results
indicate that hepaCAM may be involved in cell and
extracellular matrix interactions.3.8. Antiproliferative effect of hepaCAM
Many Ig-like adhesion molecules, such as NCAM-1 [14],
TSLC-1 [33], and OPCML [34], are known as tumor
suppressors exhibiting antiproliferative effects. To examinethe involvement of hepaCAM in cell growth control, colony
formation was carried out while growth rate was determined
in stable HepG2 clones. The results showed that the number
of colonies was reduced by 10 folds in the cells transfected
with hepaCAM (PZ0.0022, Fig. 8A), and the growth rate
was decreased by 14 folds (P!0.001, on day 5, Fig. 8B) in
cells expressing hepaCAM (H1 and H3). No clear cell death
was observed in the course of examining growth arrest,
suggesting that hepaCAM inhibits cell growth through
suppressing proliferation rather than inducing apoptosis.4. Discussion
We have identified hepaCAM as a new Ig-like adhesion
molecule. The novel protein displays the typical structure of
the adhesion molecules in immunoglobulin superfamily
(IgSF), including two extracellular Ig-like domains, a single
transmembrane region, and a cytoplasmic tail [6].
Fig. 6. Modulation of cell-matrix adhesion by hepaCAM. (A) Cell
morphology. HepG2 clones transfected with vector alone (V1 and V2)
and expressing hepaCAM-V5 (H1 and H3) were allowed to spread on
fibronectin-coated plates for 30 min or 2 h. The microscopic photos
were taken under 200!-magnification. (B) The percentage of cell
spreading. At 30 min or 2 h after plating, total number of cells and cells
showing spread morphology were counted in ten randomly selected
fields (O60 cells per field), and the percentage of cell spreading was
then computed. The data represent meansGSD (nZ6), *P!0.001 as
assessed by ANOVA.
Fig. 7. Modulation of cell motility by hepaCAM. (A) Matrigel invasion
assay. Cell migration was examined by using the transwell chambers
with 8-mm pore size membranes coated with matrigel. HepG2 cells
stably transfected with either pcDNA6 vector or hepaCAM-V5 were
allowed to migrate through the membrane for 24 h. The migrated cells
were harvested into new 24-well plate and viewed by microscopy
(100!). The migration was quantified by blind counting of the
migrated cells in 10 randomly selected fields and represented as
meanGSD (nZ6) by the bar graph. (B) In vitro wound healing assay.
Wounds were made by pipette tip on confluent HepG2 cells stably
transfected with either pcDNA6 vector alone (left) or hepaCAM-V5
(right) and allowed to be healed by cell migration for 24 h. The
diameters of wounds were measured by microscopy (200!) at 0 h and
24 h after wounding. Arrow heads show the diameters of the initial
wounds. Changes in diameter were computed into ratio (meansGSD%,
nZ6) to represent wound closure. ** PZ0.0011 as assessed by Mann–
Whitney test.
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molecules JAMs, CAR, and ESAM, which are known to be
involved in cellular interactions. Experimentally, we have
demonstrated that hepaCAM protein is glycosylated and
predominantly localized on plasma membrane, particularly
in the areas of cell–cell contacts when cells are confluent.
Such distribution is also shown with JAMs, CAR, and
ESAM. Moreover, revealed by cell spreading and motility
assays, hepaCAM is capable of modulating cell–matrix
interactions, further supporting hepaCAM to be an adhesion
molecule.
Intriguingly, our data suggest that hepaCAM may be a
tumor suppressor in human hepatocellular carcinoma.
Firstly, we show that hepaCAM is expressed in all normal
and non-tumorous liver tissues, but suppressed in 87%
(20/23) of HCC patients and 100% (5/5) of HCC cell lines,
i.e. when hepatocytes have become cancerous, indicating
that loss of hepaCAM expression is associatedwith hepatocarcinogenesis. Secondly, the accelerated cell–-
matrix adhesion mediated by hepaCAM raises the possibility
that loss of hepaCAM may ultimately lead to the disruption
of liver tissue architecture by the loss of a tumor cell’s ability
to communicate with its extracellular environment. Thirdly,
transfection studies revealed that hepaCAM reduced cell
colony formation and inhibited cell growth in HCC cell line
HepG2 through suppression of cell proliferation. The
frequent loss of hepaCAM expression in HCC together
with the antiproliferative effect of hepaCAM meets the most
important criteria widely used to define tumor suppressor.
In addition, hepaCAM is mapped to the human
chromosome 11q24. Molecular genetic and cytogenetic
studies have indicated that the long arm of chromosome 11
is one of the most common targets for chromosomal
aberrations during the progression of human malignancies.
Tumor suppressor genes encoding cell adhesion molecules
of the Ig superfamily have been identified on 11q22-qter. An
Ig-like adhesion molecule TSLC1 is a tumor suppressor at
11q23 and its expression through promoter hypermethyla-
tion has been reported in the development of many human
cancers such as cancers of the lung, cervix, breast
and prostate [35]. However, no studies have reported
Fig. 8. Inhibition of cell growth by hepaCAM. (A) Colony formation.
HepG2 cells transfected with vector (pcDNA6) or hepaCAM-V5
construct (hepaCAM) were selected with blasticidin for 3 weeks. The
cell colonies formed at the end of the experiments were visible (upper
panel) and the size and the thickness of the colonies were observed by
microscopy. The number of colonies was counted in 10 randomly
selected fields and represented by the bar graph (meansGSD, nZ6),
**PZ0.0022 as assessed by Mann–Whitney test. (B) Cell growth curve.
The growth rate of the cells from clones H1 and H3 (stably transfected
with hepaCAM-V5) was compared to that of the cells from V1 and V2
(stably transfected with vector alone) for 5 days by microtetrazolium
(MTT) assay. Data represent meansGSD (nZ6), *P!0.001 (on day 5)
as assessed by ANOVA.
M. Chung Moh et al. / Journal of Hepatology 42 (2005) 833–841840the loss of heterozygosity (LOH) of chromosome 11q in
HCC and the mode of hepaCAM gene silencing is yet to be
understood.
In conclusion, we have identified a novel gene hepaCAM
that encodes an Ig-like cell adhesion molecule. Gene
hepaCAM is found frequently silenced in human hepato-
cellular carcinoma and the gene product is shown to be
a transmembrane glycoprotein. When re-expressed inHepG2, hepaCAM is capable of mediating cell-matrix
adhesion and cell motility, and exhibits antiproliferative
effect. This study suggests that hepaCAM is a new Ig-like
cell adhesion molecule which may play roles in cell–matrix
interaction and cell growth regulation.Acknowledgements
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We have recently identified a novel gene, hepaCAM, in
liver that encodes a cell adhesion molecule of the immu-
noglobulin superfamily. In this study, we examined the
characteristics of hepaCAM protein and the relation-
ship between its structure and function, in particular its
adhesive properties. The wild-type and the cytoplasmic
domain-truncated mutants of hepaCAM were trans-
fected into the human breast carcinomaMCF7 cells, and
the physiological and biological properties were as-
sessed. Biochemical analyses revealed that hepaCAM is
an N-linked glycoprotein phosphorylated in the cyto-
plasmic domain and that it forms homodimers through
cis-interaction on the cell surface. The subcellular local-
ization of hepaCAM appears density-dependent; in well
spread cells, hepaCAM is distributed to cell protrusions,
whereas in confluent cells, hepaCAM is predominantly
accumulated at the sites of cell-cell contacts on the cell
membrane. In polarized cells, hepaCAM is recruited to
the lateral and basal membranes, and lacking physical
interaction, hepaCAM is shown to co-localize with E-
cadherin at the lateral membrane. Cell adhesion and
motility assays demonstrated that hepaCAM increased
cell spreading on the matrices fibronectin and matrigel,
delayed cell detachment, and enhanced wound healing.
Furthermore, when the cytoplasmic domain was de-
leted, hepaCAM mutants did not affect cell surface lo-
calization and dimer formation. Cell-matrix adhesion,
however, was less significantly increased, and cell mo-
tility was almost unchanged when compared with the
effect of the wild-type hepaCAM. Taken together, the
cytoplasmic domain of hepaCAM is essential to its func-
tion on cell-matrix interaction and cell motility.
Cell adhesion is a dynamic process essential for the normal
development and maintenance of tissues and organs in multi-
cellular organisms. Cell-cell and cell-matrix interactions are
mediated by a large and complex number of cell adhesion
molecules expressed on the cell surface that interact with each
other in a spatially and temporally regulated manner. Accord-
ing to their structural and functional features, cell adhesion
molecules are generally classified into at least four major fam-
ilies: the cadherins, integrins, selectins, and members of the
immunoglobulin superfamily (1–5). Apart from linking cells to
each other or to components of the extracellular matrix, an
exciting concept that has emerged from recent cell biological
research is that cell adhesion molecules function also as recep-
tors critical in modulating signal transduction (6). Such inter-
actions are vital for the regulation of cellular adhesion, prolif-
eration, apoptosis, migration, and differentiation.
We have recently reported the identification of a novel gene
in liver, designated as hepaCAM (GenBankTM AY047587),
which was differentially expressed in human hepatocellular
carcinoma. Located on human chromosome 11q24 and span-
ning 7 exons, hepaCAM encodes a novel member of the immu-
noglobulin superfamily. The predicted protein of 416 amino
acids displays a typical structure of Ig-like adhesion molecules,
including two extracellular Ig-like domains, a transmembrane
segment, and a cytoplasmic tail. In addition, when exogenously
expressed in the human hepatocellular carcinoma cell line
HepG2, hepaCAM accelerates cell spreading and increases cell
motility (7).
The mechanism of hepaCAM in mediating cell-matrix inter-
action is unknown. However, transfection studies with mutant
and chimeric constructs of other adhesion molecules have sug-
gested that the structural features of adhesion molecules play
important roles in mediating their physiological and biological
roles. Structure and function study of E-cadherin reveals that
the formation of cis-dimer is fundamental for cell adhesion, and
inhibition of cis-dimer formation is correlated with the lack of
cell-cell interaction (8). For CEACAM1, it has been proposed
that both the first extracellular Ig domain and cytoplasmic
domain are required for its adhesion function (9). Thus, defin-
ing the molecular organization of hepaCAM may help to eluci-
date the functional roles of hepaCAM.
In this study, we aimed to characterize the physiological and
biological properties of hepaCAM and to investigate the impor-
tance of the cytoplasmic domain on hepaCAM functions in the
hepaCAM-deficient MCF7 cells. We showed that hepaCAM is a
phosphorylated glycoprotein that forms cis-homodimers on the
cell surface and mediates cell-matrix interaction. In addition, the
cytoplasmic domain is required for cell-matrix modulation but
dispensable in subcellular localization and surface dimerization.
EXPERIMENTAL PROCEDURES
Plasmid Construction—The complete coding sequence of hepaCAM
and its mutants with truncated cytoplasmic domain were generated by
PCR amplification. The cDNAs of hepaCAM residues 1–416 (wild-type),
residues 1–320, or residues 1–263 were cloned into pEGFP-N2 vector
(Clontech, Palo Alto, CA) or pcDNA6/V5-His vector (Invitrogen), at the
HindIII/BamHI restriction sites. For polyclonal antibody generation,
hepaCAM (residues 260–416) was cloned into the BglII/SalI restriction
sites of the pQE40 vector (Qiagen). The sequences of the recombinant
plasmids were verified by sequencing.
Cell Culture and Transfection—The MCF7 breast carcinoma cell line
obtained from American Type Culture Collection (Manassas, VA) was
maintained in the recommended conditions. Transfections of MCF7
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cells were carried out using the reagent Lipofectamine Plus (Invitrogen)
according to the manufacturer’s instructions. Transfected cells were
selected for 4 weeks, either in the presence of 600 g/ml G418 or 10
g/ml blasticidin, and cloned.
Western Blot Analysis—Cells were lysed in radioimmunoprecipitation
assay buffer to extract the total cell lysate. Immunoprecipitation was
carried out by incubating the precleared cell lysate with the appropriate
mouse monoclonal antibody and horseradish peroxidase-rec-protein G
(Zymed Laboratories Inc., San Francisco, CA) overnight at 4 °C. Protein
was resolved by SDS-PAGE, transblotted onto membrane, and detected
by either rabbit anti-hepaCAM polyclonal antiserum, mouse anti-V5 an-
tibody (Invitrogen), mouse anti-GFP antibody (Santa Cruz Biotechnology,
Santa Cruz, CA), or mouse anti-E-cadherin (Zymed Laboratories Inc.).
Alkaline Phosphatase Treatment—Cell lysate was incubated in de-
FIG. 1. Schematic representation and
expression of wild-type and cytoplas-
mic domain mutants of hepaCAM. A,
the wild-type and cytoplasmic domain mu-
tants of hepaCAM were cloned into the eu-
karyotic expression vectors pEGFP-N2 and
pCDNA6/V5-His and transfected into the
breast carcinoma cell line MCF7. EX, extra-
cellular domain (white box); TM, transmem-
brane domain (gray box); CT, cytoplasmic
domain (dotted box).B, protein expression of
pEGFPN2 vector and GFP-fused wild-type
and mutant hepaCAM in MCF7 cells was
detected by Western blotting using anti-
GFP antibody. Lane 1, MCF7/pEGFPN2;
lane 2, MCF7/hCAM_mt1-GFP; lane 3,
MCF7/hCAM_mt2-GFP; lane 4, MCF7/
hepaCAM-GFP. C, protein expression of
pcDNA6/V5-His vector and V5-fused wild-
type and mutant hepaCAM in MCF7 cells
was detected by Western blotting using an-
ti-V5 antibody. Lane 1, MCF7/pcDNA6; lane
2, MCF7/hCAM_mt1-V5; lane 3, MCF7/
hepaCAM-V5. Positions of the molecular
size markers are shown on the left of each
panel.
FIG. 2. Phosphorylation of hepaCAM
cytoplasmicdomain.A, residues 260–416
of hepaCAM was used to generate rabbit
polyclonal antibody. Potential serine/threo-
nine and tyrosine kinase phosphorylation
sites in the cytoplasmic region were identi-
fied using NetPhos version 2.0 software. aa,
amino acids. B, cell lysate prepared from
C3A cells expressing endogenous hepaCAM
(lanes 1 and 2) or MCF7/hepaCAM-V5 cells
expressing exogenous hepaCAM (lanes 3
and 4) was either untreated () or treated
() with calf intestinal alkaline phosphatase
(CIP), as described under “Experimental
Procedures.” After dephosphorylation, hepa-
CAM protein was detected by Western blot-
ting using the rabbit anti-hepaCAM poly-
clonal antiserum.
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phosphorylation buffer for 10 min at 30 °C. Calf intestinal alkaline
phosphatase (Roche Applied Science) was added and incubated for a
further 15 min prior to Western analysis.
N-Linked Glycosylation Analysis—For inhibiting N-linked glycosyla-
tion, MCF7 cells were transiently transfected with hepaCAM-GFP and
subsequently exposed to tunicamycin (Sigma) at the indicated concen-
trations for 24 h before lysis. For enzymatic digestion of N-linked
oligosaccharides, the cell lysate of MCF7/hepaCAM-V5 was treated
with peptide N-glycosidase F (New England Biolabs) according to the
manufacturer’s instructions. The samples were then subjected to West-
ern analysis.
Chemical Cross-linking—A monolayer or a single suspension of cells
was incubated in phosphate-buffered saline containing 3 mM BS31
(Pierce) or DTSSP (Pierce) at room temperature for 30 min. The reac-
tion was quenched with the addition of 20 mM Tris-HCl, pH 7.5, for 15
min. Single cell suspension was assured by microscopic observation
before and after chemical cross-linking reaction. DTSSP-cross-linked
proteins were resuspended in Laemmli sample buffer without 50 mM
dithiothreitol, unless indicated. Cell lysate was prepared in radioim-
munoprecipitation assay buffer containing 10 mM iodoacetamide (10).
Immunocytochemistry—Cells cultured on coverslips were fixed with
2% paraformaldehyde and permeabilized with 0.2% Triton X-100. Non-
specific sites were blocked in 10% normal goat serum (Santa Cruz
Biotechnology). Protein expression of V5-tagged hepaCAMwas detected
using mouse anti-V5 antibody, biotin-conjugated goat anti-mouse IgG
antibody, and subsequently streptavidin-fluorescein. For co-localization
experiments, cells were grown to confluence on 0.4-m Transwell filters
(Costar, Cambridge, MA). Protein expression of E-cadherin was de-
tected using mouse anti-E-cadherin antibody, biotin-conjugated goat
anti-mouse IgG antibody, and subsequently avidin-TRITC conjugate
(Sigma). Fluorescence was visualized by fluorescence microscope (Carl
Zeiss) or confocal microscope LSM 510 (Carl Zeiss) with sectioning
performed at 0.5 m.
Cell Spreading—Cells were seeded onto coverslips coated with 40 g
of matrigel basement membrane matrix (Clontech) or 10 g/ml fi-
bronectin (Santa Cruz Biotechnology) and incubated under standard
culture conditions. Cell morphology was observed by microscopy. Un-
spread cells were defined as round cells, whereas spread cells were
defined as cells with extended processes (11). The percentage of cells
demonstrating spread morphology was quantified in 10 randomly se-
lected fields.
Cell Detachment—A confluent monolayer of cells was detached in 1
mM EDTA in phosphate-buffered saline at 37 °C. Cell detachment was
evaluated under the inverted microscope at 5 and 15 min of incubation.
Concurrently, the dissociated cells were harvested and counted in 10
randomly selected fields.
Wound-healing Assay—A confluent monolayer of cells was wounded
with a sterile plastic 200-l micropipette tip. The wound was observed
microscopically at 24 and 48 h. The percentage of wound filling was
calculated by measuring the remaining gap space on the pictures.
Bioinformatics and Statistical Analysis—The protein sequence of he-
paCAM was analyzed using the NetPhos version 2.0 and Prosite pro-
grams. Nonparametric analysis of variance was performed to compare the
difference among more than two means. Software InStat version 3.0
(GraphPad) was employed, and p 0.01 was considered significant.
RESULTS
Wild-type and COOH-terminal Mutants of hepaCAM—The
wild-type hepaCAM encodes a transmembrane Ig-like adhesion
molecule of 416 amino acids. To assess the importance of hepa-
CAM cytoplasmic domain in its physiological and biological
functions, we constructed two deletion mutants of hepaCAM.
hCAM_mt1, lacking the entire cytoplasmic tail, was con-
structed by truncating residues 264–416 of hepaCAM.
hCAM_mt2 was constructed by deleting residues 321–416 of
hepaCAM to obtain a partial cleavage of the cytoplasmic tail
(Fig. 1A). Wild-type hepaCAM, hCAM_mt1, and hCAM_mt2
were fused in-frame at the NH2-terminal of the green fluores-
cent protein (GFP) gene of the expression vector pEGFP-N2,
and the resulting plasmids were named hepaCAM-GFP,
hCAM_mt1-GFP, and hCAM_mt2-GFP, respectively. In addi-
tion, wild-type hepaCAM and hCAM_mt1 were inserted at the
NH2-terminal of the V5 tag of the pcDNA6/V5-His vector and
designated hepaCAM-V5 and hCAM_mt1-V5, respectively. The
constructs, as well as the empty vectors, were transfected into
MCF7 cells, and the expressed proteins were analyzed byWest-
ern blotting using anti-GFP and anti-V5 antibodies accordingly
(Fig. 1, B and C). Subsequently, MCF7 cells stably expressing
pEGFP-N2 vector (MCF7/pEGFPN2), hepaCAM-GFP (MCF7/
1 The abbreviations used are: BS3, bis(sulfosuccinimidyl) suberate;
DTSSP, 3,3-dithiobis (sulphosuccinimidyl propionate); GFP, green flu-
orescent protein; TRITC, tetramethylrhodamine isothiocyanate.
FIG. 3. N-Linked glycosylation of
hepaCAM-GFP. A, illustration of the
secondary structure of hepaCAM protein.
hepaCAM owns the typical structure of
proteins in the immunoglobulin super-
family, including an extracellular seg-
ment consisting of an NH2-terminal-prox-
imal Ig-like domain and a membrane-
proximal C2-type Ig domain with a
disulfide bond formed between two cys-
teine residues (S—S), a transmembrane
region, and a cytoplasmic tail. The six
putative N-linked glycosylation sites are
indicated by the symbol ¸. B, left panel,
cell lysate was prepared from MCF7/
hepaCAM-GFP (lanes 2 and 3) treated
without () or with () N-glycosidase F.
Untreated parental MCF7 cells (lane 1)
were included as the control. Right panel,
MCF7 cells transfected with hepaCAM-
GFP were treated with tunicamycin at
the indicated concentrations for 24 h be-
fore lysis. Protein samples were resolved
by SDS-PAGE and subjected to Western
blotting with anti-GFP antibody. Solid
and open arrowheads indicate signals for
glycosylated and deglycosylated proteins,
respectively. Positions of the molecular
size markers are shown on the left.
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hepaCAM-GFP), hCAM_mt1-GFP (MCF7/hCAM_mt1-GFP),
hCAM_mt2-GFP (MCF7/hCAM_mt2-GFP), pcDNA6 vector
(MCF7/pcDNA6), hepaCAM-V5 (MCF7/hepaCAM-V5) and
hCAM_mt1-V5 (MCF7/hCAM_mt1-V5) were generated and
cloned.
Phosphorylation of the hepaCAM Cytoplasmic Domain—We
generated a polyclonal antiserum that recognizes the hepa-
CAM cytoplasmic domain but in its dephosphorylated form.
The recombinant His bacterial fusion protein used for immu-
nization contained residues 260–416 of hepaCAM. Western
analysis showed that the resulting antiserum could specifically
detect the bacterial fusion protein, otherwise undetectable by
the pre-immune serum. However, when the antiserum was
tested on the cell lysate of MCF7/hepaCAM-V5, no specific
band was observed (data not shown). We suspected that the
antiserum was unable to recognize the cytoplasmic domain of
hepaCAM because of the presence of post-translational modi-
fications, e.g. phosphorylation. Evaluation of the region se-
lected for antibody generation by the NetPhos version 2.0
server predicted 28 potential serine-, threonine-, or tyrosine-
phosphorylated residues scattered along the cytoplasmic do-
main of hepaCAM protein, with 20 of them giving a potential
phosphorylation 0.5 (Fig. 2A). To verify that the hepaCAM
cytoplasmic domain is phosphorylated, we dephosphorylated
cell lysates of C3A cells expressing endogenous hepaCAM and
MCF7/hepaCAM-V5 cells expressing exogenous hepaCAM
with calf intestinal alkaline phosphatase. The untreated cell
lysates were included as controls. Indeed, calf intestinal alka-
line phosphatase-treated endogenous and exogenous hepaCAM
were detected by the rabbit antiserum (Fig. 2B), confirming
that the cytoplasmic domain of hepaCAM is phosphorylated.
N-Linked Glycosylation of hepaCAM—Sequence analysis of
hepaCAM predicted six N-linked glycosylation sites on its ex-
tracellular domain (Fig. 3A). To investigate whether hepaCAM
was glycosylated, the MCF7/hepaCAM-GFP cell lysate was
enzymatically digested with peptide N-glycosidase F to release
putative N-linked oligosaccharides. An untreated sample was
included as the control. The molecular mass of hepaCAM-GFP,
shown by Western analysis to be100 kDa, was shifted to75
kDa after deglycosylation. Consistently, when MCF7 cells
transfected with hepaCAM-GFP were treated with tunicamy-
cin (an antibiotic that inhibits N-linked glycosylation) at dif-
FIG. 4.Homophilic cis-dimerization of hepaCAM andmutant. A, cross-linking of hepaCAM-GFP (left panel) and hepaCAM-V5 (right panel)
on the cell surface. A monolayer of MCF7/hepaCAM-GFP or MCF7/hepaCAM-V5 cells was untreated () and treated () with 3 mM BS3 prior to
protein sample preparation in lysis buffer containing 10 mM iodoacetamide. Protein samples were subjected to Western blotting with anti-GFP
antibody or anti-V5 antibody, respectively. B, a monolayer of MCF7/hepaCAM-GFP was untreated () and treated () with 3 mM DTSSP prior to
protein sample preparation in lysis buffer containing 10 mM iodoacetamide. Protein samples were resuspended in Laemmli sample buffer in the
presence () or absence () of dithiothreitol. C, co-immunoprecipitation of hepaCAM-GFP and hepaCAM-V5. MCF7 cells were transfected with
hepaCAM-GFP, hepaCAM-V5, or both. Protein samples were prepared, immunoprecipitated with anti-GFP antibody, and subjected to Western
blotting using anti-GFP antibody (left panel) or anti-V5 antibody (right panel). The signals corresponding to hepaCAM-GFP and hepaCAM-V5
molecules are marked with arrows. D, a monolayer of MCF7/hCAM_mt1-GFP cells was untreated () and treated () with 3 mM BS3 prior to
protein sample preparation in lysis buffer containing 10 mM iodoacetamide. Protein samples were subjected to Western blotting with anti-GFP
antibody. E, a monolayer and a single cell suspension of MCF7/hepaCAM-GFP were incubated in the absence () or presence () of 3 mM BS3.
Protein samples were subjected to Western blotting with anti-GFP antibody. Solid and open arrowheads indicate signals for dimeric and
monomeric proteins, respectively. *, dimer in un-cross-linked sample. The positions of the molecular size markers are shown on the left of each
panel.
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ferent doses for 24 h, a band at75 kDa was also observed (Fig.
3B). The results verified that hepaCAM is a glycoprotein. By
subtracting the molecular mass of GFP, i.e. 27 kDa, the degly-
cosylated form of hepaCAM is 48 kDa.
Dimerization of hepaCAM and Mutant on Plasma Mem-
brane—We evaluated the pre-existing forms of hepaCAM on
cell membrane by incubating a monolayer of MCF7/hepaCAM-
GFP cells with BS3, a noncleavable membrane-impermeable
cross-linker. The cell lysate was prepared in the presence of
iodoacetamide to inhibit the formation of nonspecific disulfide
bonds (10). An untreated sample was included as the control.
The samples were analyzed byWestern blotting with anti-GFP.
In the presence of BS3, a band of 200 kDa appeared, which
seemed to represent the dimerized form of hepaCAM-GFP,
accompanied with the disappearance of the hepaCAM mono-
mers. Similarly, treatment of MCF7/hepaCAM-V5 cells with
BS3 resulted in a decrease of the 75-kDa monomeric form of
hepaCAM and an accumulation of the higher molecular weight
species at150 kDa, although no distinct band was noted (Fig.
4A). It is possible that the anti-V5 antibody did not recognize
the higher molecular weight species as efficiently as monomers.
To examine whether hepaCAM forms a homodimer on the cell
surface, MCF7/hepaCAM-GFP cells were treated with DTSSP,
a reducible membrane-impermeable cross-linker. In the ab-
sence of the reducing agent dithiothreitol, a significant in-
crease in the 200-kDa species was observed. However, when
dithiothreitol was added into the sample buffer, the higher
molecular mass was reduced to the monomeric form to a level
closely comparable with that of the untreated cells (Fig. 4B).
Additionally, we co-expressed hepaCAM-GFP and hepa-
CAM-V5 in MCF7 cells, immunoprecipitated the cell lysate
with anti-GFP antibody, and immunoblotted with anti-V5 or
anti-GFP. The result revealed co-immunoprecipitation of hepa-
CAM-GFP with hepaCAM-V5 (Fig. 4C), demonstrating that
hepaCAM molecules dimerized through homophilic interac-
tion. To examine whether tailless hepaCAM proteins form
dimers, MCF7/hCAM_mt1-GFP cells were treated with BS3
and analyzed by Western blotting (Fig. 4D). The monomeric
form of hCAM_mt1-GFP was diminished and replaced with its
dimeric form at 125 kDa in the BS3-treated sample. Inter-
estingly, in the untreated sample of hepaCAM-GFP and
hCAM_mt1-GFP, protein species that seemed to represent the
dimeric form of the proteins were observed. This phenomenon
could be due to covalent bonding between the dimers of hepa-
CAM-GFP or hCAM_mt1-GFP. To determine whether hepa-
CAM-GFP forms cis- or trans-dimers on the cell surface, both
adherent monolayer and single cell suspension of MCF7/hepa-
CAM-GFP cells were treated with BS3 (Fig. 4E). The extent of
dimerization was comparable in both adherent and suspension
cells, indicating that hepaCAM homodimerization occurs pre-
dominantly through cis-interactions rather than trans-interac-
tions within the plane of the membrane of individual cells.
Subcellular Localization of hepaCAM and Mutants in MCF7
Cells—Weexplored the subcellular distribution ofwild-typehepa-
CAM in MCF7/hepaCAM-GFP cells at low and at high cell den-
sities by fluorescence and inverted microscopy (Fig. 5A). When
FIG. 5. Subcellular localization of
hepaCAM andmutants in MCF7 cells.
A, the localization of hepaCAM-GFP in
MCF7 cells is cell density-dependent.
MCF7/hepaCAM-GFP cells were seeded
at low density and cultured for a few days.
Cells at areas of low density (top panels)
and high density (bottom panels) were ob-
served under a fluorescence (left panels)
or inverted microscope (right panels).
Magnification is 320. B, the expression
of pEGFP-N2 (a), hCAM_mt1-GFP (b),
and hCAM_mt2-GFP (c) in MCF7 cells
was detected by fluorescence microscopy.
Magnification is 320. C, MCF7/hepa-
CAM-V5 (a) andMCF7/hCAM_mt1-V5 (b)
cells were immunostained with anti-V5
antibody to detect localization of hep-
aCAM and mutant under a fluorescence
microscope. Magnification is 200.
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cells were well spread, hepaCAM protein was localized to punc-
tuate structures in the perinuclear membrane, cytoplasm, and at
the tip of the cell surface protrusions, which were about to make
contact with adjacent cell surfaces, forming zipper-like struc-
tures. Once the cells became confluent, the protein was localized
at a lesser extent in the perinuclear membrane and cytoplasm
and predominantly on the plasma membrane, particularly in the
areas of cell-cell contacts. The results suggest that the sub-
cellular localization of hepaCAM is cell density-dependent.
We also examined the effect of hepaCAM cytoplasmic domain
in its plasma membrane localization. hCAM_mt1-GFP and
hCAM_mt2-GFP were both recruited to the plasma mem-
brane of MCF7 cells (Fig. 5B). Similarly, MCF7/hepaCAM-V5
and MCF7/hCAM_mt1-V5 cells immunostained with anti-V5
showed that hepaCAM and its mutant were predominantly
expressed on cell membranes (Fig. 5C). The results indicate
that the cytoplasmic domain is dispensable for membrane
localization.
Co-localization of hepaCAM with E-cadherin—The distribu-
tion of hepaCAM was further examined in confluent polarized
MCF7/hepaCAM-GFP cells by confocal laser scanning micros-
copy (Fig. 6A). The cells were also stained for E-cadherin,
which localizes in the lateral cell surface, to compare its local-
ization with that of hepaCAM. In the X-Y sections, hepaCAM-
GFP was distributed to honeycomb-like structures at cell-cell
boundaries, which significantly co-localized with E-cadherin.
In the X-Z vertical cross-section, the distribution of E-cadherin
along the entire lateral cell surface coincided with hepaCAM-
GFP. Moreover, hepaCAMwas detected at the basal membrane
that was in contact with the Transwell membrane. Because
hepaCAM and E-cadherin appeared to co-localize, we investi-
gated whether there were any physical interactions between
them by co-immunoprecipitation (Fig. 6B). Cell lysate prepared
from MCF7/hepaCAM-V5 was precipitated with the anti-V5
antibody and subjected to Western blotting using the anti-E-
cadherin or anti-V5 antibodies. MCF7/pcDNA6 cell lysate was
included in the experiment as the control. No co-immunopre-
cipitation was observed, suggesting that E-cadherin and hepa-
CAM do not physically interact.
Cell-Matrix Interaction by hepaCAM and Mutant—We eval-
uated the adhesive properties of V5-tagged hepaCAM and mu-
tant constructs on the MCF7 cells through cell aggregation, cell
adhesion, and detachment assays. No clear change in cell ag-
gregation was observed among MCF7/pcDNA6, MCF7/
hCAM_mt1-V5, and MCF7/hepaCAM-V5 cells (data not
shown), but hepaCAM was capable of modulating cell-matrix
adhesion significantly. Fig. 7 shows that 60 and 79% of the
MCF7/hepaCAM-V5 cells exhibited spread morphology on fi-
bronectin at 30 min and 2 h of incubation, respectively, in
contrast to 40.8 and 58.2% of the MCF7/hCAM_mt1-V5 cells
and 7.3 and 18% of MCF7/pcDNA6 cells (p  0.001). Similarly
on matrigel, MCF7/hepaCAM-V5 cells showed the fastest
spreading, followed by MCF7/hCAM_mt1-V5 cells, and then
MCF7/pcDNA6 cells (p  0.001). In the cell detachment assay
(Fig. 8), MCF7/hepaCAM-V5 cells detached 18.9 and 21.6 times
slower than MCF7/pcDNA6 cells at 5 and 15 min, respectively.
MCF7/hCAM_mt1-V5 cells, on the other hand, detached 4
and 2.2 times slower than MCF7/pcDNA6 cells at time points 5
min and 15 min (p  0.001). The results showed that, in addi-
tion to its extracellular and transmembrane domains, hep-
aCAM needs its cytoplasmic domain to mediate strong cell-
matrix adhesion.
Cell Motility by hepaCAM and Mutant—Cell motility of
hepaCAM and mutant was assessed by matrigel invasion and
wound-healing assays. Barely any MCF7 cells expressing
pcDNA6, hCAM_mt1, and hepaCAM migrated through the
8-m Transwell membrane (data not shown). This observation
could be explained by the poorly invasive nature of MCF7 cells.
FIG. 6. Co-localization of hepaCAM with E-cadherin. A, MCF7/hepaCAM-GFP cells grown to confluence on the Transwell filter unit were
fixed, permeabilized, and immunostained with anti-E-cadherin. Laser scanning confocal microscopy was performed with a filter set suitable for
fluorescein and rhodamine detection. The representative sets of X-Y and X-Z sections are indicated. a, hepaCAM-GFP stained green; b, E-cadherin
stained red; c, confocal images of the hepaCAM-GFP and E-cadherin were merged to show regions of co-localization. B, co-immunoprecipitation of
hepaCAM-GFP and E-cadherin. Equal amounts of cell lysate prepared from MCF7/pcDNA6 or MCF7/hepaCAM-V5 cells was immunoprecipitated
(IP) with anti-V5 antibody and subjected to Western blotting using anti-E-cadherin (top panel) or anti-V5 antibody (bottom panel). The signals
corresponding to E-cadherin and hepaCAM-V5 molecules are marked with arrowheads. Lane 1, cell lysate of MCF7/pcDNA6 before IP; lane 2, cell
lysate of MCF7/hepaCAM-V5 before IP; lane 3, cell lysate of MCF7/pcDNA6 after IP; lane 4, cell lysate of MCF7/hepaCAM-V5 after IP; lane 5,
precipitate of MCF7/pcDNA6; lane 6, precipitate of MCF7/hepaCAM-V5.
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Moreover, MCF7/hepaCAM cells were enlarged, therefore re-
tarding migration. However, in the wound-healing assay (Fig.
9), we demonstrated that, after 24 h of incubation, MCF7/
hepaCAM-V5 cells filled 59.3% of the scratched area (p  0.01),
compared with 36.3% by MCF7/hCAM_mt1-V5 cells (p  0.05)
and 33.1% by MCF7/pcDNA6 cells. After 48 h, MCF7/hepa-
CAM-V5 cells closed 83.7% of the wound (p  0.01), compared
with 55.2% by MCF7/hCAM_mt1-V5 cells (p  0.05) and 49.5%
by MCF7/pcDNA6 cells. Hence, the cytoplasmic domain is im-
portant for cell motility modulated by hepaCAM.
DISCUSSION
In our previous work, we identified a novel Ig-like mole-
cule, hepaCAM, which exhibits typical structural character-
istics of adhesion molecules of the immunoglobulin superfam-
ily (7). In this study, we demonstrated physiological and
biological characteristics of hepaCAM and the relationship
between its structure and function, particularly with respect
to the cytoplasmic domain.
Sequence analysis revealed that the cytoplasmic domain of
hepaCAM contains a proline-rich region that provides putative
binding sites for SH3 domains and potential phosphorylation
sites of serine/threonine and tyrosine kinases. Experimentally,
we showed that the cytoplasmic domain is phosphorylated,
suggesting an important role of the hepaCAM cytoplasmic do-
main in signaling cascades controlling cellular adhesion, mo-
tility, morphology, and all processes depending on the cytoskel-
eton. To evaluate the significance of the cytoplasmic domain,
we transfected wild-type and cytoplasmic domain-truncated
constructs of hepaCAM into MCF7 cells and analyzed their
effects on hepaCAM functions.
Biochemical analysis revealed that hepaCAM is a glycosy-
lated protein and forms a cis-homodimer on the cell surface.
Deletion of the cytoplasmic domain did not interfere with dimer
formation, suggesting that dimerization may be stabilized by
the extracellular and/or transmembrane domains but not the
cytoplasmic domain. Notably, chemical cross-linking of hepa-
CAM or its mutated protein both showed the presence of high
molecular weight proteins, indicating that hepaCAMmay form
large complexes with other endogenously expressed cellular
proteins through its extracellular and/or transmembrane do-
FIG. 7. Cell spreading assay. MCF7/pcDNA6 (left panels), MCF7/hCAM_mt1-V5 (middle panels) and MCF7/hepaCAM-V5 (right panels) cells
were allowed to spread on matrigel-coated coverslips for 30 min or 2 h. Insets, cell morphology before spreading. The microscopic photos were taken
under 200 magnification. Shown is the percentage of spread cells on fibronectin and matrigel. At 30 min or 2 h after plating, the total number
of cells showing spread morphology were counted in ten randomly selected fields, and the percentage of cell spreading was then computed. The data
represent means  S.D. (n 	 6); **, p  0.001 as assessed by analysis of variance.
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mains. Alternatively, it may represent higher order homo-oli-
gomers of hepaCAM or its mutant. It is interesting to observe
the seemingly dimeric form of hepaCAM and its mutant in
their respective un-cross-linked samples. Although the mecha-
nism resulting in such interaction is unknown to us, Hunter et
al. (5) and others (12) have observed a similar phenomenon in
C-CAM and raise the possibility that C-CAM dimers become
covalently linked, perhaps through the action of transglutami-
nase, an enzyme which catalyzes the formation of -glutamyl-
-lysine bonds in a restricted number of cellular proteins.
FIG. 8. Cell detachment assay.
MCF7/pcDNA6 (left panels), MCF7/
hCAM_mt1-V5 (middle panels), and
MCF7/hepaCAM-V5 (right panels) cells
were detached in 1 mM EDTA for 5 min or
15 min. The microscopic photos were
taken under 200 and 400 magnifica-
tions. At 5 min or 15 min after incubation,
the total number of detached cells was
counted in ten randomly selected fields,
and the percentage of cell detachment
was then computed. The data represent
means  S.D. (n 	 6), **, p  0.001 as as-
sessed by analysis of variance.
FIG. 9.Wound-healing assay.Wounds
were made by pipette tip on confluent
MCF7/pcDNA6 (left panels), MCF7/
hCAM_mt1-V5 (middle panels), and
MCF7/hepaCAM-V5 (right panels) cells
and allowed to heal for 24 and 48 h. The
microscopic photos were taken under100
magnification. The diameters of wounds
were measured on the microscopic photos
at 0, 24, and 48 h after wounding. Changes
in wound diameter were computed into
percentage (means S.D.%, n	 6) to rep-
resent wound closure. *, p 0.01 as as-
sessed by analysis of variance.
Structure and Function of hepaCAM 27373
Subcellular localization of hepaCAM in nonpolarized MCF7
cells showed that hepaCAM molecules were recruited to the
cytoplasmic membranes at sites of cell-cell attachment. In po-
larized cells, hepaCAM was preferentially expressed in the
lateral and basal membranes. Co-localization analysis demon-
strated that hepaCAM co-localized laterally with E-cadherin,
but no physical interaction between the two molecules was
detected. We also showed that partial truncation and complete
deletion of the cytoplasmic domain did not alter the plasma
membrane localization. It has been reported that the
CEACAM1 cytoplasmic domain regulates its lateral localiza-
tion. Differing in their cytoplasmic domains, isoform
CEACAM1-S distribution is exclusively apical, whereas iso-
form CEACAM1-L occurs both in apical and lateral cell sur-
faces (13). However, whether the loss of cytoplasmic domain
affects the lateral and basal localization of hepaCAM remains
to be determined.
Functionally, hepaCAM is capable of modulating cell-matrix
interaction. Cell adhesion to the substratum plays a crucial
role in cell migration, which is a key aspect of many normal and
abnormal biological processes, including embryonic develop-
ment, immunity, wound healing, and metastasis of tumor cells
(14, 15). The distribution of hepaCAM on the basal membrane
of cells, in addition to the spread morphology of MCF7/hep-
aCAM-V5 cells, hinted at possible trans-interaction between
hepaCAM and the substrate. Evidently, cell spreading, cell
detachment, and wound-healing assays revealed increased cell-
substrate affinity and cell motility mediated by hepaCAM.
Deletion of the cytoplasmic domain reduced, but did not com-
pletely abrogate, cell-matrix adhesion mediated by the wild-
type hepaCAM, implicating that, to a considerable extent, the
extracellular and transmembrane domains are able to initiate
adhesion. However, the rate of wound healing of cells express-
ing mutant hepaCAM was close to the level of the control cells,
indicating that the cytoplasmic domain is essential for mediat-
ing wound recovery. The data implies that cell-matrix adhesion
and cell motility are controlled separately, and phosphorylation
of the cytoplasmic domain may play a pivotal role in the regu-
lation. Indeed, phosphorylation of CD44 was shown to regulate
melanoma cell and fibroblast migration on, but not attachment
to, a hyaluronan substratum (16). Additionally, it has been
proposed for the cadherins (8, 17, 18) and for CEA (19) that
cis-dimerization will lead to strengthened cell adhesion, and
cis-homodimer formation of ICAM-1 enhances its binding to a
leukocyte 2-integrin (20). However, the functional signifi-
cance of hepaCAM post-translational modification and dimer-
ization in regulating cell-matrix interaction is still under
investigation.
In conclusion, we have shown that hepaCAM is a phospho-
rylated glycoprotein, forms cis-homodimers on the cell surface,
and modulates cell-matrix interaction. The cytoplasmic do-
main, although unessential for cell surface localization and
dimerization, is required to maintain a complete functional
form of hepaCAM as a modulator of cell-matrix interaction.
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93rd American Association for Cancer Research. April 6-10, 2002. 
A novel intronless putative tumor suppressor gene, hepn1, frequently inactivated in 
hepatocellular carcinoma and multiple tumor types 
Mei Chung Moh, Shali Shen, Department of Physiology, National University of Singapore, 
Singapore. 
A novel gene, identified in human liver and designated as hepn1, is frequently silenced in 
hepatocellular carcinoma (HCC) and multiple tumor types. Reverse transcription-PCR 
demonstrated a suppression of hepn1 in 78% (68/87) of HCC patients and 84% (16/19) of human 
tumor cell lines. The full-length hepn1 cDNA, isolated from normal liver, is 1448 base pairs long 
which contains an open reading frame (OFR) of 267 nucleotides encoding a protein of 88 amino 
acids. For functional exploration, the ORF of hepn1 was transfected and expressed in HepG2 
cells, a hepn1-deficient HCC cell line with wild-type p53. Forty-eight hours after the transfection, 
the cell viability decreased 27.8% that coincided with the optimized transfection efficiency; 
however, the expression of p53 in the transfected cells remained unchanged. Through the green 
fluorescence protein, we localized hepn1 protein in the cytoplasm and observed a hepn1-induced 
cell death in HepG2. Sequence analysis against the available databases revealed that, at the 
amino acid level, hepn1 did not have any homology to known proteins/peptides; at the EST level, 
hepn1 had significant alignments with a number of fragmented sequences obtained from the 
brain and the breast; and at the genomic level, hepn1 was indicated to be an intronless gene 
located at human chromosome 11q24. These data suggest that the intronless gene, hepn1, may 
encode a novel tumor suppressor and its function may be p53-independent.  
95th American Association for Cancer Research. March 27-31, 2004. 
Identification and characterization of CAMSIT as a novel immunoglobulin-like cell 
adhesion molecule that exhibits growth inhibitory effect on human cancer cells 
Mei Chung Moh, Lay Hoon Lee, Chunli Zhang, Shali Shen. National University of Singapore, 
none, Singapore and National University of Singapore, Singapore. 
Alterations of cell adhesion molecules have increasingly been implicated in disruption of cell 
organization, signaling and growth control, leading to tumor development and progression. In 
this study, using the technique of suppression subtractive hybridization, we examined differential 
gene expression in human hepatocellular carcinoma (HCC) and identified a new member of the 
immunoglobulin superfamily, designated as CAMSIT (cell adhesion molecule suppressed in 
tumors). Real-time RT-PCR showed that CAMSIT lacked tissue specificity and was widely 
expressed in normal human tissues, such as liver, brain, skeletal muscle, colon and blood. Its 
expression was significantly decreased in 20/23 of HCC specimens and undetectable in 17/19 
cell lines derived from various human tumors. Sequence analyses revealed that gene CAMSIT, 
mapped to chromosome 11q24, had no significant similarities to any known genes. The predicted 
protein of 416 amino acids displayed a typical structure of Ig-like adhesion molecules, including 
two extracellular Ig-like domains, a transmembrane segment and a cytoplasmic tail. Through 
transfection studies on HepG2 and MCF7 cells, we explored the biochemical characteristics and 
biological functions of CAMSIT. The subcellular localization of CAMSIT appeared to be cell 
density-dependent. In well-spread cells, CAMSIT was distributed in punctuate structures in the 
cytoplasm and at the cell surface protrusions. In confluent cells, CAMSIT was predominantly 
localized on the cytoplasmic membrane, particularly in the areas of cell-cell contacts, but absent 
at free cell borders. Crosslinking assay suggested that, independent of the cytoplasmic tail, 
CAMSIT formed cis-dimers on cell surface. Western analysis following deglycosylation and 
dephosphorylation indicated that CAMSIT protein, approximately 75 kDa, was glycosylated and 
phosphorylated. Re-expression of CAMSIT reduced cell colony formation by 10 folds (P = 
0.0022), inhibited cell proliferation by 14 folds (P < 0.001), and induced senescence-like 
phenotype. In addition, cellular interaction assays demonstrated that CAMSIT was capable of 
enhancing cell-matrix adhesion and cell migration, but not cell aggregation. More intriguingly, 
the cytoplasmic domain of CAMSIT, a 27 kDa phophorylated fragment, was consistently 
detectable by western analysis, and it was translocated into cell nuclei and triggered cell death 
through apoptosis when exogenously expressed in cells. In conclusion, gene CAMSIT is 
frequently downregulated in a variety of human tumors. The gene encodes a new Ig-like cell 
adhesion molecule which modulates cell-matrix adhesion and cell motility. The activated 
CAMSIT, possibly through phosphorylation, may undergo proteolytic cleavage and 
consequently be involved in cell signaling and growth control. 
5th Human Genetics Organization (HUGO) Pacific Meeting & 6th Asia-Pacific Conference on 
Human Genetics. November 17-20, 2004. 
 
Identification and characterization of a putative noncoding RNA gene in human 
hepatocellular carcinoma 
 
Mei Chung Moh, Lay Hoon Lee, Shali Shen. Department of Physiology, Faculty of Medicine, 
National Univ. of Singapore, 2 Medical Drive, Singapore 117597. 
 
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, especially 
in Africa, China and Southeast Asia. Genetic changes have been defined as the hallmark of 
cancers as they are responsible for the differences between normal and malignant phenotypes. A 
widely accepted approach to study genetic instability is to identify cancer-related genes, in 
particular, the two major groups of growth regulatory genes – oncogenes and tumor suppressor 
genes. The long-term goal of this research is to identify the common genetic changes that lead to 
HCC of different etiologies, and to understand the correlation between these changes and tumor 
progression. Using the technique of suppression subtractive hybridization (SSH), we identified a 
large number of genes whose expression was either down- or up- regulated in HCC. Quantitative 
real-time RT-PCR demonstrated that a novel gene transcript, HEPT3, was overexpressed in 95% 
(22/23) of HCC patients and in all the 5 HCC cell lines tested. Sequence analysis and 
bioinformatics performed on the full-length cDNA revealed that HEPT3 is an intronless gene 
mapped to chromosome 6q13-14 and the gene transcript lacks extensive open reading frame, 
indicating a noncoding RNA. Antisense studies on an HCC cell line C3A showed that cell 
growth was significantly inhibited, possibly through G2/M arrest, when HEPT3 expression level 
was reduced. Furthermore, endogenous HEPT3 expression could be regulated when cells were 
treated with anti-cancer agents, such as 5-FU and etoposide. Our data suggest that HEPT3 may 
be a functional noncoding gene and its RNA may play a role in the malignant transformation of 
hepatocytes. 
18th Asia Pacific Cancer Conference. September 7-9, 2005. 
 
Structural and functional analyses of a novel immunoglobulin-like cell adhesion molecule 
hepaCAM that is suppressed in a variety of human cancers 
 
Mei Chung Moh, Lay Hoon Lee, Shali Shen. Department of Physiology, Faculty of Medince, 
National University of Singapore, 2 Medical Drive, Singapore 117597. 
 
Purpose: Previously, we identified a new member of the immunoglobulin superfamily, 
hepaCAM, in normal human liver. In this study, we examined the expression and characteristics 
of hepaCAM as well as the relationship between its structure and function. Methods: Real-time 
RT-PCR was used to determine gene expression. Bioinformatics was performed for sequence 
analyses. Transfections, coupled with immunochemistry, cellular interaction analyses, cell 
motility assays, and colony formation, were employed to elucidate the characteristics and 
functions of hepaCAM. Results: Gene hepaCAM was widely expressed in normal human tissues, 
such as liver, brain, skeletal muscle, colon and blood, but was significantly suppressed in 20/23 
of HCC specimens and in 17/19 cell lines derived from various human tumors. Mapped to 
chromosome 11q24, hepaCAM had no significant similarities to any known genes. The predicted 
protein of 416 amino acids displayed a typical structure of Ig-like adhesion molecules, including 
two extracellular Ig-like domains, a transmembrane segment and a cytoplasmic tail. The 
subcellular localization of hepaCAM appeared to be cell density-dependent. In well-spread cells, 
hepaCAM was distributed in punctuate structures in the cytoplasm and at the cell surface 
protrusions. In confluent cells, hepaCAM was predominantly localized on the cytoplasmic 
membrane, particularly in the areas of cell-cell contacts, but absent at free cell borders. The 75 
kDa protein was glycosylated and phosphorylated, and formed cis-dimers on cell surface. 
Functionally, hepaCAM reduced cell colony formation (P = 0.0022), inhibited cell proliferation 
(P < 0.001), and induced senescence-like phenotype. In addition, hepaCAM increased cell 
spreading on matrices fibronectin and matrigel, and enhanced cell migration. When the 
cytoplasmic domain was deleted, the mutant could less significantly increase cell-matrix 
adhesion, cell motility and growth inhibition compared to the wildtype. Conclusion: Gene 
hepaCAM is frequently downregulated in a variety of human tumors. The gene encodes a new 
membrane-associated glycoprotein, an Ig-like cell adhesion molecule, modulating cell-matrix 
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ASBMB Annual Meeting and Centennial Celebration. April 1-5, 2006.  
 
hepaCAM, a novel immunoglobulin-like cell adhesion molecule, is associated with the actin 
cytoskeleton and the lipid rafts and is involved in cell-matrix interaction  
 
Mei Chung Moh, Shali Shen. Department of Physiology, National University of Singapore, Yong 
Loo Lin School of Medicine, Singapore 117597, 2 Medical Drive, Singapore. 
 
We have recently identified a novel gene hepaCAM which encodes a cell adhesion molecule of 
the immunoglobulin superfamily. Biochemical analyses reveal that hepaCAM is an N-linked 
glycoprotein phosphorylated in the cytoplasmic domain, and forms homodimers through cis-
interaction on cell surface. Immunocytochemistry shows that the wild-type hepaCAM 
colocalizes with filamentous actin (F-actin) on the plasma membrane while depolymerization of 
F-actin leads to an increased solubilization and a disruption of the subcellular distribution of 
hepaCAM. Sucrose density gradients demonstrate that hepaCAM partitions into the lipid rafts 
while dispersion of cholesterol in the lipid rafts alters the buoyancy of hepaCAM. In addition, 
hepaCAM colocalizes with the lipid raft markers, caveolin-1 and fyn. Functionally, hepaCAM 
increases cell spreading on matrices fibronectin and matrigel, delays cell detachment, and 
enhances wound healing. Furthermore, when the cytoplasmic domain is deleted, hepaCAM 
mutants do not affect cell surface localization and dimer formation; however, these mutants are 
less significantly involved in cell-matrix adhesion and cell motility. Overall, these data indicate 
that hepaCAM interacts with the actin cytoskeleton and resides in the lipid rafts, and that the 
cytoplasmic domain of hepaCAM is essential to its function on cell-matrix interaction and cell 
motility. 
 
  
  
  
  
  
 
